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Introduction
Cardiomyopathies are diseases of the heart muscle, classified according to 
distinct structural and functional features (1, 2). Noncompaction cardiomyopathy 
(NCCM) is characterized by excessive trabeculation of the endocardial layer of 
the myocardium of the left ventricle. It is also referred to as left ventricular non-
compaction (LVNC) (3). The left ventricle shows a spectrum of hypertrabeculation 
ranging from physiologic remodeling in adults to perinatal cardiomyopathy 
in children requiring heart transplantation (4, 5). The diagnosis is established 
by imaging noncompaction of the left ventricle, usually by transthoracic 
echocardiography or cardiac magnetic resonance imaging. NCCM is classified as a 
genetic cardiomyopathy according to the America Heart Association (AHA), while 
the European society of cardiology (ESC) has classified NCCM as an unspecified 
cardiomyopathy (1, 2). The reason the AHA classified NCCM as a genetic 
cardiomyopathy was that mutations in cardiomyopathy genes are equally frequent 
causes for NCCM as for the more prevalent inherited hypertrophic – and dilated 
cardiomyopathies. The first report of a genetic cause for NCCM dates back to 1997 
describing a family with NCCM linked to a mutation in the X-linked tafazzin (TAZ) 
gene (6). In 2008 the first sarcomere mutations were identified in NCCM patients 
(7). Since then more and more of the cardiomyopathy genes (genes associated with 
hypertrophic (HCM) - and dilated (DCM) cardiomyopathy have been associated 
with NCCM, leading to the current recommendations for DNA testing of panels 
of more than 50 cardiomyopathy genes in NCCM. A disease causing (likely) 
pathogenic variant, is observed in 32% to 38% of all NCCM patients (8-10). However, 
in approximately half of familial NCCM no (likely) pathogenic variant is found, 
indicating additional genetic causes have to be identified, resulting in an even 
higher prevalence of genetic NCCM. The motive of the ESC to classify NCCM as 
an unspecified cardiomyopathy was based on the ongoing debate whether NCCM 
is a distinct clinical entity or is an epiphenomenon of other cardiomyopathies 
(11-14), giving the overlapping phenotypes and genotypes with HCM and DCM 
and because cardiac features complying with the current NCCM imaging criteria 
may occur in the healthy population (15-17). The aim of this thesis is to establish 
the genetic spectrum of NCCM and the correlations between genetics and the 
phenotypic manifestations. 
Diagnostic criteria
The first description of a noncompacted myocardium can be traced back to a 
pathology report by Grant et al. in 1926 describing a spongy myocardium (18). It was 
until 1990 that Chin et al. proposed the first diagnostic criteria for NCCM (3). With 
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the progress in diagnostic imaging techniques, recognition of NCCM increased 
and with it the number of diagnostic criteria. At first mainly echocardiography 
criteria were used, later criteria for magnetic resonance imaging (MRI) were 
introduced (19). All the different composed criteria on various imaging modalities 
for the diagnosis of NCCM require some kind of measurement of trabeculations, 
although different thresholds for the area or thickness of the noncompaction are 
used. In practice only echocardiographic and MRI criteria are used. Currently, the 
most frequent used criteria on echocardiography are the Jenni criteria (20). 
 The Jenni criteria for NCCM are composed of four echocardiographic features: 
1. an excessively thickened left ventricular myocardial wall with a two-layered 
structure consisting of a compact epicardial layer (C) and a noncompacted 
endocardial layer (NC) of prominent trabeculations and deep intertrabecular 
recesses; 2. an end-systolic NC/C ratio > 2, measured at the parasternal short axis; 
3. Color-Doppler evidence of ventricular perfused intertrabecular recesses; 4. 
absence of coexisting cardiac anomalies (21). The fourth feature however is under 
debate since congenital heart defects occur frequently in NCCM patients and 
there is no convincing evidence for this exclusion (22). In fact, some specific defect 
in sarcomere genes have been associated with distinct congenital heart defects 
(i.e. and Ebstein anomaly) in NCCM patients (23). Also defects in genes associated 
with heart development in NCCM patients with a congenital heart defect indicate 
otherwise (24). 
For MRI diagnostics the Petersen criteria are most widely used (20). The Petersen 
criteria were based on only seven patients with NCCM and require a noncompacted/
compacted ratio (NC/C) of >2.3, measured in end-diastole to diagnose NCCM (25). 
So far the diagnosis of NCCM is solely based on imaging of trabeculation of left 
ventricle, without taking into account clinical, genetic or functional parameters.
The sensitivity of the echocardiographic and CMR imaging criteria is under 
debate since it is apparently not uncommon that healthy people (without a 
cardiomyopathy) meet the current diagnostic criteria for NCCM. Overdiagnosis 
may occur, as some studies suggested with up to 43% of the general population 
meeting the current diagnostic criteria as discussed below (16, 17, 26-29). Images 
of papillary muscles and false tendons can easily be mistaken for trabeculation, 
therefor these features may be diagnosed erroneously as NCCM. Further issues 
complicating the diagnosis of NCCM are poor agreement between different imaging 
criteria (30, 31), and poor inter-observer agreement between NCCM specialist. One 
study showed that observers agreed in 65% of the cases. After reviewing discordant 
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cases, still no consensus was achieved resulting in an ambiguous/ questionable 
diagnosis in 11% (32). 
Epidemiology
Prevalence of  NCCM 
The exact prevalence of NCCM in the general population has not been established. 
However, estimates of prevalence of NCCM have been presented for specific groups 
of cardiologic patients. Estimates of the prevalence among patients undergoing 
echocardiography ranges from 0.014% to 1.3% (33-37). The prevalence is much 
higher (3.7%) when selecting patients with left ventricular systolic dysfunction and 
further increases when patients with left ventricular dilatation (6.8%) were selected 
(35, 37). The estimated prevalence of NCCM in patients with left ventricular systolic 
dysfunction on echocardiography ranged from 3% to 24% (31, 38). The difference in 
estimated prevalence may be explained the selection of the study population; one 
study excluded the diagnosis NCCM when patients had another cardiac diagnosis, 
i.e. HCM, DCM, coronary artery disease, hypertension. Whereas the study with 
the high prevalence included all patients suffering from left ventricular systolic 
dysfunction and presented the measured NC/C ratios in this group of patients. 
In patients referred for cardiac MRI the prevalence of NCCM ranged from 3 to 39 
percent depending on the applied diagnostic criteria (30). In this population 39% 
of the patient met the Petersen criteria, the most widely used diagnostic criteria 
on MRI. Prevalence according to the other criteria was: Jacquier 25%, Stacey 
23% and Captur only 3%. The large discrepancy in diagnostic yield between the 
different diagnostic criteria, each with their own specificity, shows that there is a 
need for more reliable, improved diagnostic criteria. In large cohorts of pediatric 
cardiologic patients, estimated prevalence of NCCM was 9% and NCCM was 
the third most frequent cardiomyopathy, after DCM and HCM (39). Since some 
patients with NCCM may be asymptomatic, and in some patients signs of NCCM 
are only detected by MRI without sufficient echo graphic features, the prevalence 
estimations relying on echocardiography, underestimate the true prevalence in 
the general population. On the other hand, patients referred for cardiac MRI may 
be more likely to have cardiac pathology with left ventricular dysfunction, which 
may lead to an overestimation of the prevalence of NCCM.
Prevalence of  hypertrabeculation in healthy population
Four large population-based studies were designed to establish the occurrence 
of hypertrabeculations in the general population (16, 17, 28, 29). These studies 
showed that 14.8% to 43% of the study populations were meeting diagnostic 
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criteria for NCCM on MRI. The large differences between these studies and the 
fact that prevalence was similar to that in cardiac patient referred for cardiac 
MRI, remains difficult to explain. As discussed above, this may be the result of 
the lack of specificity of the current diagnostic MRI criteria for NCCM. Endorsing 
that more accurate diagnostic criteria for NCCM are needed, preferably 
including besides the imaging, also functional and genetic parameters. There 
may be an effect of ethnicity on prevalence of hypertrabeculation, which may 
have influenced the results (17, 29, 31, 40). Based on these observations one may 
conclude that high prevalence of hypertrabeculation in the population indicates 
that hypertrabeculation could be an anatomical phenomenon. In our point of view, 
the validity of this interpretation is questionable, given the broad heterogeneity 
of the phenotype, as will be discussed below (17, 29). Interestingly, in addition, 
two of the population-based studies suggested an effect of hypertrabeculation 
on heart function or vice versa, since decreased left ventricular function was 
associated with the extent of hypertrabeculation (16, 28). In addition, the other 
two studies suggested that signs of hypertrabeculation might be associated with 
LV functioning. In the study of Weir-McCall et al. (17) patients meeting more 
imaging criteria for NCCM had also a significantly lower left ventricular ejection 
fraction, indicating the presence of cardiomyopathy in some of these seemingly 
healthy individuals (20). In the study of Zemrak et al. (29) the cohort was divided 
by level of trabeculation into quintiles. Similar risk of major adverse cardiac 
events was observed in the cases with high (>2.46) noncompacted/compacted 
ratios (quintile 5) and cases with lower levels of trabeculations (≤2.0, quintile 1-3). 
The conclusion was that hypertrabeculation had no impact on cardiac outcome. 
In this study however, the group with high (>2.46) noncompacted/compacted 
ratios had significantly lower incidence of cardiovascular risk factors like obesity, 
hypertension and diabetes. These factors are predictors for adverse cardiovascular 
events. Correcting outcome for these risk factors could have led to an association 
between major adverse cardiac events and hypertrabeculation (>2.46), concluding 
the opposite of the paper (41). In line, a more recent study conducted with cases 
from the same MESA cohort, higher rates of trabeculations were associated with 
worse myocardial strain and outcome (42). 
Other studies focused on the occurrence of hypertrabeculation in athletes 
with excellent cardiac function. Two studies estimated that the prevalence of 
hypertrabeculation in athletes ranged from 1.4% to 21% (26, 27). Caselli et al. (26) 
used the Jenni criteria on echocardiography and detected hypertrabeculation in 
1.4% of athletes, whereas Luijkx et al. (27) used the Petersen criteria on MRI and 
detected hypertrabeculation in 21% of the athletes. These observations may lead 
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again to the conclusion again that better diagnostic criteria are needed to diagnose 
NCCM accurately. 
Pathology
Reports on macro – and microscopic characteristics of NCCM are scarce and 
have been summarized comprehensively by Stöllberger and Finsterer (43). The 
macroscopic characteristic of NCCM is a two-layered myocardium, with an 
endocardial layer containing excessive trabeculations and an epicardial layer 
comprised of compact myocardium (figure 1). This hypertrabeculation affects 
primordially the apical and the midventricular inferior and lateral wall of the left 
ventricle (43). The two-layered structure is better visible on short axis cuts (43). 
The ratio of noncompacted/compacted myocardium in different reports may vary 
from 0.6 to 5.0 in short axis (44, 45). However, also on pathologic examination 
it remains difficult to distinguish papillary muscles from hypertrabeculation. 
Also left ventricular aberrant bands and false tendons can easily be confused 
with trabeculations (46, 47). Pathologic examination of long axis cuts may help 
to differentiate between trabeculations and papillary muscles and between 
trabeculations and muscle bands. Indicating that additional information like 
genetic and functional data may help interpreting the macroscopic pathology 
examination.
Microscopic reports of NCCM showed that the trabeculae in NCCM were covered 
with endocardium and were not communicating with the coronary arteries (43). 
Interstitial fibrosis (81%) and endocardial or sub-endocardial fibrosis or fibro-
elastosis (63%) were the most frequent histopathological findings (43). In eight 
pathology studies in which fibrosis was described cardiac MRI was performed and 
6 showed late gadolinium enhancement (43). Interstitial fibrosis may be the result 
of dysregulation of the myocardium in ischemia, degeneration, inflammation or as 
a reaction on mechanical stress in chronic pressure overload (48). The interstitial 
fibrosis in HCM consists of predominantly of collagen I fibers and is probably 
resulting from mechanical stress induced upregulation of TGF-beta signaling and 
related pathways (49). Since inflammation and atherosclerosis are rare in NCCM 
(43), mechanical stress either by failing sarcomere function or overload may be 
the main mechanism underlying fibrosis. Since the examined heart tissues are 
usually from patients with the most advanced stages of heart failure, it is difficult 
to draw conclusions about the general pathological mechanisms in NCCM based 
on pathological features. Hypertrophy (47%) and disarray of cardiomyocytes (15%) 
was also frequently described in NCCM, these are the hallmark s of HCM (43). 
14
Introduction
These findings highlight overlapping phenotypes in cardiomyopathies. 
To date pathologic exams of only five NCCM patients with a known genetic cause 
have been presented. One study reported on an autosomal dominant inherited 
mutation carrier of the ACTC gene and on a patient with an autosomal recessively 
inherited mutation in FKTN (50, 51). The patient with the ACTC mutation had 
besides NCCM also an atrial septal defect. The cardiac coupes of this patient showed 
trabeculations, fibrosis and disarray (50). The patient with the FKTN mutation had 
elevated creatine kinase levels, but did not have muscle weakness. The patient 
had left ventricular dilatation with prominent trabeculations. Microscopically 
the patient had prominent fibrous band separating the noncompacted from the 
compact myocardium. The compact myocardium showed myocyte disarray and 
anisonucleosis with mild interstitial fibrosis (51). Another study reported on a heart 
of a patient with an autosomal dominant inherited mutation in the MBL gene. 
However the association of NCCM with the MBL gene, which has an role in innate 
immunity, is questionable as this gene is hardly expressed in cardiac tissue (52). 
One third report concerned a Duchenne muscular dystrophy patient with NCCM 
who had a mutation in X-linked DMD gene (46). In this report the compacted 
layer consisted of fibrous tissue and some normal and dystrophic cardiomyocytes, 
while the noncompacted layer consisted of little fibrous tissue in which no 
dystrophic cardiomyocytes were detected (46). Finally, one NCCM patient with 
a rare variant in the mitochondrial gene MT-CO3 was reported (53). The patient 
with the variant in MT-CO3 gene was identified in a study of six NCCM patients 
who underwent cardiac transplantation. These hearts of these 6 transplantation 
cases were compared to 20 control hearts without a history of heart disease. The 
NCCM myocardium specimens had significant lower mitochondrial DNA content 
in myocardium and morphological abnormalities of mitochondria (53). Additional 
evidence is needed to establish whether these mitochondrial features may help 
to distinguish histologically NCCM and may shed novel insights on the etiology 
of NCCM. Regarding hereditary NCCM no specific pathologic findings can be 
observed. 
In
tr
od
uc
ti
on
15
Genetics
Since DNA diagnostics for cardiomyopathies were introduced around 20 years ago, 
there have been major changes in the assessment in the effect of genetic variants. 
Before the start of this thesis and before the introduction of the latest stringent 
variant classification, sarcomere mutations were reported in 17% to 41% of NCCM 
patients (7, 54). These variants however were classified using different classification 
for pathogenicity than the classification system used nowadays. The currently 
widely applied and accepted sequence variant classification system is that from 
the American College of Medical Genetics and Genomics (55). This classification 
system classifies variants into classes 1 to 5. Class 5 includes variants with the 
highest likelihood of being pathogenic, while class 1 includes most likely common 
innocent genetic variants. This classification is based on population frequency, in 
silico prediction tools and functional evidence. With the advancing knowledge of 
Figure 1 : Short axis fresh autopsy specimen showing hypertrabeculation.
NCCM Patient from the Erasmus Medical Center with two mutations in MYBPC3 (c.932C>A, 
p.Ser311* and c.442G>A, p.Gly148Arg) who had a cardiac transplant at the age of 23 years. The 
explanted heart was 400g, with dilatation of the left ventricle, marked hypertrabeculation and 
interventricular septum width of 9 mm. Microscopie showed hypertrophied and architectural 
disarray of cardiomyocytes with anisonucleosis and polychromasia of the cell nuclei. At the site 
of the macroscopic hypertrabeculation, round oval clusters of cardiomyocytes encircled with sub-
endocardial fibrosis. Interstitial low to moderate levels of fibrosis was observed. Mainly the left 
ventricle showed degenerative changes with ischemic changes including hyper-eosinophilia and 
contraction band necrosis. Mild atherosclerosis was present.
16
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genetic variants and the wider application of DNA testing, refinement of variant 
classification will continue. As an example, the effect of variant reclassification 
was presented in a recent comprehensive study, reclassifying missense variants 
reported in NCCM studies, showing that 46% of the previously reported mutations 
could be regarded as benign or as variants of unknown clinical significance (56). 
Current practice is that large cardiomyopathy gene panels consisting on more 
than 50 genes are analyzed. However, as a review of prevalence of genetic defects 
in cardiomyopathy population showed, for some genes there is little evidence for 
association based on population frequency and may lead to more selective DNA 
testing (57). Overall, improved variant classification, identification of novel genetic 
causes will help to improve diagnosis of genetic NCCM.
Aim and outline of  this thesis 
NCCM is a genetically and phenotypically heterogeneous cardiomyopathy and 
still not completely understood. To establish the genetic spectrum, and draw valid 
conclusion on genotype-phenotype correlations, a large study population was 
needed. We performed a multi-center study as presented in chapter 2. In chapter 
3 we investigated the different left ventricular phenotypes of NCCM and the 
prevalence of familial disease. In chapter 5 we used the literature to confirm the 
findings of chapter 2 and 3. To establish phenotypic differences between genetic 
and sporadic patients using cardiac MRI we performed a study presented in 
chapter 4. In chapter 6 we broaden the genetic spectrum of NCCM. Concluding 
that this thesis focused on the following issues:
- What proportion of NCCM patients have a genetic cause.
- Are there phenotypical and clinical differences between genetic and sporadic NCCM 
- Do NCCM genotypes correlated with distinct phenotypes and cardiac risks. 
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Abstract
In at least half the patients diagnosed with noncompaction cardiomyopathy 
(NCCM) genetics plays an important role. In familial NCCM, like in other inherited 
cardiomyopathies, timely identification and treatment of relatives at risk is important. 
This chapter focusses on the process of identifying a genetic cause, predicting risk for 
relatives, and informing index cases and relatives on subsequent recommendations 
for family screening.
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Introduction
Noncompaction cardiomyopathy (NCCM) is characterized by endocardial 
hypertrabeculation of the myocardium of the left ventricle. In 1997 the first genetic 
cause for NCCM, a mutation in the X-linked TAZ gene, was identified in a family 
were six boys had Barth syndrome with hypertrabeculation of the left ventricle 
(6). The link of familial NCCM to defects in the sarcomere genes previously 
been linked to the more frequent hereditary hypertrophic (HCM) and dilated 
cardiomyopathies (DCM), came in 2007 by the report of MYH7 mutations in 
NCCM and was followed by reports of other sarcomere gene mutations in familial 
NCCM (figure 1) (7, 58). 
Figure 1: Pedigree of family with a MYH7 mutation.
Pedigree of family A. The proband is indicated by the arrow. ND, not determined; OC, obligate 
carrier; +/−, heterozygous for the p.Leu301Gln MYH7 mutation; −/−, p.Leu301Gln absent. The figure 
was adapted from Hoedemaekers YM et al. Cardiac β-myosin heavy chain defects in two families 
with non-compaction cardiomyopathy: Linking non-compaction to hypertrophic, restrictive, and 
dilated cardiomyopathies. Eur Heart J. 2007;28(22):2732-7.
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In NCCM the sarcomere genes are the most prevalent genetic causes. More recently 
the introduction of next generation sequencing (NGS ), allowing simultaneous 
analysis of panels of 50 or more cardiomyopathy genes, showed that around 35% 
of NCCM patients have a mutation, and that mutations occur more frequently in 
children diagnosed with NCCM than in patients diagnosed as adults (8, 10). 
Overall, approximately 50% of NCCM patients are considered to have a genetic 
cause (8). Some because they have inherited a mutation in a cardiomyopathy 
gene, other patients have family members with a cardiomyopathy without 
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having a mutation in a known cardiomyopathy gene. In 45% of familial NCCM 
no mutation can be identified (8), indicating that many genetic causes for NCCM 
are still unknown. Overall, around 50% of cases diagnosed today with NCCM 
have no mutation in a cardiomyopathy gene or familial disease. In these -mostly 
adult patients- NCCM may be attributed to non-genetic, secondary causes for 
hypertrabeculation. Alternatively, these cases may have yet unknown (complex) 
genetic cause(s) carrying small risk for relatives (8). For NCCM, like for HCM and 
DCM, it is important for relatives of patients to be informed about the increased 
risk of having a cardiomyopathy. 
For that reason referral of patients diagnosed with NCCM for genetic counseling, 
has become common practice (59). This allows, by taking family histories 
and performing DNA testing of the index case, to estimate the risk of having a 
cardiomyopathy for relatives. When there is a mutation, DNA testing for the 
familial mutation of first degree relatives is advised, with subsequent cardiologic 
screening of mutation carriers. In NCCM, the specific genetic defects may predict 
risk of having severe cardiac events (MACE). Some genes, like MYH7, carry lower 
risk for MACE than other genes. In this perspective DNA testing may help stratify 
risk for MACE of patient and relatives and help guide clinical management 
of genetic NCCM accordingly (8). For families of patients without a mutation, 
cardiologic screening of first degree relatives is recommended, also in absence of 
a family history of cardiomyopathy, because we cannot exclude that these patients 
may have an unknown genetic predisposition with low penetrance that conveys a 
small risk to relatives. 
The aim of this chapter is to give an overview of the genetic causes for NCCM, and 
describe the routine of genetic diagnostics i.e. genetic counseling, DNA testing and 
initiating family screening. Illustrating in this way the importance of integrating 
genetic diagnostics to clinical management of NCCM patients by conveying 
appropriate information to patients and their families, in order to make early 
diagnosis and timely treatment accessible for the families of all NCCM patients. 
The genetics of  NCCM 
Genetics plays a more important role in some patients with hypertrabeculation of 
the left ventricle than in others. Currently three main categories of genetic burden for 
noncompaction are recognized (figure 2). 1) Patients with a genetic noncompaction 
cardiomyopathy. These are the patients with a mutation in a cardiomyopathy 
gene and/or relatives with a cardiomyopathy (familial cardiomyopathy). In genetic 
NCCM relatives have an increased risk of having a cardiomyopathy. In 45% of 
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familial NCCM no mutation is found (8). The majority of the genes associated with 
NCCM also play an important role in genetic hypertrophic (HCM) and dilated 
cardiomyopathy (DCM) (19, 54). For now, there is no explanation how overlapping 
genetic defects in these sarcomere genes cause the spectrum of phenotypes 
ranging from hypertrophic, dilated and noncompaction cardiomyopathy. 2) 
Cardiomyopathy patients with noncompaction without a genetic cause; in these 
‘sporadic’ NCCM cases no evidence for a genetic cause is found by DNA analysis, 
and the family history and/ or family screening are uninformative. These patients 
have similar cardiac outcomes as genetic NCCM patients. In sporadic patients 
NCCM may be the result of pathologic cardiac remodeling, activated by other 
(now unknown genetic or non-genetic) causes leading to hypertrabeculation. In 
these patients high incidences of left bundle branch blocks were identified (8). 
Also cardiac comorbidities like hypertension may play a role in these patients 
(8). We cannot exclude that apparently sporadic patient may have defect in a 
yet unknown cardiomyopathy gene, since not all cardiomyopathy genes have 
been identified yet. We know that at least one third of the NCCM patients with a 
mutation in a cardiomyopathy gene, did not report familial disease, indicating that 
negative family history does not exclude a genetic cause (8). Another possibility is 
that a group of apparently sporadic NCCM patients may have variants in known 
or unknown cardiomyopathy genes that have insufficient genetic effects and need 
additional interaction with other genetic or non-genetic factors to cause NCCM. 3) 
Healthy individuals with a benign LV hypertrabeculation; large population based 
studies have reported that LV hypertrabeculation may occur as frequently as in 
43% of the healthy adult population (60). A higher susceptibility for having more 
prominent trabeculations, without features of a cardiomyopathy was reported in 
blacks and athletes (27, 61). The cause might be a genetic or epigenetic regulation 
of gene expression or translation, activating similar pathways as mutations in 
sarcomere genes, causing hypertrabeculation without cardiomyopathy. The high 
incidence of hypertrabeculation supports that the currently used echo and MRI 
diagnostic criteria, relying on the ratio between noncompacted and compacted layer 
of myocardium, cannot distinguish pathologic noncompaction cardiomyopathy 
from benign, sometimes reversible, left ventricle hypertrabeculation without 
cardiomyopathy and therefore more sensitive diagnostic criteria are needed.
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NCCM genes
In familial NCCM around 55% of NCCM patients have a mutation, indicating that 
the genetic cause has not been found for a large proportion of familial NCCM 
(8). In children and in adult patients the majority of the mutations occur in genes 
encoding for proteins of the cardiac sarcomere structure and function (figure 3) 
(8, 10). Less frequent genetic causes for NCCM are defects in genes encoding for 
intracellular signaling, homeostasis and cytoskeletal integrity associated with 
NCCM (62). Genetic causes are identified more frequently in patients diagnosed in 
childhood than in adults with NCCM (8). In figure 4 the frequency of all mutations 
reported in the literature are summarized. These observations show how little 
we understand about the development of the hypertrabeculation, because they 
suggest that the genetic effects might involve cardiac development as well as 
cardiac remodeling at older age. 
Figure 2 : Etiology of NCCM.
From the myocardial phenotype of LVNC to noncompaction cardiomyopathy, pathologic or 
physiologic reversible remodeling. LVNC: left ventricular noncompaction, NCCM: noncompaction 
cardiomyopathy. The figure was adapted from Oechslin E, Left Ventricular Noncompaction: From 
Physiologic Remodeling to Noncompaction Cardiomyopathy. J Am Coll Cardiol. 2018;71(7):723-6.
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Genes for autosomal dominant inherited NCCM 
Defects in sarcomere genes are the most common genetic cause for NCCM 
(figure 3) (8, 10). These forms of NCCM have an autosomal dominant inheritance 
pattern. Patients (usually) inherited the mutation from one of the parents. Siblings 
and offspring of these patients have a 50% risk of having inherited the familial 
mutation. Reduced penetrance is a well-known feature of sarcomere mutations in 
genetic cardiomyopathies (63), meaning that for unknown reasons, around 30% 
(the percentage may vary by gene and variant) of the carriers (i.e. relatives with the 
familial mutation) do not have a cardiomyopathy. In a small proportion (4%) of 
the patients the mutation has occurred de novo (8, 64). In that case the mutation is 
not inherited from the parents and there is no increased risk for siblings, although 
risk for offspring of having the mutations remains 50%. Compound heterozygosity 
for sarcomere mutations, occurs when a patient inherited a (different) mutation 
from each parent. This is not uncommon, since sarcomere mutations are relatively 
frequent in the population (65). Patients with two sarcomere gene mutations 
may have more severe clinical features than their relatives with single mutations 
(66). In NCCM the most frequent genetic causes (71%) are defects in sarcomere 
genes: MYH7 (58), TTN (67) and MYBPC3 (8, 68). Less frequently (11%) affected are 
the other sarcomere genes: ACTC1 (69), LDB3 (70), TNNC1 (71), TNNI3 (72) and 
TNNT2 (73). Rare genetic causes are the other autosomal dominantly inherited 
cardiomyopathy genes HCN4 (74), KCNH2 (75), KCNQ1(76), RYR2 (77) and SCN5A 
Figure 3 : Genetics of NCCM.
Darker shades indicate complex genotypes. DNA testing of approximately 45 cardiomyopathy genes 
and family histories showed that children were more likely to have a mutation (p=0.036). TTN 
occurred only in adult cases. Complex MYBPC3 genotypes occurred only in children (teal). The 
figure was adapted from van Waning JI, et al. Genetics, Clinical Features, and Long-Term Outcome 
of Noncompaction Cardiomyopathy. J Am Coll Cardiol. 2018;71(7):711-22.
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(78), involved in ion transport and genes affecting other cardiomyocyte functions 
or structure like, DSP (79), LMNA (80), MIB1 (81), MIB2 (82) and PLN (8), occurring 
altogether in approximately 6% of the patients (8, 10). 
Genes for X-linked inherited NCCM 
Defects of genes on the X chromosome affect only males and are inherited in an 
X-linked pattern. With this type of inheritance sons of unaffected female carriers 
have 50% risk of being affected. Daughters of patients or of female carriers have 50% 
risk of being an (unaffected) carrier and transmitting the trait to their sons. Barth 
syndrome is caused by defects in the TAZ gene on the X chromosome (6). Among 
the other X-linked causes for NCCM are some genes causing neuromuscular 
disorders; DMD (83), FHL1(84), GLA (85), LAMP2 (86),and rare neurodevelopmental 
Figure 4: Prevalence of mutations in the literature.
Genetic noncompaction cardiomyopathy. Other sarcomere genes: ACTN2, DES, LDB3, MYL2, 
NEBL, OBSCN, TNNC1, and TNNI3. Other arrhythmia genes: ABCC9, ANK2, CACNA2D1, CASQ2, 
KCNE3, KCNH2, and KCNQ1. Non-sarcomere, non-arrhythmia-cardiomyopathy genes: DMPK, DSP, 
DTNA, FKTN, HFE, JUP, LMNA, PKP2, PLEC, PLN, PRDM16, RBM20, and SGCD. Other X-linked 
genes: DMD, FHL1, GLA, LAMP2, and RPS6KA3. Other genes associated with CHD:MIB2, NKX2.5, 
NOTCH1, NSD1, PTPN11, TBX20, and TBX5. Mitochondrial-functioning: HADHB, HMGCL, MIPEP, 
MLYCD, MT-ATP6, MT-CO1, MT-CO3, MTFMT, MT-ND1, MT-ND2, SDHA, SDHD, TMEM70, and 
VARS2. The figure was adapted from van Waning JI, et al. Meta-analysis of the genotype- phenotype 
correlation in noncompaction cardiomyopathy. J Am Heart Assoc. 2019 Dec 3;8(23):e012993.
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disorders caused by mutations in the NONO (87), and RPS6KA3 (88) genes. 
Genes for autosomal recessive inherited NCCM
Recessive inherited NCCM is rare and was reported in single childhood cases with 
inborn errors of metabolism, related to a FKTN (51) or SDHD (89) mutation.
Mitochondrial defects and NCCM
Mitochondrial disorders are caused by defects in the mitochondrial (Mt) DNA or 
by a defect in nuclear DNA genes encoding mitochondrial structure or functioning. 
Defects in Mt genes are passed on cytoplasmatically in germ cells from mother to 
child. Defects in nuclear genes have dominant, recessive or X-linked inheritance 
pattern. Mutations in genes affecting the mitochondrial functioning lead to 
insufficient energy production required in various organs, particularly those 
with high energy demands, like the central nervous system, skeletal and cardiac 
muscles. These disorders present with a wide spectrum of clinical features 
including cardiomyopathy, visual impairment, deafness, stroke, epilepsy and 
diabetes. Mt genes linked to NCCM are MT-ATP6, MT-ATP8, MT-CO1, MT-CO3, 
MT-CYB, MT-ND1, MT-ND2 and MT-ND6 (90, 91). Nuclear genes coding for the 
mitochondria linked to NCCM are DNAJC19 (92), GARS (93), HADHB (94), MIPEP 
(95), MTFMT (96)and NNT(97). To find Mt gene defects a specific analysis of the Mt 
DNA and nuclear DNA is needed, since these genes are not routinely sequenced in 
NGS cardiomyopathy gene panels. 
Chromosomal defects
A number of chromosomal deletions and duplications have been associated 
with NCCM. These chromosomal defects are usually identified in children. 
Because they affect multiple genes they lead to complex congenital malformation 
syndromes. The 1p36 deletion syndrome is frequently reported presenting with 
NCCM, intellectual disability, delayed growth, hypotonia, seizures, limited speech 
ability, hearing and vision impairment and distinct facial features (98). Other 
chromosome anomalies linked to NCCM are deletions of 1q (99), 5q35 (100), 
8p23.1 (101), 22q11 (102) and Xq28 (103). In addition NCCM has been observed in 
monosomy X (Turner syndrome) (104), trisomy 13 (105), trisomy 18 (106), trisomy 
21 (107) and trisomy 22 (108) patients. To detect a small chromosome anomaly, an 
array analysis has to be performed, since these defects are not recognized by NGS 
sequencing of cardiomyopathy genes. 
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Genetic Counseling and Genetic diagnosis of  NCCM 
Genetic counseling is recommended for all patients fulfilling diagnostic criteria 
for NCCM to perform DNA analysis and detect familial disease. This information 
is needed to estimate risk for relatives, convey information on the risks to index 
cases and their families and subsequently initiate family screening. Like in HCM 
and DCM family screening for NCCM is recommended because it allows accurate 
and timely diagnosis of NCCM improving prognosis of patients in the family. To 
initiate genetic diagnostics for NCCM, index patients are counseled about the 
consequences of the results of DNA testing, and an informed consent for DNA 
testing is requested. 
Genetic counseling involves communicating the goal of genetic testing and the 
explaining the importance of informing family members. Genetic counselors are 
trained to explain the clinical features of the disease and the inheritance pattern, 
to the index case and organize informing and screening family members. Genetic 
counseling has grown out of the need to personalize scientific information and 
to translate it into a user-friendly language that is accessible intellectually and 
emotionally for the patient and its family. Helping index cases and their relatives 
– if necessary-to handle the information on heredity, and discuss the subsequent 
risks and consequences, is an important part of the process of genetic counseling. 
The routine for genetic diagnosis and family screening for NCCM is summarized 
in figure 5. It is hereby the role of the genetic counselor to identify and help, 
during pre- and post-test counseling, coping with adverse feelings that some 
patients or relatives may experience like distress, anxiety or guilt, evoked by the 
possibility of a genetic cause for NCCM (109). It is important, in particular for 
asymptomatic relatives, to discuss that having a genetic risk and having a choice 
of predictive testing, whether by DNA analysis or cardiologic exam, may have 
medical implications, as well as psychological and socio -economic consequences. 
The genetic counselor may offer access to specialized psychologic support when 
needed by families.
Family history
At the departments of clinical genetics information on the occurrence of 
cardiomyopathies in the family of NCCM patients is obtained, and medical 
records of affected relatives are retrieved for verification of the diagnosis, when 
possible. Family history taking helps to determine if cardiomyopathy is familial 
and to identify the mode of inheritance (110). It is importance to acknowledge that 
an uninformative family history cannot completely exclude a genetic cause for 
NCCM. Because around 20% of NCCM patients without affected relatives may still 
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Figure 5: Family screening if a cardiomyopathy is identified at all ages.
*Presymptomatic DNA testing for relatives above 18 years. Cardiac screening for relatives from 10-12 
years, without DNA testing. In blue: at the clinical genetics department. In red: at the cardiology 
department. CMR: cardiac magnetic resonance imaging.
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have a mutation (8). The reasons for underreporting of familial cardiomyopathy 
might be that affected relatives might not have been diagnosed with NCCM. It 
is known that approximately 30% of the NCCM patients have a cardiomyopathy 
without the typical symptoms of cardiomyopathy at time of diagnosis (111). Also, 
like in HCM, non-penetrance occurs in around 30% of the carriers of a familial 
(sarcomere) mutations and these carriers do not have a cardiomyopathy (111). 
Another explanation for underreporting familial disease may be that family 
histories are not informative when families are small or patients have little 
information on relatives. Important questions when taking a family history 
for the purpose of establishing whether there is a familial cardiomyopathy is 
asking if relatives have had heart failure, arrhythmias, accidental or unexpected 
deaths, thromboses (including stroke), any kind of cardiac surgery, or if they had 
a congenital heart defect or neuromuscular disease. When family screening is 
performed the family histories are adjusted according to the results of the DNA 
and cardiac screening of relatives. 
DNA testing for NCCM
The purpose of DNA testing - irrespective of the age of the patient - is to identify 
the genetic cause for NCCM (8, 112). An important aspect of DNA testing is that 
finding a mutation allows asymptomatic relatives to have a predictive DNA test 
that identifies accurately which relatives have a mutation and have an increased 
risk of developing a cardiomyopathy. In this way identifying the causative mutation 
facilitates genetic cascade screening. In families with a mutation, relatives who do 
not carry the familial mutation can be excluded from regular cardiac follow-up 
and can be reassured that there is no increased risk for their offspring. DNA testing 
may help to confirm the diagnosis for patient with borderline features of NCCM. 
In addition as we have shown recently, the genotype (specific genetic defect) may 
help to predict risk for ventricular systolic dysfunction and major cardiac adverse 
events for patients and guide clinical management accordingly (8), as discussed in 
more detail below in the paragraph on genotype-phenotype correlations. 
NGS Cardiomyopathy gene panels
Since a large number of genes are involved in NCCM, the application of novel 
methods of DNA analysis like NGS and exome based testing improved the yield 
of genetic testing with the simultaneous analysis of panels with large numbers of 
cardiomyopathy genes (3). Current cardiomyopathy gene panels used in diagnostic 
and commercial laboratories may include the following genes: ABCC9, ACTC1, 
ACTN2, ANKRD1, BAG3, CALR3, CRYAB, CSRP3, DES, DMD, DSC2, DSG2, DSP, 
EMD, GLA, JPH2, JUP, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, 
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MYL2, MYL3, MYPN, MYOZ1, MYOZ2, PKP2, PLN, PRKAG2, RBM20, RYR2, SCN5A, 
SGCD, TAZ, TCAP, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN and VCL (in bold 
the genes that were associated so far with NCCM). These genes encode proteins 
constituting structure and function of the sarcomere, cytoskeleton, desmosome, 
ion channels or nuclear lamina, and proteins participating in calcium (Ca2+) 
handling during contraction phase of action potential of the cardiomyocyte 
or affecting cardiac energy metabolism and are related to a large spectrum of 
cardiomyopathies. In case a cardiomyopathy gene panel is not available, DNA 
testing for NCCM of a smaller number of genes including MYH7, MYBPC3 and 
TTN, which have a large proportion of the genetic defects in NCCM, is advised. 
Gene variant classification system
For a correct interpretation of the results of DNA analysis stringent novel guidelines 
for classification of genetic variants are applied since 2015 (113). The outcome of DNA 
analysis for clinical purpose are currently classified into pathogenic variants (PV), 
likely pathogenic variants (LPV), variants of unknown clinical significance (VUS), 
likely benign or benign variants. This classification system for variants is based on 
in silico prediction of pathogenicity, population frequencies and previous reports 
providing (functional) evidence of the pathogenic nature of the specific variants (55). 
Variants classified as PV or LPV in sarcomere genes are usually nonsynonymous 
substitutions or deletions of a nucleotide classified as missense, nonsense, or 
frameshift mutations and have a deleterious effect on the protein. Older results 
of DNA testing, without current classification, should be re-evaluated, because 
some of the variants previously reported as (pathogenic) mutations may now be 
reclassified as not pathogenic. Application of novel classification system to a large 
number of variants in sarcomere genes in NCCM patients showed recently that 
50% of variants previously reported to be pathogenic, were reclassified as VUS or 
benign variants (56). Similarly a large proportion of variants reported previously as 
mutations in sarcomere genes in HCM patients, were reclassified recently as VUS 
or benign variants (57). This endorses that the continuous surveillance of variant 
classification is needed, because new evidence on DNA variants like population 
frequencies, results of novel functional tests or in silico predictor tools becomes 
available(57). DNA testing of pre-symptomatic family members is only indicated 
when there is a PV or LPV in the family. Since the effect of VUS is not known, 
these variants cannot reliably predict risk for NCCM in relatives and therefor 
these variants are not of used for family screening.
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DNA testing of  NCCM patients with Congenital Heart Defect, neuromuscular 
disease or NCCM with multiple congenital anomalies syndrome
Around 10% of NCCM patients have a concomitant congenital heart defect (CHD) 
(22). Some families with NCCM and Ebstein anomaly, have a mutation in MYH7 
(23). There is little evidence that the combination of NCCM with other forms of 
CHD segregate in families or are caused by specific genetic defects. Thus it remains 
unknown if there are common (epi)genetic causes affecting embryologic cardiac 
development explaining the co-occurrence of NCCM and CHD, or that they co-
occur by coincidence. NCCM in some patients represent cardiac manifestations 
of inherited neuromuscular disorders, for which specific diagnostic gene panels 
need to be analyzed since these genes are usually not included in the regular 
cardiomyopathy gene panels (114). Also NCCM patients with multiple congenital 
malformations, usually children, need additional DNA testing and/ or chromosome 
analysis (array), according to clinical features. These tests may include screening 
for mitochondrial defects or metabolic disorders occurring predominantly in 
childhood NCCM. 
Family screening
Risk for cardiomyopathy in relatives 
Overall affected relatives of NCCM patients have less severe cardiac features than 
the index cases, and relatives of index cases with a mutation have more risk of 
having a cardiomyopathy than the relatives of cases without a mutation. Because, 
at diagnosis affected relatives have usually less attenuated cardiac symptoms 
than the index case, independent of age at diagnosis, since most relatives are 
asymptomatic (111). And some of the index cases without a mutation may have 
a non-genetic, secondary cause for NCCM, with low risk for relatives. The risk 
for relatives of having a cardiomyopathy is furthermore related to the genetic 
defect in the index case, the mode of inheritance, the gene specific penetrance 
and the chance of having asymptomatic disease. These factors and also the age 
at diagnosis of the index case may help to determine the genetic risk for relatives. 
Also family history of cardiomyopathy or sudden cardiac death in the family may 
add information about the genetic risk for relatives. It is important for relatives to 
know that carriers of a familial mutation may have no signs of cardiomyopathy 
at cardiologic examination. Non-penetrance was observed in 17% of carriers of 
familial MHY7 mutations, 33% of carriers of MYBPC3 and 28% of carriers of TTN 
mutations (111). Intra-familial variability of cardiac features is a well-known feature 
of familial cardiomyopathies. The left ventricle (LV) dimension of the NCCM index 
case may be a predictor for disease severity in relatives. The dimension of the LV 
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Figure 6: Classification of NCCM according to cardiac phenotype.
Classification of NCCM according to cardiac phenotype into isolated NCCM (51 index, 41 relatives), 
NCCM with DCM (84 index, 31 relatives) and NCCM with HCM (8 index and 1 relative) in 39 families 
with and 19 families without a mutation. Genotyping and family screening showed that isolated NCCM 
was linked to mutations in the head domain of MYH7 (p<0.001), isolated NCCM in relatives (p<0.001) 
and a lower risk for LV dysfunction (p<0.001). NCCM with DCM was linked to the MYH7 tail domain 
(p<0.001) and TTN and was associated with relatives with DCM without signs of noncompaction 
(p=0.002) and severe outcome (p=0.016). The HCM phenotype was linked to MYBPC3 in NCCM 
families (p<0.001) and HCM without signs of noncompaction in relatives (p<0.001). Factors reducing 
risk for relatives were absence of a mutation in index patients, non-penetrance of familial mutations 
or having asymptomatic disease. Underscoring that the NCCM phenotype of the index case and the 
genotype are important predictors of risk in relatives. The figure was adapted from van Waning JI et 
al. Cardiac Phenotypes, Genetics, and Risks in Familial Noncompaction Cardiomyopathy, J Am Coll 
Cardiol. 2019 Apr 9;73(13):1601-1611.
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in NCCM relatives corresponded significantly with the LV phenotype of the index 
case (figure 6). In addition, since the LV dimension in NCCM patients was related 
to the course of the disease, the LV function may predict severity for relatives. 
Patients with NCCM and normal LV-dimensions, as observed in approximately 
43% of the patients, had a mild course of the disease, with less frequent LV-systolic 
dysfunction or cardiac events. Patients with NCCM with a dilated LV-dimensions 
(like in DCM), occurring in approximately 53%, had a more severe disease course 
with frequent LV-systolic dysfunction and adverse events. The relatives these 
NCCM/DCM patients were more likely to have dilated LV. These patients were 
also more likely to have relatives with DCM without hypertrabeculation. In a small 
percentage of NCCM patients, (4%) there are concomitant signs of HCM. The 
relatives of the NCCM/HCM patients may have HCM without hypertrabeculation. 
In the families of NCCM patients, 20% of the affected relatives have HCM or DCM 
without signs of hypertrabeculation (111). In addition relatives of NCCM patients 
may have an increased risk for CHD, compared to population risk (111). 
Screening adult relatives of  NCCM patients 
In families with a causative mutation, adult relatives can be offered predictive DNA 
testing. Predictive DNA testing of relatives can reliably identify which relatives 
carry a mutation and have an increased risk of developing a cardiomyopathy and 
thus need clinical surveillance. In addition since genotype are linked to the cardiac 
features and the outcome, genotyping of the index patient may help predict the 
cardiac phenotype and the risk of having a severe cardiomyopathy for the whole 
family (111). Relatives who do not carry the familial mutation can be excluded from 
regular cardiac follow-up and also can be reassured that there is no increased risk 
for cardiomyopathy for their offspring. 
In families without a mutation, cardiologic family screening of first-degree relatives 
is recommended. Family screening can be initiated by asking the index patients 
to distribute a letter to their first and second-degree relatives with information 
on counseling for genetic risk for NCCM and recommendations for predictive 
DNA and/or cardiologic family screening. The legal framework for informing 
relatives varies. In most countries the index patient ( not the clinician) is expected 
to pass the information on genetic risk and screening to the family on behalf of 
the healthcare system (115). It is important that relatives consent and are correctly 
informed, before they are tested, about the risk of having a cardiomyopathy and 
about the eventual consequences when they are carriers of a familial mutation 
and/or signs of cardiomyopathy are detected at cardiologic exam. Diagnosis 
of a mutation or a cardiomyopathy, even when a relative is asymptomatic may 
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have medical, psychologically as well as socio- economically consequences. For 
instance regarding life insurance, pension, life style (sporting activities), and 
eligibility for fostering and adoption (116). Most relatives have no symptoms of 
cardiomyopathy and have not been diagnosed with a cardiomyopathy when they 
have a predictive DNA test or have the first cardiologic examination. The incentive 
for having a predictive test for some relatives is the wish to be in control of their 
life and gain clarity on the risk they and their offspring may be facing. For others, 
making a decision is more complicated and they prefer not knowing about the risk 
because they have a different perspective of the risk, giving the chance of being 
asymptomatic for years. A genetic counselor can help to guide in their decisions to 
have a pre-symptomatic test.
Screening young relatives for NCCM
Like in other age dependent hereditary cardiomyopathies, the recommendations 
for pre-symptomatic screening are not the same for adults and children. 
Cardiologic screening is usually recommended from the age that first symptoms 
may appear. For instance for HCM, cardiologic screening starts around 10-12 years 
for asymptomatic children with unknown genetic status (116). In practice these 
guidelines are followed for NCCM as well. In families with a mutation, predictive 
DNA testing in children is usually postponed until the age that they can make 
an informed decision. Because the medical benefit of pre-symptomatic DNA 
diagnosis of having a familial mutation has not been established for children. 
The main advantage of pre-symptomatic DNA testing of children is that when 
a familial mutation can be excluded the child can be discharged from life-long 
follow-up. In contrast, for the asymptomatic children who are found to be carriers 
of a familial mutation, recommendations include regular cardiologic follow-up 
and address life style, like refraining from competitive sports (116). The burden 
for children of regular hospital visits, may have adverse psychological like anxiety 
or depression and may harm a child’s self-esteem (117, 118). Another adverse effect 
of pre-symptomatic testing in children and adults alike are possible economic 
disadvantages like higher life insurance or mortgages later in life. For that reason 
predictive DNA testing for a familial mutation is usually performed in relatives 
above the age of 18 years. Clinical and/or genetic screening should be considered 
from younger age if the child has symptoms which can point to a cardiomyopathy 
or in families with a history of early-onset cardiomyopathy. 
Pregnancy and prenatal testing 
An important aspect of the counseling and cardiologic care of young women with 
NCCM is to inform patients that a pregnancy may carry a risk for themselves 
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as well as for their offspring. For women with NCCM, the maternal risk in 
pregnancy for developing heart failure and/or arrhythmias or severe post-
partum cardiomyopathy requires extensive follow-up during pregnancies as 
well as postpartum. Women with a cardiomyopathy who have symptoms before 
pregnancy have an increased risk and need specialized obstetric care (119). Women 
with asymptomatic cardiomyopathies usually tolerate pregnancy well and these 
women may have a spontaneous labor and vaginal delivery (120). NCCM patients 
have an increased risk of having a child with a cardiomyopathy. Depending on 
whether the patient has a mutation and the estimated risk for the child, prenatal 
diagnosis of NCCM (prenatal DNA testing and/or prenatal cardiac ultrasound of 
the fetus) can be discussed. Prenatal diagnostics for NCCM, however, are rarely 
requested, because the risk that a child has severe congenital NCCM is small, 
given that onset of symptoms of NCCM are age related, and patients/ carriers of 
mutations may not have symptoms. Unless there is an affected child in the family, 
in which case prenatal diagnostics for NCCM will be recommended. 
The individual options and limitations of prenatal diagnosis of NCCM are 
discussed with NCCM patients with reproductive wishes. Pre- and post-test 
counseling is necessary because risks and prenatal testing in these pregnancies 
may evoke anxiety in parents and they may need help to make far reaching 
decisions during the pregnancy. It is important to acknowledge the likelihood 
that testing may cause distress, meaning that steps should be taken to minimize 
distress and provide support, not that testing should be denied. 
For prenatal testing for NCCM the familial mutation is important. In families 
with a mutation, prenatal DNA testing can be performed. We have the choice of a 
DNA testing in chorionic villus sampling (conducted at 10-12 weeks of gestation) 
or amniocentesis (conducted at 14-20 weeks of gestation). The DNA test results are 
known within 2 – 3 weeks, well within the legal framework in most countries for 
terminating a pregnancy affected with a severe disorder. The parents need to be 
informed that these interventions carry a risk for the mother and fetus including 
miscarriage (121). If the child is shown to have the familial mutation that may 
causes (severe) childhood cardiomyopathy, parents may choose to terminate the 
pregnancy or have additional prenatal echocardiography for structural defects 
and assessment of cardiac function to detect a congenital cardiomyopathy (122). 
Prenatal cardiac sonography is performed in specialized tertiary prenatal centers, 
and allows to detect fetal cardiac malformations, cardiomyopathies, systolic and 
diastolic function and arrhythmia in the second –and third trimester of pregnancy. 
Prenatal cardiac sonography is also the method of choice for prenatal screening 
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of NCCM when there is no mutation in the family. A major limitation of prenatal 
sonography for NCCM is that little is known about the onset and prenatal 
development of NCCM, and we do not know in which NCCM patients we may 
and in which we cannot find prenatally signs of noncompaction and in which 
trimester the first cardiac signs of noncompaction be may observed. There are few 
reports, showing early prenatal onset of NCCM in cases with a MYH7 mutation 
(123). Since prenatal diagnosed NCCM may remain asymptomatic after birth, 
prediction of disease severity from the results of prenatal testing remains difficult 
(124). However, prenatal testing does have a role in assessment which pregnancy 
may need perinatal cardiac monitoring.
Psychological impact of  genetic testing for index and for relatives 
Having a genetic cardiomyopathy implies that your children and other family 
members may have an increased risk of having a cardiomyopathy. For patients, this 
knowledge may add to the burden of having a cardiomyopathy. For insight in the 
psychological effects of genetic testing, we depend on studies focusing on familial 
cardiomyopathies or other genetic disorders. The studies looking at the impact 
of having a genetic cardiomyopathy showed that overall the burden of cardiac 
symptoms had greater psychosocial impact than the burden of the condition being 
genetic (109, 125). Index cases might be pressured by their relatives to have genetic 
testing. But this did not negatively affect satisfaction with the genetic counseling 
process or getting the results of DNA testing (125). Overall clinical symptoms are 
the principal source of concern: index cases showed more distress when having 
a diagnostic DNA test than relatives having a predictive DNA test, probably 
because the index cases had a cardiomyopathy, while the relatives usually are 
asymptomatic (126). Predictive testing can evoke anxiety about risk of being affected 
and transmitting the predisposition for disease to offspring, but it may also bring 
clarity about a subject that has been on the mind for a significant time. Overall 
relatives at risk for hereditary cardiac diseases did not have more emotional distress 
the normal population (127). Understandably, relatives with a positive genetic test 
showed more distress than relatives where a familial mutation could be excluded 
(126). Despite the result of the genetic test, the vast majority (80%) of the patients 
was satisfied with the decision of undergoing a genetic test (126). Patients who had 
less understanding of carriership of the mutation or had stronger belief in serious 
consequences had more symptoms of depression (125). High levels of anxiety were 
linked to a younger age, females, less formal education and fewer social contacts 
(125, 128). From these studies we have learned the importance of focusing during 
pre- and post-test counseling on the individual perception of risk and disease and 
helping the patients to cope with the consequences of the test result. The way of 
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giving the test result, by telephone or by a face to face appointment, did not have 
an impact on contentment of the patient (125). 
Cardiologic family screening
Cardiologic screening is o recommended for the relatives from a family with a 
mutation, who were shown to have the familial mutation as well as the relatives 
who choose not to have a predictive DNA test. Likewise, in families were no 
mutation is found, relatives are advised to have a cardiologic examination from 
age of 10 years onwards. Cardiologic screening may be initiated before the age of 
10 years if the child is planning to engage in competitive sports, or there is a family 
history of sudden cardiac death. Cardiologic screening in family members includes 
a physical examination, twelve-lead electrocardiography and echocardiography. 
When abnormalities are found the cardiac work up should be expanded. For 
example when signs of a cardiomyopathy on echocardiography are identified, 
additionally cardiac magnetic resonance imaging (CMR) can be performed. A 48-
hour ambulatory electrocardiography should be performed when patients have 
palpitations or there are other indications for an arrhythmia.
In familial NCCM, relatives have less severe cardiac features than the index cases. 
Early detection in relatives is important and allows treatment and prevention 
of severe complications. Another reason why cardiologic family screening is 
recommended for the families of all cases, is that in this way asymptomatic relatives 
with a cardiomyopathy even in families without evidence for genetic disease can 
be detected. Family screening may thus help to identify familial NCCM and stratify 
risk for relatives into a high genetic risk. 
Cardiologic follow-up
In general, the diagnosis NCCM requires lifelong follow-up to detect changes in 
symptoms, risk for adverse events, LV function and cardiac rhythm. Prevalence 
of LV systolic dysfunction and atrial arrhythmias increases with age (129, 130). 
The frequency of monitoring is determined by the severity of disease, age and 
symptoms. A clinical examination, including 12-lead ECG and TTE, should be 
performed every 1 to 2 years or sooner if patients have new cardiac symptoms 
(116). In 50-70% of the mutation carriers a cardiomyopathy is identified by first 
screening, 30% of these patients are asymptomatic (111, 131). These asymptomatic 
carriers with a phenotype should also have follow-up every 1 to 2 years. The 
clinical significance of mild morphological and functional abnormalities is 
uncertain but probably minor in most (131, 132). In 30% of the adult relatives with 
a mutation no cardiomyopathy at first cardiologic screening is identified, these 
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are mutation carriers without a phenotype (111). Studies suggest a benign clinical 
course for mutation carriers without a phenotype in HCM families (133, 134). 
However, a proportion of mutation carriers without a phenotype will develop a 
cardiomyopathy later in life, because of age-related increase in penetrance (63). 
According to current insight, mutation carriers without a phenotype should have 
cardiac examination at least every five years (116). Also first degree family members 
without a phenotype in familial NCCM s without a mutation cannot be discharged 
from medical follow-up and should also be screened at least every 5 years (116). 
Similarly adult relatives of cases without a family history or mutation, who do not 
show signs of cardiomyopathy will be screened until the age that occurrence of a 
signs of a genetic cardiomyopathy is small. This is because we cannot fully exclude 
a genetic cause even when the index has no mutation and no other cases of NCCM 
occur in the family.
Genotype-phenotype correlation
Knowing the genetic cause for familial NCCM may help to predict the outcome. 
Specific genetic defects were associated with the phenotype, and associated 
clinical features, including risk for major adverse cardiac events for the index case 
and affected relatives. In other words, complementing cardiologic diagnosis with 
genetic status may allow tailoring clinical management and follow-up of familial 
NCCM according to genetic burden. In the future the associations between specific 
mutations and clinical features or risks may become clearer, by more extended 
methods of DNA testing and the analysis of the features large numbers of patients. 
Although specific genotype based cardiomyopathy treatments are not available, 
the established genotype-phenotype correlations for NCCM can help to guide 
clinical management of the patients.
Genetic versus sporadic NCCM
There are distinct differences between the genetic (the NCCM patients with a 
mutation and/or patients with a family history of cardiomyopathy) and the patients 
without a mutation or family history, the sporadic cases (8). Sporadic patients 
presented more often at adult age (figure 7). In children, genetic NCCM was 
associated with severe outcome and cardiac symptoms, LV systolic dysfunction, 
and a high risk for major adverse cardiac events (MACE). In contrast to sporadic 
children, who had a good prognosis, with a mild clinical course and low risk for 
complications. In severe forms of NCCM occurring in childhood the possibility 
there may be a complex genotype. For that reason if a child is diagnosed with a 
cardiomyopathy in the family of an adult NCCM case, we recommend to perform 
a full panel of genes testing instead of only testing for the familial mutation. 
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Adults with a mutation had high risk for LV and RV systolic dysfunction (8). 
Prognosis in adult NCCM patients with a mutation was correlated with left 
ventricular function (figure 8). Adult NCCM patients with a mutation and a 
persevered LV ejection fraction had a good prognosis. In contrast to adults with 
a mutation and LV systolic dysfunction, who had worse outcome. In sporadic 
adult patients prognosis was not related to LV systolic function. The sporadic 
NCCM patients had frequently hypertension, suggesting an acquired form of 
NCCM, which eventually, may have consequences for recommendations of family 
screening
Figure 7: Age at Diagnosis in 327 Dutch NCCM Cases.
In blue the genetic patients, these are the patients with a mutation. In red the probably genetic 
patients, these are the patients without a mutation, but with familial cardiomyopathy. In grey the 
sporadic patients, these are the patients without a mutation and without a familial cardiomyopathy. 
Chance of having a mutation decreased with age (odds ratio: 0.983 per year; 95% confidence interval: 
0.97 to 0.99; p=0.01). The figure was adapted from van Waning JI, et al. Genetics, Clinical Features, 
and Long-Term Outcome of Noncompaction Cardiomyopathy. J Am Coll Cardiol. 2018;71(7):711-22.
Genetics and family screening for noncompaction cardiomyopathy
Ch
ap
te
r 
1
45
Figure 8: Overview of genetics, clinical features and outcome in NCCM.
Noncompaction cardiomyopathy (NCCM) is a heterogeneous condition, and genetic stratification 
has a role in clinical care. In children, genetic causes with severe outcome are more common than 
in adults. In non-genetic NCCM, which occurs frequently in adults, acquired causes for NCCM 
may be involved. In adults with a normal left ventricular (LV) systolic function, genetics helps to 
predict cardiac events. MYH7, MYBPC3, and TTN mutations were the most common in genetic 
NCCM. Patients with MYH7 mutations had low risk for cardiac events. Distinguishing genetic 
from non-genetic NCCM complements prediction of outcome and allows tailoring management to 
genetic status. MACE: major adverse cardiac events; RV: right ventricular. The figure was adapted 
from van Waning JI, et al. Genetics, Clinical Features, and Long-Term Outcome of Noncompaction 
Cardiomyopathy. J Am Coll Cardiol. 2018;71(7):711-22.
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Sarcomere genes
MYH7 gene mutations are the most prevalent genetic cause for NCCM are 
associated with a relatively milder course of disease with low risk for complications, 
compared to other genetic causes (figure 8)(8). The prognosis for patients with 
mutations in the head of the MYH7 gene was better than for patients with mutations 
in the tail of the gene (111). Mutations in the head of MYH7 were associated with 
NCCM with normal dimensions of the LV and a milder course of the disease 
(figure 9). Mutations in the tail had high incidence of LV dilatation and LV systolic 
dysfunction. An explanation for the association between mutations in the tail and 
the dilated subtype could be that tail mutations may infer with the binding site for 
TTN, and thus may have a similar effect as the effect of TTN mutations. Similar 
to NCCM patients with a TTN mutation, the mutations in the tail of MYH7 were 
associated with DCM without hypertrabeculation in relatives. Another feature of 
the MYH7 was that this is one of the rare sarcomere genes that was observed in 
families where Ebstein anomaly occurred in NCCM patients (23). The TTN gene, 
which is a major cause of DCM, is also a frequent cause of NCCM, predominantly 
in adult NCCM patients (figure 8) (8). This could indicate that younger TTN 
carriers are not symptomatic, which may be important information for relatives 
(children) who are carriers of a TTN mutation. The adult NCCM patients with 
TTN mutations had high prevalence of LV systolic dysfunction and LV dilatation, 
similar to DCM patients with TTN mutations (111). MYBPC3 (compound) 
homozygous mutations were observed in NCCM cases with a severe phenotype 
and major cardiac events at young age (66). NCCM patients with a single MYBPC3 
mutation had high prevalence of RV systolic dysfunction and an increased risk 
for LV hypertrophy (HCM) (8). In the families of NCCM patients with a MYBPC3 
mutation, HCM without signs of hypertrabeculation may occur in relatives (111). 
Figure 9: MYH7 mutations in NCCM.
Head, purple, families with isolated NCCM. Tail, yellow, families with NCCM with DCM. Mixed 
purple and yellow mark, families with both isolated NCCM and NCCM with DCM. Mutations in 
the head, isolated NCCM phenotype vs in the tail, NCCM with DCM (p<0.001). Figure adapted 
from Alamut® visual -interactive biosoftware, 12-2016. The figure was adapted from Waning JI et al. 
Cardiac Phenotypes, Genetics, and Risks in Familial Noncompaction Cardiomyopathy, J Am Coll 
Cardiol. 2019 Apr 9;73(13):1601-1611.
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Other cardiomyopathy genes
Mutations in HCN4 were associated with NCCM with bradycardia (135). Mutations 
in RYR2 lead to catecholaminergic polymorphic ventricular tachycardia (CPVT) 
and may also cause NCCM, especially variants in exon 3 (136). LMNA and RBM20 
are rare causes for NCCM and may be associated with worse outcome, like in 
DCM (10). SCN5A was reported to be a genetic modifier, increasing the risk for 
arrhythmias in NCCM (78). 
Future directions of  genetic diagnosis and family screening for NCCM
The application of whole exome or genome sequencing of NCCM patients in the 
near future will reveal novel genetic causes or genetic interactions with modifiers, 
some of which may explain cardiac remodeling into different cardiomyopathy 
phenotypes within families. A disease model may be developed to obtain functional 
evidence of the deleterious effect of genetic variants for better understanding 
and a more accurate classification of the DNA variants in cardiomyopathy 
genes, especially for the variants that are now regarded as variants of unknown 
significance. The expected broad application in the general population of predictive 
DNA testing for genetic susceptibilities for a large range of disease, may achieve 
a change in attitude towards and the perception of having a genetic susceptibility. 
Because it is clear that all of us are carrying genetic defects for one disease or 
another. This awareness hopefully leads to ban the discriminatory socio economic 
sanctions experienced currently when revealing personal genetic burden. 
Prospective large follow up studies are needed to confirm the genotype-phenotype 
correlations in NCCM, and adjust guidelines for clinical follow up of patients 
and at risk relatives accordingly. Leading eventually to family- and gene tailored 
follow-up and management of NCCM patients and their families. The risk for 
cardiomyopathy for relatives of sporadic NCCM patients seems low, also risk for 
mutation carriers without a phenotype seems low. Follow-up studies of these 
relatives at low risk are needed to establish guidelines for the follow-up screening 
of these groups and to confirm the low risk. When al NCCM genes are known, 
excluding a genetic predisposition in a proportion of patients may be achieved, 
thus allowing making the important distinction between genetic and non-genetic 
NCCM, and design follow-up strategies according to genetic burden. In the distant 
future genetic classification may lead to the development of genotype specific 
treatment and eventually gene therapy for NCCM. 
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Abstract
Children were more likely to have a mutation, whereas the majority of the patients 
diagnosed in adulthood were ‘sporadic’ cases without a mutation or familial disease. In 
carriers of mutations risk of major adverse cardiac events was related to left ventricular 
systolic dysfunction. In contrast, in sporadic cases left ventricular function did not 
determine risk of complications. Patients with the most prevalent genetic cause, MYH7 
mutations, had low risk for adverse events. These findings highlight the heterogeneity 
of hypertrabiculation and show that genetic testing and taking family histories may 
have important implications for the management and prediction of adverse events for 
patients and their relatives. 
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Introduction
Noncompaction cardiomyopathy (NCCM), also known as left ventricular 
noncompaction (LVNC), is a cardiomyopathy with excessive trabeculations 
of predominantly the left ventricle with a more than twofold thickening of the 
endocardial noncompacted (NC) layer compared to the epicardial compacted 
(C) layer of the myocardium(NC/C>2)(2, 21, 137)Initially referred to as ‘spongy’ 
heart, NCCM has gained attention with the improvements in cardiac imaging 
allowing more detailed visualization and increasing clinical awareness(138, 139). 
Clinical symptoms range from severe prenatal manifestations to asymptomatic 
cardiomyopathy presenting at adult age(4, 5).
Genetics play an important role in NCCM since 17-50%(140, 141) of the patients 
have a family member with a cardiomyopathy and the yield of DNA testing ranges 
from 17 to 41% depending on patient selection and the number of genes screened(7, 
54). In most families, an autosomal dominant pattern of inheritance is observed 
with variable penetrance(142). The majority of the genetic defects associated with 
NCCM has also been reported in hypertrophic (HCM) and dilated cardiomyopathy 
(DCM)(19, 54). In NCCM, mutations in the sarcomere genes, particular in MYH7, 
are the most common (7, 54). However, the role of the sarcomere gene defects in 
the development of the cardiac hypertrabeculation has not been established yet. 
The diagnosis of NCCM requires genetic counseling because timely screening and 
diagnosis of at risk relatives is important. Finding a mutation allows to distinguish 
accurately the relatives at risk for NCCM. As NCCM is not as common as HCM 
and DCM, associations between mutations in cardiomyopathy genes, family 
history and the age of onset, left ventricular (LV) systolic dysfunction and long 
term outcome have not been investigated in detail before.
We conducted a large multicenter study in four cardiogenetic centers in the 
Netherlands to investigate the role of genetics in NCCM. The focus of the study 
was to investigate the relationship between clinical and cardiologic features at 
diagnosis, the risk of LV systolic dysfunction and occurrence of major adverse 
cardiac events (MACE) during follow-up in NCCM patients diagnosed in childhood 
or adulthood. These insights may help to improve management of NCCM patients 
and their families.
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Methods
Study Population 
The retrospective study consisted of 327 unrelated NCCM patients referred to one 
of the participating departments of Clinical Genetics for genetic counseling and 
DNA testing (with informed consent) between January 2005 and January 2016. 
Sixteen patients who did not have DNA testing were excluded (see online methods). 
Diagnosis of NCCM was based on consensus of re-evaluated echocardiographic and 
MRI images according to the Jenni and Petersen criteria by JVW and a dedicated 
participating cardiologist(21, 139). Echocardiographic and MRI data were available 
for all patients except for 34 with only MRI and 80 with only echocardiographic 
data. One patient was diagnosed at autopsy.
Genetics
Specifics on the genes tested and methods of classification of variants are described 
in detail in the online methods. The core-panel of tested cardiomyopathy genes 
included 45 cardiomyopathy genes. All variants were evaluated according to the 
current Dutch guidelines and classification of each variant was achieved with 
consensus of the participating molecular geneticists. Patients were classified as 
genetic if they had a (likely) pathogenic mutation (online table 1a, 2a, 1b and 2b). 
Variants of unknown clinical significance (VUS) were reported in online table 3. 
Patients with only a VUS were not classified as genetic because these variants have 
not been proven to be pathogenic. Patients were classified as probably genetic if 
they had a family history of cardiomyopathy and DNA testing did not identify a 
mutation. Patients were classified as sporadic if patients had no mutation or family 
history of cardiomyopathy (figure 1).
Figure 1: Noncompaction cardiomyopathy study population.
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Clinical data
Clinical data were retrieved retrospectively from the medical records, including age, 
gender, cardiac diagnosis, ECG, echocardiography and cardiac magnetic resonance 
imaging (MRI) when available. In case the images of the first echocardiographic 
examination were unavailable, more recent echocardiographic imaging was used. 
Ventricular function
LV systolic dysfunction was defined as LV ejection fraction < 45% on MRI or 
fractional shortening < 19% in men and < 21% in women on echocardiography if 
MRI images (n=80) were missing(143). Abnormal right ventricular (RV) systolic 
function was defined as a tricuspid annular plane systolic excursion (TAPSE) <17 
mm on echo or RV ejection fraction <45% on MRI(144). For children dimensions 
of the ventricles of more than two standard deviations from reference range were 
classified as abnormal.(145, 146).
Adverse events 
Information on the occurrence of clinical events at follow-up was collected from 
the medical records. Heart failure requiring hospitalization was defined as new-
onset or worsening signs of heart failure requiring therapy and hospitalization. 
Sustained VT/VF was identified when at least 30 seconds of hemodynamically 
stable VT or hemodynamically unstable VT/VF of any duration was documented 
by electrocardiograms, pacemaker or defibrillator data. We used a combined end-
point for our hazard models, because of low incidence of death. The occurrence 
of cardiac death, implantation of a left ventricular assistance device (LVAD), 
heart transplantation, (aborted) sudden cardiac death, appropriate ICD shock, or 
ischemic stroke were classified as major adverse cardiac events (MACE). Seventeen 
patients were lost to follow-up. Information on vital status was confirmed by 
checking municipal registries for all patients.
Family history
Family histories were ascertained at the departments of Clinical Genetics. Patients 
were classified as familial, if at least one first-degree or two second- degree relatives 
were reported with a cardiomyopathy. None of the patients had only one affected 
second degree relative. Medical records confirmed the diagnosis of 82% of the 
relatives reported to have a cardiomyopathy; in 18% of the affected relatives, no 
medical records were available. The occurrence of (aborted) sudden cardiac death 
(SCD) at age <50 years in the family of the index patients was recorded. In families 
with multiple cases of NCCM, only one case per family, the first diagnosed was 
included. 
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Statistical analysis
Categorical data were compared with Pearson Chi-Squared test or Fisher’s exact 
test. For continuous variables, unpaired t-tests were used for two groups and ANOVA 
tests for more than two groups. Logistic regression was used to find associations 
between genetic status and left ventricular dysfunction at baseline. Kaplan–Meier 
survival curves were estimated and differences between groups were assessed by 
the log-rank test, using time at diagnosis as time zero. Risk factors for MACE, was 
calculated by Cox proportional hazards regression analysis. Patients lost to follow-
up were considered at risk until the date of last contact, at which time-point they 
were censored. Analysis was performed with SPSS statistical software, version 
21.0(SPSS Inc., Chicago, IL).
Results
NCCM genetics
The 327 NCCM patients were categorized into the three groups; 104 genetic (32%; 81 
adults, 23 children), 53 probably genetic (16%; 45 adults, 8 children) and 164 sporadic 
(52%; 149 adults, 21 children; table 1, figure 2). The complete list of mutations in 
children and adult NCCM patients with reference to previous reported variants, 
the reported cardiomyopathy (NCCM, HCM or DCM) and the yield per tested 
gene are presented in the online tables 1a, 2a and figure 1) In addition, 192 VUS 
in cardiomyopathy genes were identified in 111 patients (Online table 3); thirteen 
(12%) patients with a mutation had an additional VUS. Of the patients without a 
mutation 98 (30%) had a VUS. Forty-one percent (n=71) of the sporadic cases had a 
VUS, compared to 63% of the probably genetic cases (n=27, p=0.013).
From the 104 genetic cases, 82% involved a sarcomere gene (figure 2), the majority 
(71%) had a mutation in MYH7, MYBPC3 or TTN and 11% in ACTC1, ACTN2, MYL2, 
TNNC1, TNNT2 or TPM1. Mutations were more frequent in children (44%) than in 
adults (30%; p=0.036)(table 1). MYH7 was the most frequently mutated gene; in 19% 
(n=10) of children and 11% (n=29) of adults. TTN occurred frequently in adults (7%, 
n=18) not in children. Non-sarcomere gene mutations were detected in DES, DSP, 
FKTN, HCN4, KCNQ1, LAMP2, LMNA, MIB1, NOTCH1, PLN, RYR2, SCN5A and TAZ. 
One patient classified as genetic had a 1p36 deletion. Mutations occurred more 
frequently in female patients irrespective of age at diagnosis (male 27% vs female 
38%, p=0,039). The yield per tested gene was highest for MYH7 (13%), TTN (11%) 
and MYBPC3 (5%). 
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Complex genotypes
Complex genotypes (multiple mutations in one patient) in cardiomyopathy genes 
were more prevalent in children (10%) than in adults (3%) (p=0.038; table1, online 
Tables 1b and 2b). Three children had complex MYBPC3 mutations presenting with 
severe clinical phenotypes. Complex MYBPC3 genotypes were not observed in 
adults. Four adult patients had the same two MYH7 mutation in cis (c.1633G>A and 
c.2863G>A), that were not considered as complex genotypes, and are expected to 
have a common ancestor. Three adult patients had the combination of a MIB1 and 
a TTN mutation. One patient had three pathogenic mutations in three different 
genes; FKTN, RBM20 and HCN4. This patient was 53 years old when he was first 
admitted to the hospital for bradycardia. He had no structural heart defect and did 
experience serious adverse effects at end of follow-up (58 years).
Figure 2: Genetics of noncompaction cardiomyopathy.
Darker shades indicate complex genotypes. DNA testing of approximately 45 cardiomyopathy genes 
and family histories showed that children were more likely to have a mutation (p=0.036). TTN 
occurred only in adult cases. Complex MYBPC3 genotypes occurred only in children (dark green)
Chapter 2
64
Ta
bl
e 1
: B
as
eli
ne
 ch
ar
ac
te
ris
tic
s a
nd
 cl
in
ica
l f
ea
tu
re
s a
t d
ia
gn
os
is 
of
 32
7 n
on
co
m
pa
ct
io
n 
ca
rd
io
m
yo
pa
th
y (
NC
CM
) p
at
ien
ts.
Ch
ild
re
n 
n=
52
* 
Ad
ul
ts 
n=
27
5
M
ut
at
io
n 
n=
23
 (4
5%
)
No
 m
ut
at
io
n 
n=
29
 (5
5%
) 
M
ut
at
io
n 
n=
81
 (3
0%
)
No
 m
ut
at
io
n 
n=
194
 (7
0%
) 
Fa
m
ili
al
n=
8 (
15%
)
No
t f
am
ili
al
n=
21 
(4
0%
)
Fa
m
ili
al
n=
45
 (1
6%
)
No
t f
am
ili
al
n=
14
9 (
54
%
)
Ge
ne
tic
Pr
ob
ab
ly
 
ge
ne
tic
Sp
or
ad
ic
To
ta
l
Ge
ne
tic
Pr
ob
ab
ly
 
ge
ne
tic
Sp
or
ad
ic
To
ta
l
p v
al
ue
M
al
e
8 (
35
%
)
4 (
50
%
)
15 
(71
%
)
27
 (5
2%
)
39
 (4
8%
)
39
 (6
2%
)
80
 (5
4%
)
14
8 (
54
%
)
NS
M
ed
ia
n 
ag
e y
rs
 (I
QR
)
Ge
ne
tic
s
Co
m
pl
ex
 ge
no
ty
pe
Fa
m
ili
al 
ca
rd
io
m
yo
pa
th
y
SC
D 
be
fo
re
 ag
e 5
0 y
ea
rs 
in
 fa
m
ily
Sa
ng
er
, n
o N
GS
 ca
rd
io
pa
ne
l
5 (
0-
14
)
5 (
22
%
)
13 
(57
%
)
1 (
4%
)
15 
(65
%
)
5 (
0-
13)
8 (
10
0%
)
1 (
13%
)
3 (
38
%
)
8 (
1-1
5)
3 (
14
%
)
7 (
0-
14
)
5 (
10
%
)
21 
(4
0%
)
2 (
4%
)
21 
(4
0%
)
41
 (3
1-5
4)
9 (
11%
)
54
 (6
7%
)
7 (
9%
)
36
 (4
0%
)
45
 (3
4-
57
)
45
 (1
00
%
)
1 (
2%
)
16
(4
0%
)
47
 (3
5-5
7)
13 
(9
%
)
45
 (3
1%
)
45
 (3
3-5
6)
9 (
3%
)
99
 (3
6%
)
21 
(8
%
)
97
 (3
5%
)
NS 0.0
38
†
<0
.00
1‡
NS NS
Co
-m
or
bi
di
ty
Co
ro
na
ry
 ar
ter
y d
ise
as
e
Hy
pe
rte
ns
io
n
Di
ab
ete
s
Hy
pe
rc
ho
les
ter
ol
em
ia
CO
PD
1 (
4%
)
1 (
2%
)
19
 (2
3%
)
1 (
1%
)
12 
(15
%
)
3 (
4%
)
5 (
6%
)
6 (
7%
)
16
 (3
5%
)
2 (
4%
)
12 
(27
%
)
3 (
7%
)
5 (
11%
)
5 (
11%
)
49
 (3
3%
)
9 (
6%
)
38
 (2
6%
)
6 (
4%
)
11 
(7%
)
9 (
6%
)
84
 (3
1%
)
12 
(4
%
)
62
 (2
3%
)
12 
(4
%
)
21 
(8
%
)
20
 (7
%
)
NS NS 0.0
47
‡
NS NS NS
CH
D
AS
D
VS
D
Eb
ste
in
 an
om
aly
BA
V
Co
A
5 (
22
%
)
2 (
9%
)
2 (
9%
)
2 (
9%
)
1 (
4%
)
1 (
4%
)
2 (
25
%
)
2 (
25
%
)
7 (
33
%
)
4 (
19
%
)
4 (
19
%
)
1 (
5%
)
14
 (2
7%
)
6 (
12%
)
8 (
15%
)
2 (
4%
)
1 (
2%
)
2 (
4%
)
2 (
3%
)
2 (
3%
)
3 (
7%
)
1 (
2%
)
2 (
4%
)
9 (
6%
)
5 (
3%
)
3 (
2%
)
2 (
1%
)
1 (
1%
)
14
 (5
%
)
6 (
2%
)
3 (
1%
)
2 (
1%
)
4 (
2%
)
1 (
0%
)
NS NS NS NS NS NS
LB
BB
LV
 sy
sto
lic
 
dy
sfu
nc
tio
n 
RV
 sy
sto
lic
 
dy
sfu
nc
tio
n
LV
 an
d R
V 
sy
sto
lic
 dy
sfu
nc
tio
n
1 (
6%
)
16
 (7
0%
)
4 (
17%
)
4 (
17%
)
4 (
50
%
)
2 (
11%
)
1 (
5%
)
1 (
2%
)
22
 (4
2%
)
5 (
10
%
)
4 (
8%
)
7 (
10
%
)
49
 (6
0%
)
17 
(21
%
)
16
 (2
0%
)
4 (
11%
)
23
 (5
1%
)
7 (
16
%
)
5 (
11%
)
40
 (2
7%
)
80
 (5
4%
)
15 
(10
%
)
11 
(7%
)
51 
(21
%
)
152
 (5
8%
)
39
 (2
2%
)
32
 (1
2%
)
0.0
10
§
0.0
01
#
0.0
29
‡
0.0
20
‡
*d
ia
gn
os
is
 b
ef
or
e 
th
e 
ag
e 
of
 1
8 
ye
ar
s,
 †
si
gn
ifi
ca
n
t 
fo
r 
ch
il
d
re
n
 c
om
p
ar
ed
 t
o 
ad
u
lt
s 
‡s
ig
n
ifi
ca
n
t 
fo
r 
ad
u
lt
s 
w
it
h
 m
u
ta
ti
on
 c
om
p
ar
ed
 t
o 
ad
u
lt
s 
w
it
h
ou
t 
a 
m
u
ta
ti
on
 §
si
gn
ifi
ca
n
t f
or
 (p
ro
b
ab
ly
) g
en
et
ic
 c
om
p
ar
ed
 to
 s
p
or
ad
ic
 a
d
u
lt
s 
#S
ig
n
ifi
ca
n
t f
or
 c
h
il
d
re
n
 w
it
h
 m
u
ta
ti
on
 c
om
p
ar
ed
 to
 c
h
il
d
re
n
 w
it
h
ou
t a
 m
u
ta
ti
on
 
AS
D:
 at
ria
l s
ep
ta
l d
ef
ec
t, B
AV
: b
icu
sp
id
 ao
rti
c v
alv
e, 
CH
D:
 C
on
ge
ni
ta
l h
ea
rt 
di
se
as
e, 
Co
A:
 co
ac
ta
tio
n o
f t
he
 ao
rta
, L
V:
 le
ft 
ve
nt
ric
ul
ar
, N
GS
: N
ex
t-g
en
er
at
io
n 
se
qu
en
cin
g, 
RV
: r
igh
t v
en
tri
cu
lar
, S
CD
: s
ud
de
n 
ca
rd
iac
 de
at
h,
 V
SD
: v
en
tri
cu
lar
 se
pt
al 
de
fe
ct.
Genetics, clinical features and long-term outcome of  noncompaction cardiomyopathy:
A Dutch multicenter study 
Ch
ap
te
r 
2
65
De novo mutations
De novo mutations involving DES and PLN were observed in two children and 
PRDM16 and MYH7 in two adult patients. The children had a severe heart failure 
and had a heart transplantation at young age (the DES patient at the age of 10 
years, the PLN patient at age 17 years). In contrast, the adult patients with a de novo 
mutation had a mild course of the disease without severe complications.
Family history
Forty percent (n=21) of the children had a family history of cardiomyopathy 
and 36% (n=99) of the adults (table 1). Of the 120 familial cases, 56% (n=67) had 
a (likely) pathogenic mutation. Of the 207 patients without a family history of 
cardiomyopathy 18% (n=37) had a mutation (p<0.001). Overall, NCCM occurred in 
23% (n=76) of the affected relatives in 12% (n=39) of the families DCM was reported, 
in 3% (n=11) HCM, and in one family a relative was diagnosed with Arrhythmogenic 
Cardiomyopathy. Sudden death (SD) below the age of 50 of a relative was reported 
by 7% (n=23) of the patients; in 8% (n=21) of the families of adult index cases and 
4% (n=2) of the families of pediatric index cases. 
Age at diagnosis
The study population included 16% (n=52) pediatric patients diagnosed before 
the age of 18 years, and 84% (n=275) adult patients (Figure 3) the median age at 
diagnosis of NCCM was 41 years (range 0-79 year, IQR 27-54 years), 44 years (range 
18-79 IQR 33-56) for adult patients and 8 years (range 0-17 IQR 0-14) for children 
(table 1). Thirty percent (n=16) of the children were diagnosed before the age of 
1 year. Age at diagnosis was inversely associated with the probability of finding a 
mutation (OR 0.983 per year; CI 95% 0.97-0.99; p=0.01).
Figure 3: Age at diagnosis in 327 Dutch noncompaction cardiomyopathy cases.
Chance of having a mutation decreased with age (OR 0.983 per year; CI 95% 0.97-0.99; p=0.01).
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Congenital heart defect (CHD)
CHD was observed in 9% of the patients (n=28). In particular children (p=0.027; 
table 1) had more ASD (p=0.005) and VSD (p<0.001). Six of the 16 patients 
diagnosed before the age of one year had a congenital heart defect. Two children 
and two adults) had Ebstein anomaly and an MYH7 mutation (figure 4). Familial 
segregation of NCCM and Ebstein anomaly was observed in one family. MYH7 
was the only sarcomere gene associated with CHD. Two children with a CHD had 
a chromosomal defect: one with a 1p36 deletion had an ASD, multiple VSD’s and 
an open ductus arteriosus and a trisomy 21 patient with a MYH7 mutation had an 
ASD and a VSD. The other congenital heart defects were observed in patients with 
defects in non-sarcomere genes, in probably genetic and in sporadic cases. 
Clinical features
Among children 83% and 85% of the adults were symptomatic at presentation. 
Heart failure (27%) and arrhythmias (26%) were the most common presentations 
in children and adults (online figure 2). In 4% (n=14) the primary presentation 
was a cardiac arrest. Thrombo-embolic events were the first sign of NCCM in 3% 
(n=10). Three patients had a CHD. Seven patients presenting with a thrombo-
embolic event had a stroke, two a kidney infarction and one a mesenteric occlusion. 
Thirty patients, of which 16 had a mutation, were identified through family 
cardiologic family screening for i.e. HCM, DCM, SCD, familial hypertension, or 
hemochromatosis. Cardiologic screening for other reasons g identified 42 patients, 
of which 12 had a mutation. , Thirty-four percent (n=24) of these 42 patients were 
asymptomatic, seven asymptomatic cases had a mutation. 
Hypertension occurred frequently in adults (n=62, 23%), in particular adults 
without a mutation (p=0.047, table 1). Also a left bundle branch block (LBBB) was 
significantly more common in sporadic adult patients (27%) compared to the adult 
genetic (10%) and probably genetic cases (11%, p=0.01; table 1). Information on 
echocardiographic, ECG and CMR parameters of the NCCM patients is presented 
in online table 4. 
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Figure 4: Central illustration: Noncompaction cardiomyopathy.
NCCM is a heterogeneous condition and genetic stratification has a role in clinical care. In children, 
genetic causes with severe outcome are more common than in adults. In non-genetic NCCM, 
occurring frequently in adults, acquired causes for NCCM may be involved. In adults with a normal 
LV systolic function, genetics helps to predict cardiac events. MYH7, MYBPC3 and TTN mutations 
were the most common in genetic NCCM. Patients with MYH7 mutations had low risk for cardiac 
events. Distinguishing genetic from non-genetic NCCM complements prediction of outcome and 
allows tailoring management to genetic status.
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Reduced ventricular systolic function
The risk of having a LV systolic dysfunction was higher for genetic patients 
compared to the probably genetic and sporadic cases (p=0.024), with highest risk 
for patients with multiple mutations and TTN mutations (table 3 and in figure 
4). LV systolic dysfunction occurred in 44% of the children and 58% of the adult 
patients (p=0.067).LV dysfunction was observed more often than dysfunction of 
the right ventricle (RV 14% and LV 53 %). The RV function was measured in 31 of the 
52 pediatric patients (12 genetic, 5 probably genetic, and 14 sporadic) at admission, 
detecting reduced RV function in four genetic cases (with a DES de novo, PLN de 
novo, homozygous MYL2, and MYH7 defect) with a LV systolic dysfunction and 
in one sporadic patient with a normal LV function. The risk for having a reduced 
right ventricular function was increased for genetic patients (p=0.008). 
Major adverse cardiac events (MACE)
During median follow-up (FU) of 60 months (IQR 18-113), MACE occurred in 14 
(27%) children and 58 ( 21%) of the adults during a median FU of 25 months (IQR 
4-58 months; table 2). An increased risk for MACE was observed in children with 
(probably) genetic NCCM (p=0.025; figure 5A), children diagnosed before the 
age of 1 year (HR 2.1; 95% CI 1.0-4.4; p=0.048; table 4) and children with multiple 
mutations in MYBPC3 (HR 5.2; 95% CI 1.62-16.5; p=0.006) and risk for MACE in 
Table 3: Risk for ventricular dysfunction in noncompaction cardiomyopathy.
Reduced LV 
function
OR (95% CI) p value
Reduced 
RV function
OR (95% CI) p value
Genetic 1.73 (1.07-2.78) 0.024 2.55 (1.28-5.06) 0.008
 MYH7 1.30 (0.66-2.55) 0.456 1.74 (0.66-4.53) 0.258
 MYBPC3 single 1.02 (0.34-3.10) 0.855 5.33 (1.15-24.79) 0.033
 TTN 5.03 (1.44-17.61) 0.012 2.19 (0.70-6.92) 0.180
 Other sarcomere 0.36 (0.10-1.43) 0.148 1.51 (0.28-8.03) 0.632
 Non-sarcomere 2.10 (0.84-5.24) 0.113 1.53 (0.46-5.13) 0.491
 Complex genetic defect 8.24 (1.03-65.78) 0.047 2.54 (0.41-15.69) 0.316
Probably genetic 0.89 (0.49-1.60) 0.698 0.87 (0.36-2.16) 0.770
Sporadic 0.67 (0.43-1.03) 0.069 0.45 (0.23-0.90) 0.024
LBBB 6.04 (2.73-13.38) <0.001 0.77 (0.27-2.16) 0.620
Presentation under 1 year 1.48 (0.53-4.18) 0.456 0.74 (0.08-6.46) 0.781
CI: confidence interval, LBBB: Left bundle branch block, LV: left ventricular, OR: odds ratio, 
RV: right ventricular.
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children was associated with LV systolic dysfunction (HR 7.7; 95% CI 1.70-34.7; 
p=0.008). The risk for adverse events in sporadic children was low (HR 0.1; 95% CI 
0.02-0.93; p=0.043). No difference in risk for MACE was observed between adults 
with genetic, probably genetic and sporadic NCCM (Figure 5B). 
LV systolic dysfunction was associated with increased risk for MACE (HR 1.7; 95% 
CI 1.1-2.8; p=0.028). In line with these observations, genetic patients with a good 
left ventricular function had low risk of adverse cardiac events (p=0.002; figure 
5C). For patients with an MYH7 mutation, low risk for MACE was observed (HR 
0.17; 95% CI 0.04-0.69; p=0.013; table 4 and figure 4). The reduced risk for MACE in 
patients with a MYH7 mutation remained after correction for LV systolic function. 
In sporadic patients risk for MACE was not related to LV function (figure 5D); 
patients without a mutation and a normal LV-function had similar risk of MACE 
as patients with LV systolic dysfunction.
Cardiac arrest occurred significantly more in female patients than in male patients 
(11%, vs 2%, p=0,003). More adult females had an ischemic stroke than males (9%, 
vs 3%, p=0,045). Patients with congenital heart defects were more often associated 
with stroke (with 56% vs without CHD 5% p=0,001).
Table 4: Risk for major adverse cardiac events in noncompaction cardiomyopathy.
All patients HR (95% CI)† p value
Genetic 0.83 (0.50-1.37) 0.459
 MYH7 0.17 (0.04-0.69) 0.013
 MYBPC3 single 1.44 (0.52-3.94) 0.482
 MYBPC3 complex 5.17 (1.62-16.48) 0.006
 TTN 1.02 (0.37-2.79) 0.973
 Other sarcomere 0.41 (0.06-2.94) 0.374
 Non-sarcomere 1.60 (0.77-3.34) 0.211
 Complex genetic defect 2.11 (0.85-5.24) 0.108
Probably genetic 1.29 (0.73-2.29) 0.375
Sporadic 1.01 (0.63-1.61) 0.971
LBBB 1.20 (0.65-2.22) 0.563
Reduced LV 1.72 (1.06-2.80) 0.028
Reduced RV 1.73 (0.94-3.20) 0.080
Presentation under 1 year* 2.11 (1.01-4.41) 0.048
*Presentation under 1 year HR in children, †HR (95% CI) for Composite Endpoint, CI: confidence 
interval, HR: hazard ratio, LBBB: Left bundle branch block, LV: left ventricular, RV: right ventricular.
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Figure 5: Risk for major adverse cardiac events (MACE) in NCCM.
Kaplan Meier curves of MACE; (A) genetics and freedom from MACE in children. (B) genetics and 
freedom from MACE in adults. (C) left ventricular systolic dysfunction and freedom from MACE in 
genetic NCCM. (D) left ventricular systolic dysfunction and freedom from MACE in sporadic NCCM.
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Discussion
In this large cohort of NCCM patients we investigated the correlations between 
genetics, clinical presentation and the long-term outcome. We showed that nearly 
one third of the NCCM patients had a mutation in a cardiomyopathy gene. In this 
heterogeneous cardiomyopathy, age at diagnosis, left ventricle systolic dysfunction 
and risk for MACE were linked to genetic status. Children diagnosed with NCCM 
had more often a genetic cause than adults. Left ventricular systolic dysfunction at 
presentation and long-term outcome were related to genetics. 
It is important to distinguishing genetic NCCM because genetic status may add 
to prediction of risk for major adverse cardiac events and may guide clinical 
management and intensity of follow-up for specific groups of patients and their 
relatives. Children with a mutation were diagnosed frequently before the age of 
1 year, and had cardiac symptoms, LV systolic dysfunction, and a high risk for 
MACE. In contrast, children with sporadic NCCM were diagnosed incidentally, 
had normal cardiac function and low risk for MACE. In adults with a mutation 
high risk for MACE was strongly correlated to left ventricular systolic dysfunction. 
However, risk of MACE in sporadic adults was not determined by LV systolic 
dysfunction.
In approximately half (48%) of the NCCM patients genetics played a role; 32% of 
the patients had a mutation and 16% of the patients had familial disease without a 
mutation. Sporadic NCCM was more prevalent in adults than in children. These 
results suggest that apart from genetic causes for NCCM, acquired (non-genetic) 
causes for hypertrabiculation may play a role, particularly in the sporadic adult 
cases(11). In addition our results endorse the heterogeneity of NCCM and the 
importance of genetics, simultaneously evoking questions on different etiologies 
for hypertrabicularisation in children and adults. 
Three of the 22 different cardiomyopathy genes were not reported previously in 
NCCM, expanding the genetic spectrum of NCCM with the DES, PLN and RBM20 
genes. In the genetic cases mutations in MYH7, MYBPC3and TTN were the most 
frequent. MYH7 was the most affected gene, as described previously(7,10). The risk 
for MACE was lower in MYH7 patients (5%). MYH7 was the only sarcomere gene 
associated with congenital heart defects, four patients with MYH7 mutation had 
Ebstein anomaly(23). Compound heterozygosity of MYBPC3 was associated with 
severe early onset NCCM. In three patients TTN mutations co-occurred with MIB1 
mutations, endorsing the hypothesis that a TTN-mutation may not be a sufficient 
genetic cause for NCCM(147). TTN defects were not observed in pediatric cases. 
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High prevalence of TTN mutations in women with a peripartum cardiomyopathy 
and in chemotherapy induced cardiomyopathy(148-150), also suggests involvement 
of co-factors accumulated during life in the development of TTN associated 
cardiomyopathies. 
Acquired causes for NCCM are expected in a large proportion of patients, the 
sporadic adults. The role of acquired causes in late onset NCCM challenge the 
general assumption of the embryological nature of hypertrabeculation. If NCCM 
is a developmental disorder, a higher rate of diagnosis would be expected shortly 
after birth or in childhood than the observed 16% of childhood cases in our cohort. 
Late onset NCCM may be explained by an enhancement of a latent asymptomatic 
congenital defect by disruptions of the cardiac homeostasis later in life. Recent 
studies endorse the hypothesis that acquired causes may lead to characteristic 
hypertrabeculation. Conditions with an increased cardiac preload which are 
associated with hypertrabeculation included sickle cell anemia, pregnancy and 
intensive sports(24-26)(61, 151, 152). Our observation that LBBB was more prevalent 
in adults with sporadic NCCM may be explained by a role of increased cardiac 
preload in the development of hypertrabeculation. LBBB leads to higher end-
diastolic volumes, which leads to an increased cardiac preload(153). Hypertension 
may also lead to increased preload and may be another secondary cause, as it was 
also more frequent in sporadic patients(154). 
One third of the mutations were found in patients who did not report relatives with 
a cardiomyopathy, i.e. when family history was negative. This illustrates that DNA 
testing should not be restricted to cases with a positive family history, and that 
DNA testing of patients without a family history is as important. DNA testing is 
important because when a mutation is found it allows families to have DNA testing 
and identify accurately which relatives have a mutation and an increased risk. In 
this way identifying the causative mutation facilitates genetic cascade screening. 
Also relatives who do not carry the mutation can be excluded from regular cardiac 
follow-up and can be reassured that there is no increased risk for their offspring. 
The proportion of genetic patients is expected to be higher than 48% because in 
thirty percent of the patients without a mutation, Sanger sequencing of a small 
number of cardiomyopathy genes was performed and these may have a mutation 
in a cardiomyopathy gene that was not tested. In 71 (41%) of the sporadic cases 
had a VUS that may be reclassified in the future as 9likely pathogenic. Moreover, 
cardiomyopathy genes, that have not been identified yet, and may play a role in the 
familial cases without a mutation as well as in the sporadic cases.
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Study Limitations 
A referral bias of more severe cases cannot be excluded. Consequently, 
asymptomatic or mildly affected cases may be underrepresented leading to an 
overestimation of severe clinical features. In addition we might have introduced 
a selection bias of symptomatic NCCM by including only index cases (to control 
for overrepresentation of genetic causes). By doing so we might have missed 
asymptomatic cases that would only be recognized by family screening. We may 
have underestimated the role of genetic causes for NCCM because not all patients 
were tested for the complete genetic cardio-panel(~45 genes). Some patients had 
a rare variant of unknown significance, that are for now not classified as disease 
causing, but these may in the future be reclassified as likely pathogenic. On the 
other hand, some variants, although they were classified by current stringent 
criteria as (likely) pathogenic, could in the future turn out to be benign. 
We used the current widely used diagnostic criteria for NCCM, despite the fact 
that they lack specificity and novel criteria, preferably using both morphologic 
and genetic data are needed. We cannot rule out for now to have included patients 
with benign hypertrabeculation as NCCM. Family screening and obtaining 
accurate diagnosis of relatives is more difficult in families of adult patients, this 
might be one of the causes of the high prevalence of sporadic NCCM in adults. In 
addition given the retrospective design clinical data may have been missing. We 
may have an underestimation of heart failure related events because we selected 
only heart failure requiring hospitalization. 
Conclusion 
NCCM is a heterogeneous condition and genetic stratification has a role in clinical 
care. Distinguishing genetic from non-genetic NCCM may complement prediction 
of outcome and subsequently guide management of patients with follow-up 
tailored to genetic status.
Perspectives
Competency in medical knowledge: NCCM is heterogeneous and genetics plays a 
more important role in children than in adults. Mutations and family history carry 
information that may complement cardiologic management and predict prognosis 
of NCCM, since high risk for cardiac events was related to left ventricular systolic 
dysfunction in mutation carriers, but not in sporadic cases. Hence, showing the 
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importance of genetic testing in NCCM in addition to cardiomyopathy family 
screening.
Translational outlook: Taking family histories, DNA testing and family screening 
are important for a correct genetic classification of NCCM. Prospective large 
follow up studies are needed confirm the genotype-phenotype correlations, 
determine the effects of risk related follow-up strategies and design gene tailored 
management of NCCM patients and their families.
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Supplementary methods
Patient selection
The current study used retrospective cardiologic and DNA data of noncompaction 
cardiomyopathy patients referred from 2005 – 2016 for genetic counseling to the 
four participating Departments of Clinical Genetics. All consecutive NCCM 
patients who fulfilled Jenni or Petersen diagnostic criteria, were referred for 
genetic counseling and had a DNA test were selected. For this study the diagnosis 
of NCCM was reconfirmed by re-evaluation of the echocardiograms or/and MRI 
of all patients by JVW and a dedicated (pediatric) cardiologist specialized in 
cardiomyopathy of the participating cardiogenetic centers. Only index cases with 
a DNA test were included in this study to avoid overrepresentation of specific 
genetic defects, affected family members were excluded. 
From the 394 patients selected for the study 67 were excluded (online figure 3).
- 16 because they did not have a DNA test. 
- 7 because the echo and MRI images were missing.
- 44 (14 children and 30 adults) because the diagnosis of NCCM was rejected after careful re-
examination of the echocardiograms and/or MRI by JVW and an experienced cardiologist. 
Genetic testing
DNA was isolated from peripheral blood of the patients to analyze coding 
regions of the tested genes, with informed consent of the patients. From 2012 on, 
next generation sequencing of a targeted panel of 45 cardiomyopathy genes was 
gradually introduced in the participating clinical genetic centers. Currently, the 
national core panel of cardiomyopathy genes consists of at least the following 
genes: ABCC9, ACTC1, ACTN2, ANKRD1, BAG3, CALR3, CRYAB, CSRP3, DES, DMD, 
DSC2, DSG2, DSP, EMD, GLA, JPH2, JUP, LAMA4, LAMP2, LMNA, MYBPC3, MYH6, 
MYH7, MYL2, MYL3, MYPN, MYOZ1, MYOZ2, PKP2, PLN, PRKAG2, RBM20, RYR2, 
SCN5A, SGCD, TAZ, TCAP, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN, VCL 
and LDB3. 
Target enrichment and sequencing 
Targeted enrichment was performed according to manufacturer’s instructions on 
different machines in the different medical centers. Information is available upon 
request. 
Variant Filtering and Classification
Assessment of the pathogenic effect of genetic variants was performed with of 
Alamut Interactive Biosoftware (Rouen, France). This software incorporates 
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SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human 
Splicing Finder for the prediction of splicing variants and the programs Align 
GVGD, SIFT, Polyphen-2 and Mutation Taster for in silico prediction of the effect of 
amino acid changes. Additionally, it gives population frequencies for dbSNP, ESP, 
ExAC and GoNL and shows whether or not a variant has been reported before 
in the Human Gene Mutation Database (HGMD). The classification system of 
variants was adapted from the sequence variation classification proposed by Plon 
et al. (113). The criteria for classification of variants included the allele frequency in 
the dbSNP/ESP/ExAC/GoNL (cutoff 0.01, in at least 300 ethnically matched control 
alleles), predicted effects on splicing, the in silico prediction of effect on the protein 
and previously described links to disease. For each variant present in HGMD the 
supporting evidence was reviewed and previous reports evaluated whether linking 
specific variants to cardiomyopathy were supported by co-segregation data, data 
on the identification of the variant in multiple independent cases, functional 
studies and/or expression assays. Additionally, a variant only predicted by in silico 
prediction to be pathogenic would not automatically be classified as such because 
of lack of additional evidence. This resulted in categorizing variants into five 
classes: pathogenic, likely pathogenic, unknown significance (VUS), likely benign, 
and benign (Richards et al. (55). All variants classified as pathogenic and probably 
pathogenic were reported in this paper. In addition online table 3 reports all the 
variants of unknown clinical significance observed in the study population. A 
single previous description of a variant in a patient was not considered as sufficient 
evidence for causation and these variants were classified as variants of unknown 
significance instead of likely pathogenic. Familial segregation of the variants 
with NCCM in families was examined when affected relatives were available and 
consented for DNA testing. All four participating centers reached consensus on 
the classification of all variants.
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Online Table 2b: Complex genotypes in adults with NCCM.
Patient 
number in 
online table 2a
Mutation 1 Mutation 2 Mutation 3
1 ACTN2 c.574C>T,  
p.(Arg192*)
SCN5A c.4299+1delG p.(?)
2 HCN4 c.1441T>C , 
p.(Tyr481His)
FKTN c.1112A>G, 
p.(Tyr371Cys)
RBM20 c.846_853delTTACGG-
AC p.(Tyr283Glnfs*14)
3, 4, 5, 6 MYH7 c.2863G>A,  
p.(Asp955Asn)†
MYH7 1633G>A, 
p.(Asp545Asn)†
7 TTN c.4459C>T,  
p.(Glu1487*)
MIB1 c.2701C>T, 
p.(Arg901*)
8 TTN c.77254_77255delAA
p.(Lys25752fs*18)
MIB1 c.1096_1097del, 
p.(Leu366fs)
9 TTN c.7967delG , 
p.(Gly2656fs)
MIB1 c.2589_2590dupTG, 
p.(Glu864fs)
†in cis.
Online Table 3: Variants of unknown significance in 327 NCCM patients.
Gene Nucleotide substitute Amino acid substitute NM-Number GRCh37 (hg19)
ABCC9 c.3238C>A p.(Pro1080Thr) NM_020297.2
ACTC1 c.635G>A p.(Arg212His) NM_0051594.4
ACTN2 c.2569G>C p.(Asp857His) NM_001103.2
ALPK3 c.830C>A p.(Thr277Asn) NM_020778.4
ANKRD1 c.222dupA p.(Leu75fs*8) NM_014391.2
CALR3 c.-14C>T p.(?) NM_145046.4
CALR3 c.564delT p.(Gln189Serfs*8) NM_145046.4
CALR3 c.403G>A p.(Asp135Asn) NM_145046.4
CTNNA3 c.1507A>C p.(Ile503Leu) NM_013266.3
DES c.1009G>A p.(Ala337Thr) NM_001927.3
DES c.1123C>T p.(Arg375Trp) NM_001927.3
DES c.934G>A p.(Asp312Asn) NM_001927.3
DSC2 c.1231A>G p.(Lys411Glu) NM_024422.3
DSC2 c.2126G>C p.(Cys709Ser) NM_024422.3
DSC2 c.865C>T p.(Pro289Ser) NM_024422.3
DSG2 c.1003A>G p.(Thr335Ala) NM_001943.3
DSG2 c.1912G>A p.(Gly638Arg) NM_001943.3
DSG2 c.2140A>G p.(Met714Val) NM_001943.3
DSP c.1138C>A p.(Gln380Lys) NM_004415.2
DSP c.3121C>T p.(Leu1041Phe) NM_004415.2
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DSP c.423G>T p.(Arg141Ser) NM_004415.2
DSP c.5676_5678del p.(Lys1892del) NM_004415.2
FHL1 c.944C>T p.(Thr315Ile) NM_001159702.2
FLNC c.2617G>A p.(Glu873Lys) NM_001458.4
FLNC c.6397C>T p.(Arg2133Cys) NM_001458.4
JPH2 c.2001_2006dup p.(Val668_Glu669dup) NM_020433.4
JPH2 c.572C>G p.(Pro191Arg) NM_020433.4
LAMA4 c.*7A>G p.(?) NM_001105206.1
LAMA4 c.2900C>T p.(Ser967Leu) NM_001105206.1
LAMA4 c.3868_3870del p.(Thr1290del) NM_001105206.1
LDB3 c.1145C>A p.(Ala382Glu) NM_001171610.1
LDB3 c.664G>A p.(Ala222Thr) NM_007078.2
LDB3 c.98C>T p.(Thr33Ile) NM_007078.2
LMNA c.215G>A p.(Arg72His) NM_170707.3
LMNA c.71C>T p.(Thr24Ile) NM_170707.3
MYBPC3 c.2330C>T p.(Ala777Val) NM_000256.3
MYBPC3 c.1246G>A p.(Gly416Ser) NM_000256.3
MYBPC3 c.131G>A p.(Arg44His) NM_000256.3
MYBPC3 c.2164G>A p.(Glu722Lys) NM_000256.3
MYBPC3 c.2479C>A p.(Gln827Lys) NM_000256.3
MYBPC3 c.3425A>C p.(Gln1142Pro) NM_000256.3
MYBPC3 c.529C>T p.(Arg177Cys) NM_000256.3
MYBPC3 c.713G>A p.(Arg238His) NM_000256.3
MYBPC3 c.814C>T p.(Arg272Cys) NM_000256.3
MYBPC3 c.2441_2443del p.(Lys814del) NM_000256.3
MYH6 c.1545C>T p.(=) NM_002471.3
MYH6 c.2827C>T p.(Arg943Cys) NM_002471.3
MYH6 c.5026G>A p.(Val1676Met) NM_002471.3
MYH7 c.2384T>C p.(Val795Ala) NM_000257.2
MYH7 c.1245_1247dup p.(Gln415_Asn416insLys) NM_000257.2
MYH7 c.2453T>A p.(Ile818Asn) NM_000257.2
MYH7 c.2945T>C p.(Met982Thr) NM_000257.2
MYH7 c.345C>T p.(=) NM_000257.2
MYH7 c.4048_4050del p.(Glu1350del) NM_000257.2
MYH7 c.4076G>A p.(Arg1359His) NM_000257.2
MYH7 c.4377G>T p.(Lys1459Asn) NM_000257.2
MYH7 c.541G>A p.(Gly181Arg) NM_000257.2
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MYH7 c.5534G>A p.(Arg1845Gln) NM_000257.2
MYH7 c.644C>T p.(Thr215Ile) NM_000257.2
MYH7 c.2704G>A p.(Glu902Lys) NM_000257.2
MYH7 c.4463A>G p.(Tyr1488Cys) NM_000257.2
MYH7 c.2453T>A p.(Ile818Asn) NM_000257.2
MYH7 c.3928C>G p.(Gln1310Glu) NM_000257.2
MYH7 c.698C>T p.(Ala233Val) NM_000257.3
MYL2 c.263A>C p.(Glu88Ala) NM_000432.3
MYL2 c.421G>A p.(Ala141Thr) NM_000432.3
MYL2 c.247C>T p.(Leu83Phe) NM_000432.3
MYL3 c.*8G>A p.(?) NM_000258.2
MYL3 c.463C>T p.(His155Tyr) NM_000258.2
MYOZ1 c.167G>C p.(Gly56Ala) NM_021245.3
MYOZ2 c.148C>T p.(Leu50Phe) NM_016599.4
MYOZ2 c.488T>C p.(Leu163Ser) NM_016599.4
MYPN c.1012C>T p.(Arg338Cys) NM_032578.3
MYPN c.2428C>T p.(Arg810Cys) NM_032578.3
MYPN c.3046A>G p.(Asn1016Asp) NM_032578.3
MYPN c.3046A>G p.(Asn1016Asp) NM_032578.3
NEXN c.1878_1880del p.(Glu626del) NM_144573.3
NEXN c.1090delA p.(Ile364fs*19) NM_144573.3
PKP2 c.1652A>G p.(Asp551Gly) NM_004572.3
PKP2 c.464G>C p.(Ser155Thr) NM_004572.3
PKP2 c.1048G>A p.(Glu350Lys) NM_004572.3
PRDM16 c.1040C>T p.(Thr347Met) NM_022114.3
PRDM16 c.1633G>A p.(Ala545Thr) NM_022114.3
PRDM16 c.1840G>A p.(Asp614Asn) NM_022114.3
PRDM16 c.567T>G p.(Ser189Arg) NM_022114.3
RBM20 c.2737G>A p.(Glu913Lys) NM_001134363.1
RBM20 c.2761A>T p.(Ile921Phe) NM_001134363.2
RBM20 c.2986G>T p.(Asp996Tyr) NM_001134363.1
RBM20 c.3115C>T p.(Pro1039Ser) NM_001134363.2
RBM20 c.929C>T p.(Pro310Leu) NM_001134363.2
RYR2 c.11084T>C p.(Met3695Thr) NM_001035.2
RYR2 c.12047T>A p.(Phe4016Tyr) NM_001035.2
RYR2 c.12341G>A p.(Arg4114Gln) NM_001035.2
RYR2 c.13291G>A p.(Glu4431Lys) NM_001035.2
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RYR2 c.13822C>T p.(Arg4608Trp) NM_001035.2
RYR2 c.1827+140_1961+426del p.(?) NM_001035.2
RYR2 c.8147A>T p.(Lys2716Ile) NM_001035.2
SCN5A c.-27_-15del p.(?) NM_198056.2
SCN5A c.1735G>A p.(Gly579Arg) NM_198056.2
SCN5A c.1993G>T p.(Ala665Ser) NM_198056.2
SCN5A c.5692C>T p.(Arg1898Cys) NM_198056.2
SCN5A c.1735G>A p.(Gly579Arg) NM_198056.2
SCN5A c.665G>A p.(Arg222Gln) NM_198056.2
TBX1 c.199C>A p.(Pro67Thr) NM_080647.1
TBX5 c.556G>A p.(Val186Met) NM_000192.3
TCAP c.209G>A p.(Arg70Gln) NM_003673.3
TMEM43 c.1178G>A p.(Arg393Gln) NM_024334.2
TMEM43 c.206C>T p.(Ser69Leu) NM_024334.2
TMEM43 c.862C>T p.(His288Tyr) NM_024334.2
TNNC1 c.205A>G p.(Ser69Gly) NM_003280.2
TNNI3 c.539A>G p.(Asp180Gly) NM_000363.4
TNNT2 c.652A>T p.(lle218Phe) NM_001001430.1
TNNT2 c.230C>T p.(Pro77Leu) NM_001001430.1
TNNT2 c.381C>T p.(=) NM_001001430.1
TNNT2 c.431G>A p.(Arg144Gln) NM_001001430.1
TNNT2 c.522G>T p.(Lys174Asn) NM_001001430.1
TNNT2 c.40G>T p.(Glu14*) NM_000364.3
TPM1 c.850A>G p.(Met284Val) NM_000366.5
TTN c.102155G>A p.(Arg34052Gln) NM_001267550.1
TTN c.105383C>G p.(Ala35128Gly) NM_001267550.1
TTN c.106784A>T p.(Lys35595Ile) NM_001267550.1
TTN c.106975G>A p.(Asp35659Asn) NM_001267550.1
TTN c.107723T>C p.(Ile35908Thr) NM_001267550.1
TTN c.13006_13008del p.(Glu4336del) NM_001267550.1
TTN c.13241T>G p.(Leu4414Arg) NM_001267550.1
TTN c.18470T>C p.(Ile6157Thr) NM_001267550.1
TTN c.23581C>A p.(His7861Asn) NM_133378.4
TTN c.26047C>T p.(Leu8683Phe) NM_001267550.1
TTN c.26949A>T p.(Leu8983Phe) NM_001267550.1
TTN c.28786C>T p.(Leu9596Phe) NM_001267550.1
TTN c.31594G>A p.(Val10532Ile) NM_001267550.1
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TTN c.33911-6_33911-5insG p.(?) NM_001267550.1
TTN c.38214A>T p.(Glu12738Asp) NM_001267550.1
TTN c.39643+5G>C p.(?) NM_133432.3
TTN c.44586G>C p.(Gln14862His) NM_001267550.1
TTN c.45508G>A p.(Asp15170Asn) NM_001267550.1
TTN c.46296A>C p.(Glu15432Asp) NM_001267550.1
TTN c.49165G>A p.(Glu16389Lys) NM_001267550.1
TTN c.49322C>T p.(Pro16441Leu) NM_001267550.1
TTN c.54313C>T p.(Arg18105Cys) NM_001267550.1
TTN c.56654C>G p.(Pro18885Arg) NM_001267550.1
TTN c.61699C>T p.(Leu20567Phe) NM_001267550.1
TTN c.62317C>G p.(Leu20773Val) NM_001267550.1
TTN c.62546C>T p.(Thr20849Met) NM_001267550.1
TTN c.62567A>G p.(Tyr20856Cys) NM_001267550.1
TTN c.65144G>T p.(Arg21715Leu) NM_001267550.1
TTN c.659G>A p.(Arg220Gln) NM_133378.4
TTN c.69116A>T p.(Asp23039Val) NM_001267550.1
TTN c.70710A>C p.(Glu23570Asp) NM_001267550.1
TTN c.73073A>T p.(Tyr24358Phe) NM_001267550.1
TTN c.73567C>G p.(Pro24523Ala) NM_001267550.1
TTN c.75259G>A p.(Ala25087Thr) NM_001267550.1
TTN c.77894T>C p.(Ile25965Thr) NM_001267550.1
TTN c.82001T>C p.(Leu27334Pro) NM_001267550.1
TTN c.84353G>T p.(Arg28118Leu) NM_001267550.1
TTN c.84652G>A p.(Gly28218Ser) NM_001267550.1
TTN c.8641A>G p.(Thr2881Ala) NM_133378.4
TTN c.87041G>A p.(Arg29014Gln) NM_001267550.1
TTN c.88037A>T p.(Asp29346Val) NM_001267550.1
TTN c.92267T>C p.(Leu30756Pro) NM_001267550.1
TTN c.9226A>G p.(Met3076Val) NM_001267550.1
TTN c.92451G>T p.(Glu30817Asp) NM_001267550.1
TTN c.93775C>T p.(Arg31259Cys) NM_133378.4
TTN c.94827C>T p.(=) NM_001267550.1
TTN c.96449G>C p.(Arg32150Thr) NM_001267550.1
TTN c.96544G>A p.(Glu32182Lys) NM_001267550.1
TTN c.97604T>C p.(Ile32535Thr) NM_001267550.1
TTN c.99779A>T p.(Gln33260Leu) NM_001267550.1
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TTR c.190T>C p.(Phe64Leu) NM_000371.3
TXNRD2 c.1575A>C p.(*525Tyrext*?) NM_006440.4
VCL  c.2046A>T p.(Leu682Phe) NM_014000.2
VCL c.1534C>T p.(Arg512Cys) NM_014000.2
VCL c.20G>T p.(Arg7Leu) NM_014000.2
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Online figure 1: Yield of genetic testing.
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Online figure 2: Clinical presentation.
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Online figure 3: Patient inclusion.
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Abstract
Half of the NCCM index cases had at least one relative with a cardiomyopathy. NCCM 
with DCM was associated with LV systolic dysfunction, increased risk for MACE, 
mutations in the tail of MYH7, and DCM without NCCM in relatives. Isolated NCCM 
was associated with a milder course, mutations in the head of MYH7, asymptomatic 
NCCM and isolated NCCM in relatives. NCCM with HCM was associated with MYBPC3 
and HCM without NCCM in relatives. These findings highlight that phenotype of 
relatives may be predicted by NCCM phenotypes and the mutation of index patients. 
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Introduction
Noncompaction cardiomyopathy (NCCM), also known as left ventricular 
noncompaction (LVNC), is a cardiomyopathy characterized by excessive 
trabeculations of the left ventricle (LV)(1, 2). Current imaging diagnostic criteria, 
including the most frequent used echocardiographic Jenni criteria, are based on 
the ratio between a severely thickened myocardium, with an noncompacted layer 
which is at least twice as thick as the compacted layer, measured in systole in the 
short axis view(21). Clinical features of NCCM range from asymptomatic patients 
with noncompaction of the left ventricle to patients with or without a mutation 
in a cardiomyopathy gene with symptoms of heart failure, arrhythmias or major 
adverse cardiac events (MACE)(8).
In approximately 50% of the NCCM patients there is evidence for a genetic 
cause; because there is a mutation in a cardiomyopathy gene and/or at least 
one family member with a non-ischemic cardiomyopathy(8, 155). Mutations 
in mostly sarcomere genes explain approximately 32% of NCCM. In 15% of the 
patients familial disease occurs without a mutation, indicating that many genetic 
causes are still unknown. Novel genetic causes conveying small risk for relatives 
or alternatively non-genetic, secondary causes for noncompaction of the left 
ventricle are expected in NCCM cases without a mutation and without familial 
disease. Among the NCCM genes MYH7, MYBPC3 and TTN are the most prevalent 
and are also frequent causes for hypertrophic cardiomyopathy (HCM) and dilated 
cardiomyopathy (DCM)(156, 157). Previous family studies of NCCM reported 
occasionally relatives with HCM or DCM apparently without noncompaction in 
familial NCCM(54, 80, 158-160). 
NCCM patients may have additional ventricular dilatation or septal hypertrophy 
(68, 161-164) similar to HCM and DCM. Subsequently, NCCM can be classified 
phenotypically into isolated NCCM, NCCM with DCM, and NCCM with 
HCM(165). In children subtyping of NCCM according to cardiac phenotype was 
a good predictor for adverse events(166). Prediction of phenotype and associated 
clinical features for relatives is important, from the point of view of informing 
family members of NCCM patients and eventually guiding family screening and 
follow-up of relatives according to estimated risk. 
In this study we examined the clinical features, outcome, genetics, and familial 
recurrence of NCCM phenotypes (isolated NCCM, NCCM with DCM and NCCM 
with HCM), by using the results of cardiac and genetic family screening comprising 
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of 473 family members of 143 NCCM index patients. Our goal was to investigate if we 
could predict risk for relatives of NCCM patients by establishing if cardiac NCCM 
phenotypes were related to outcome and to genotype, and if NCCM phenotype of 
the index case was related to cardiac features in relatives.
Methods 
Study population
The retrospective study population consisted of the families of 143 index patients 
diagnosed with NCCM between January 2005 and January 2017 at the Department 
of Cardiology and referred for genetic counseling to the Department of Clinical 
Genetics of the Erasmus Medical Center Rotterdam (EMC) in the Netherlands. 
Genetic screening included DNA testing of a cardiomyopathy gene panel, 
ascertainment of family history and initiating cardiologic family screening. 
Family screening 
Family screening was initiated by asking the index patients to distribute a letter 
with information on heritability of NCCM and the recommendations for family 
screening(54, 167). In families with a mutation, adult relatives were counseled 
about predictive DNA testing. For children at risk, cardiologic screening from the 
age of 10 years was recommended, with DNA testing in case of a cardiomyopathy. 
Cardiac screening for relatives consisted of physical examination, a twelve-lead 
electrocardiography and echocardiography. In families with a mutation, cardiologic 
screening was offered to relatives with the mutation and to adult relatives refusing 
DNA testing. In families without a mutation, relatives had cardiologic screening. 
Specific on the DNA diagnostics for NCCM were described previously(8). Online 
table S1shows the list of mutations in the participating NCCM patients.
Diagnostic criteria
NCCM diagnosis was based on consensus of evaluated echocardiographic and 
Cardiovascular Magnetic Resonance (CMR) images according to the Jenni and 
Petersen criteria for NCCM by JIVW and a dedicated cardiomyopathy cardiologist 
(KC, MM, AFLS, MDH)(21, 139). All patients had echocardiographic images and 
CMR data were available for 176 (82%) NCCM patients. Patients were classified 
according to cardiac phenotype into isolated NCCM, NCCM with DCM or NCCM 
with HCM. The NCCM with DCM phenotype was diagnosed in NCCM patients 
according to dilatation criteria for DCM on echocardiography and was defined 
as a LV end diastolic dimension (LVEDD) of greater than 112% of predicted 
values (168). Predicted LVEDD was calculated according to the formula of Henry: 
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LVEDD = (45.3 x body surface area0.3) - (0.03 x age) - 7.2 (169). The NCCM with 
HCM phenotype was diagnosed in NCCM patients using the hypertrophic 
cardiomyopathy (HCM) criteria for adult family members, maximum LV wall 
thickness of ≥13mm, not explained by loading conditions(170). For children we 
used either ventricular septal or left ventricular (LV) posterior wall thickness for 
body-surface area more than 2 standard deviations different from the value for a 
normal population of children with similar body-surface area, or the presence of 
localized LV hypertrophy in children(171). Patients were categorized in the NCCM 
with HCM category despite of left ventricular dilatation. The diagnosis of DCM 
or HCM in relatives without hypertrabeculation was made according to current 
European guidelines(1, 170). 
Ventricular function and adverse events
LV systolic dysfunction was defined as LV ejection fraction < 45% on CMR. 
Alternatively LV systolic dysfunction was measured on echocardiography by using 
a wall motion score index that was lower than mildly reduced, for patients without 
CMR imaging (n=39). Systolic dysfunction was visually assessed using the wall 
motion score index on echocardiography and was described as normal (≥55%), 
mildly reduced (45% to 54%), moderately reduced (30% to 44%), or poor (<30%) 
according to the echocardiography guidelines(172). Abnormal right ventricular (RV) 
systolic function was defined as RV ejection fraction <45% on CMR. For patients 
without CMR imaging (n=39) tricuspid annular plane systolic excursion (TAPSE) 
<17 mm on echocardiography was used to define RV systolic dysfunction(144). For 
children dimensions of the ventricles of more than two standard deviations from 
reference range were classified as abnormal(145, 146). We used the same definition 
for adverse cardiac events as described before(8). The occurrence of cardiac death, 
implantation of a LV assistance device, heart transplantation, (aborted) sudden 
cardiac death, appropriate implantable cardioverter-defibrillator (ICD) shock, 
or ischemic stroke were classified as major adverse cardiac events (MACE). For 
the hazard models a combined endpoint for MACE was used because of the low 
incidence of death. Information on vital status of patients was retrieved from 
municipal registries. 
Statistical analysis
Categorical data were compared with Pearson Chi-Squared test or Fisher’s exact 
test. For continuous variables, unpaired t-tests were used for two groups and 
ANOVA for more than two groups. Odds ratios were calculated using binary 
logistic regression. Statistics for variables at follow-up were compared using the 
log-rank test, using time at diagnosis as time zero. Hazard ratios for major adverse 
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cardiac events (MACE) were calculated by Cox proportional hazards regression 
analysis, and presented as MACE per 100 patients years. Follow-up data were 
obtained in July 2017, five patients were lost to follow-up. Patients ( lost to follow-
up) were considered at risk until the date of last contact, at which time-point they 
were censored. Statistical analysis was performed with SPSS statistical software, 
version 21.0 (SPSS Inc., Chicago, IL).
Results
Figure  1: Family screening for noncompaction cardiomyopathy (NCCM) .
In 113 of 143 families (54 with a mutation) cardiologic screening identified 107 relatives with a 
cardiomyopathy; 73 with NCCM, 19 with DCM without noncompaction and 15 with HCM without 
noncomapction. Thirty-eight carriers of a familial mutation were unaffected..
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Family screening 
Seventy nine percent (113/143) of the families of NCCM index cases participated 
in genetic and cardiologic family screening (figure 1). In total 473 relatives were 
screened; 286 (60%) first-degree relatives, and 187 (40%) second degree or more 
distantly related relatives. We found a mutation in 54/113 (48%) of the index 
patients. Subsequently 187/283 (66%) relatives of the index cases with a mutation 
had a genetic testing, showing that 109 (58%) of the tested relatives had a mutation. 
In 78 relatives a mutation was excluded. Cardiologic screening was performed 
in 102 of the 109 relatives with a mutation, showing that 64 (63%) relatives with a 
mutation had a cardiomyopathy, and 38 (37%) did not have a cardiomyopathy. In 
addition 16 relatives, who refused DNA testing, from the families with a mutation, 
were diagnosed with a cardiomyopathy. In 39 of the 54 families with a mutation 
(72%), 267 of 283 participating relatives had a cardiologic examination, showing 
that 80 of the examined relatives were affected (29%). For 15/54 (28%) of the families 
with a mutation, family screening was inconclusive. Family screening of 59 
families without a mutation identified a cardiomyopathy in 27/190 (14%) relatives 
from 19 families. In total family screening showed familial cardiomyopathy in 58 
of the screened families with 107 (23%) affected relatives. In 34 families all affected 
family members had NCCM. In 17 families there were relatives with DCM without 
noncompaction, and in 7 families relatives with HCM without noncompaction 
were observed. In families with a mutation the yield of the family screening was 
higher than in families without a mutation (mutation 72%, without mutation 32%; 
p<0.001; central illustration; online table S2). 
Characteristics and outcome of  the NCCM phenotypes; isolated NCCM, NCCM 
with DCM and NCCM with HCM
The 216 patients diagnosed with NCCM were classified according to NCCM 
phenotype into; 92 isolated NCCM patients (51 index cases and 41 relatives), 115 
NCCM with DCM patients (84 index cases and 31 relatives) and 9 NCCM with 
HCM patients (8 index cases and 1 relative; table 1). Affected relatives with NCCM 
had less severe clinical features at diagnosis and follow-up compared to NCCM 
index patients (table 1 and 2): 48% of the relatives with NCCM were asymptomatic 
compared to 24% of the index patients (p<0.001). The NCCM with DCM phenotype 
was more frequent in index cases (p=0.010) and LV systolic dysfunction was more 
frequent (p<0.001) in index cases than in affected relatives (table 1). Patients with 
isolated NCCM had less RV- and LV systolic dysfunction than NCCM patients with 
DCM or HCM (p=0.023, p<0.001; table 1). Patients with NCCM and HCM had more 
often hypertension (p=0.014). During a median follow-up of 44 months (IQR: 9 to 
93 months), MACE occurred in 45 patients (table 2). The hazard ratios at follow-up 
showed that NCCM with DCM had highest risk for MACE (HR 2.29, CI95% 1.17-
4.47, p=0.016; figure 2, table 3).
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Figure  1: Family screening for noncompaction cardiomyopathy (NCCM) .
In 113 of 143 families (54 with a mutation) cardiologic screening identified 107 relatives with a 
cardiomyopathy; 73 with NCCM, 19 with DCM without noncompaction and 15 with HCM without 
noncomapction. Thirty-eight carriers of a familial mutation were unaffected..
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Familial segregation of  NCCM phenotypes 
Of the 107 relatives diagnosed with a cardiomyopathy 73 had NCCM. Fifty relatives 
had the same NCCM phenotype as the index patient in the family. The risk of 
having isolated NCCM was higher for relatives of index patients with isolated 
NCCM than for relatives of NCCM with DCM index cases (p<0.001)(central 
illustration). NCCM with DCM in relatives occurred in families of index cases with 
isolated NCCM and NCCM with DCM. These patterns of familial segregation 
of NCCM phenotypes were observed in families with and in families without a 
mutation. In some families, all patients had the same phenotype; in 8 families 
all patients had isolated NCCM, in 9 families all had NCCM with DCM and in 1 
family all had NCCM with HCM. In 17 families relatives were diagnosed with DCM 
or HCM without noncompaction. Relatives with DCM (without noncompaction) 
were most frequently observed in the families of the NCCM with DCM index cases 
(p=0.049). Relatives with HCM (without noncompaction) occurred only in families 
of index cases with NCCM with HCM (p<0.001;central illustration). Mutations in 
the MYH7 head domain predicted isolated NCCM (OR 7.5 95%CI 2.9-19.5; p<0.001), 
while MYH7 tail domain mutations predicted NCCM with DCM (OR 9.8 95%CI 2.8-
34.0; p<0.001). TTN mutations predicted risk for DCM without noncompaction in 
relatives (OR 10.9 95%CI 2.3-51.1; p=0.002). Risk for HCM without noncompaction 
in relatives was increased in families with MYBPC3 mutations (OR 585.0 95%CI 
49.5-6915.4; p<0.001). In families of index cases without a mutation, fewer relatives 
were diagnosed with a cardiomyopathy, because there are probably fewer cases 
with a genetic cause in this group of patients. 
Table 3: MACE in Noncompaction cardiomyopathy (NCCM).
Univariate analysis MACE /100 patient 
years
HR (CI 95%) p-value
Isolated NCCM
NCCM with DCM*
NCCM with HCM*
2.80
6.55
3.44
1.00
2.29 (1.17-4.47)
1.30 (0.29-5.81)
NA
0.016
0.733
Index patient
Male
<18 years at presentation
Mutation
Congenital heart disease
Cardiovascular co-morbidities†
Asymptomatic at presentation
Right bundle branch block
Left bundle branch block
Left atrial diameter >45 mm
Reduced LV systolic function
Reduced RV systolic function
5.69
4.44
3.24
4.93
1.02
8.24
2.32
0
6.47
6.39
7.34
8.36
1.95 (0.96-3.95)
0.91 (0.51-1.65)
1.46 (0.65-3.28)
1.2 (0.63-2.08)
0.21 (0.03-1.53)
2.08 (1.09-3.97)
0.40 (0.18-0.90)
0.05 (0.00-14.32)
1.56 (0.75-3.24)
1.55 (0.79-3.05)
3.16 (1.60-6.27)
2.47 (1.29-4.73)
0.065
0.763
0.365
0.646
0.123
0.027
0.027
0.292
0.239
0.204
0.001
0.006
* Reference was isolated NCCM, † Hypertension, hypercholesterolemia, coronary art disease and 
diabetes.
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Central illustration.
Classification of NCCM according to cardiac phenotype into isolated NCCM (51 index, 41 relatives), 
NCCM with DCM (84 index, 31 relatives) and NCCM with HCM (8 index and 1 relative) in 39 families 
with and 19 families without a mutation. Genotyping and family screening showed that isolated 
NCCM was linked to mutations in the head domain of MYH7 (p<0.001), isolated NCCM in relatives 
(p<0.001) and a lower risk for LV dysfunction (p<0.001). NCCM with DCM was linked to the MYH7 
tail domain (p<0.001) and TTN and was associated with relatives with DCM without signs of 
noncompaction (p=0.002) and severe outcome (p=0.016). The HCM phenotype was linked to MYBPC3 
in NCCM families (p<0.001) and HCM without signs of noncompaction in relatives (p<0.001). Factors 
reducing risk for relatives were absence of a mutation in index patients, non-penetrance of familial 
mutations or having asymptomatic disease. Underscoring that the NCCM phenotype of the index 
case and the genotype are important predictors of risk in relatives.
Cardiac phenotypes, genetics, and risks in familial noncompaction cardiomyopathy
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Phenotypes of  MYH7 mutations
In total 69 MYH7 mutation carriers were identified of which 55 (23 index) had 
NCCM; 34 patients had a mutation in the head domain and 21patients had a 
mutation in the tail of MYH7 (table 4). Nearly half (n=24, 44%) of the NCCM patients 
with a MYH7 mutation were asymptomatic. Non-penetrance was observed in 12 
(17%) of the MYH7 mutation carriers (50% with a mutation in the head and 50% 
in the tail domain). NCCM with DCM was associated with, mutations in the tail 
domain of MYH7 (outside of the MYH7 p-loop) (29% isolated NCCM vs 86% NCCM 
with DCM, p<0.001; figure 3). Two relatives with a mutation in the tail domain of 
MYH7 had DCM without noncompaction. Overall patients with a mutation in the 
MYH7 head were younger at presentation (p=0.036). Mutations in the MYH7 tail 
were associated with RV-dysfunction (6% vs. 33%, p=0.01). There was no difference 
in risk for MACE for patients with mutations in the head and tail domain of MYH7. 
Ebstein anomaly occurred in 4/34 of the patients with a MYH7 mutation in the head 
domain; two NCCM and Ebstein patients from one family, and one family with a 
NCCM with Ebstein patient and a relative with Ebstein without noncompaction. 
Phenotypes of  TTN mutations
TTN mutations occurred in 30 cases; 18 (15 index) with NCCM, and 12 relatives 
with DCM. Ten (67%) of the mutations occurred in the A-band (table 4). Of the 
five patients with a mutation outside of the A-band, two had a complex genotype 
involving a MIB1 mutation. Nine of the 14 relatives with a familial TTN mutation 
had no signs of a cardiomyopathy. For mutations outside of the A-band non 
penetrance (57% vs 6%, p=0.004), asymptomatic disease (2/3) and older age at 
diagnosis was observed (non-A-band 59 years vs A-band 39 years, p=0.006). 
Phenotypes of  MYBPC3 mutations
Eleven MYBPC3 mutations in 8 families with 9 NCCM patients were observed. Three 
NCCM index patients had two MYBPC3 mutations (table 4). Three patients with a 
MYBPC3 mutation had NCCM with HCM. Five patients with a MYBPC3 mutation 
had NCCM with DCM and 1 had isolated NCCM, 7 (78%) had LV-dysfunction and 5 
(56%) had a MACE. Eleven (33%) of the relatives with a mutation, 5 with the Dutch 
founder mutation c.2373dupG, had no signs of cardiomyopathy. 
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Figure 3: MYH7 mutations in NCCM.
Head, purple, families with isolated NCCM. Tail, yellow, families with NCCM with DCM. Mixed 
purple and yellow mark, families with both isolated NCCM and NCCM with DCM. Mutations in 
the head, isolated NCCM phenotype vs in the tail, NCCM with DCM (p<0.001). Figure adapted from 
Alamut® visual -interactive biosoftware, 12-2016.
Discussion
Prediction of risk for a cardiomyopathy phenotype and associated risk for adverse 
events is important for counseling the relatives of NCCM patients and eventually 
tailoring cardiologic family screening. This study showed that the cardiac features 
and the genetic defect of index cases may help to predict the cardiomyopathy 
phenotype and associated risk for relatives. Familial segregation of isolated NCCM, 
NCCM with DCM, or NCCM with HCM was observed as well as families in 
which a range of different NCCM phenotypes occurred. When the index case had 
isolated NCCM, relatives were more likely to have similarly isolated NCCM, linked 
to a better prognosis with less RV- and LV systolic dysfunction and low risk for 
MACE. Almost half of the isolated NCCM patients had a mutation, predominantly 
in the head domain of MYH7. NCCM with DCM was overall the most frequent 
NCCM phenotype and was associated with mutations in the tail domain of MYH7 
and in TTN with increased risk for LV systolic dysfunction and MACE in patients. 
Relatives of index cases with NCCM with DCM had an increased risk of having 
DCM without hypertrabiculation, compared to the relatives of the index cases 
with other NCCM features. For relatives of index cases with NCCM with HCM 
risk for HCM without noncompaction was increased.
NCCM phenotypes
The cardiomyopathy phenotypes in relatives included DCM without signs 
of NCCM, in particular in families of index cases with NCCM with DCM. It is 
unknown if LV dilation in NCCM with DCM is secondary to advanced NCCM 
or represents hypertrabeculation that may occur in a distinct subgroup of DCM 
patients. In this study 70% of the patients with NCCM with DCM had heart-
failure, indicating that in NCCM, like in other cardiac diseases, progressive heart-
failure may lead to LV dilatation. On the other hand a normal LV function in 
approximately 30% of the patients with NCCM and DCM could not explain the 
LV dilatation. Similarly, the novel DCM diagnostic criteria include DCM without 
LV dysfunction(173). Our results suggest that mutations in the tail of MYH7 and in 
TTN may predispose to LV dilatation, with or without LV dysfunction and in some 
cases with RV dysfunction. Most important is that there was no apparent difference 
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in outcome for DCM, with or without hypertrabeculation(174). Similarly, in a 
smaller number of cases, the nosology of concomitant NCCM with HCM remains 
part of the poorly understood spectrum of hypertrabeculation. In families with 
a mutation, relatives with DCM and HCM, all had the familial mutation, and 
therefor belong together with NCCM to a wider cardiomyopathy spectrum. The 
mechanism of hypertrabeculation needs to be explored by focusing on the role of 
additional genetic defects or non-genetic factors. 
Risk for relatives
Family screening showed that relatives had less severe cardiac features than the 
index patients among all subtypes of NCCM, which can be explained by early 
detection through screening that allows early treatment and prevention of severe 
complications. Risk for finding a cardiomyopathy in relatives was higher in 
families from index cases with a mutation, than for families without a mutation. 
Nevertheless, cardiologic family screening is recommended for all cases, because 
family screening may also identify asymptomatic relatives with a cardiomyopathy 
in families without evidence for genetic disease(8). The fact that familial NCCM 
occurs in families with and without a mutation, showed that not all genetic causes 
for NCCM have been identified. Although we cannot exclude unkown genetic 
defects in cases without a mutation, it is more likely that non-genetic causes with 
a low genetic risk are involved than unkown genetic causes, because the relatives 
had low risk for cardiomyopathy.
Genes
NCCM phenotypes were related to genetic causes. The MYH7 gene was a major 
genetic cause for NCCM. The location of the mutations in MYH7 could predict 
cardiac phenotypes. An explanation for the association between mutations in 
the tail and NCCM with DCM could be that mutations in the tail domain may 
interfere with the binding site for TTN, and thus may have a similar effect as TTN 
mutations, which are important causes of DCM and also predict DCM without 
NCCM in relatives. Although mutations in the head of MYH7 were previously 
associated with HCM our study did not endorse that MYH7 head mutations was 
related to NCCM with HCM(52). Our results endorse the previously reported 
association of concomitant Ebstein anomaly and NCCM with MYH7 mutations. 
Similarly MYBPC3, a major cause for HCM, was observed in families with NCCM 
with HCM and increased risk for HCM without hyertrabiculation in relatives. 
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Study Limitations 
Not all participating NCCM index cases had NGS DNA testing using the latest 
genetic cardio-panel, indicating the possibility of underreporting of genetic 
causes. Another cause of underreporting of familial disease might be that 
cardiomyopathy phenotypes in families may have been missed because not all 
relatives participated. Given the retrospective design of the study, clinical data of 
index cases and relatives may be missing. Furthermore, age-dependent penetrance 
may play a role rendering more relatives affected in the future.
Conclusions
NCCM phenotypes of index patients and the genetic defect may predict the 
cardiomyopathy phenotype and the severity of the disease in relatives. The 
strongest familial segregation of NCCM phenotypes was observed for isolated 
NCCM. NCCM with DCM was associated with MYH7 tail domain and TTN 
mutations, with worse outcome and with DCM without NCCM in relatives. NCCM 
with HCM was related to MYBPC3, and HCM without NCCM in relatives. 
Perspectives
Competency in knowledge:
In familial NCCM, the genetic cause and the distinct NCCM phenotype, of isolated 
NCCM, NCCM with DCM, or NCCM with HCM, of index cases may help predict 
risk for relatives. 
Translational outlook:
The etiologic and genetic heterogeneity of NCCM demands stratification for 
genetic risk to distinguish families with a high genetic burden, and high risk for 
relatives. Families of patients where NCCM may be caused by non-genetic causes 
or by (yet unknown) genetic causes with small effects, (like genetic modifiers), may 
have low risk for relatives. Ultimately designing a risk model to predict risk for 
relatives with genetic and clinical data of index case may be achieved by collecting 
data from large family screening studies. 
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Table S1: (likely) pathogenic mutations.
Gene NM-Number Nucleotide change Amino change
ACTC1 NM_0051594.4 c.811A>G p.(Met271Val)
ACTN2 NM_001103.2 c.574C>T p.(Arg192*)
ACTN2 NM_001103.2 c.586delG p.(Asp196fs)
DSP NM_004415.2 c.3084+1G>A p.(?)
DSP NM_004415.2 c.6687delA p.(Arg2229fs)
LMNA NM_170707.3 c.1608+5G>C p.(?)
MIB1 NM_020774.2 c.2589_2590dupTG p.(Glu864fs)
MIB1 NM_020774.2 c.2701C>T p.(Arg901*)
MIB1 NM_020774.2 c.2827G>T p.Val943Phe
MYBPC3 NM_000256.3 c.1831G>A p.(Glu611Lys)
MYBPC3 NM_000256.3 c.2373dupG p.(Trp792fs)
MYBPC3 NM_000256.3 c.2827C>T p.(Arg943*)
MYBPC3 NM_000256.3 c.442G>A p.(Gly148Arg)
MYBPC3 NM_000256.3 c.897delG p.(Lys301fs)
MYBPC3 NM_000256.3 c.932C>A p.(Ser311*)
MYH7 NM_000257.2 c.1633G>A p.(Asp545Asn)
MYH7 NM_000257.2 c.2678C>T p.(Ala893Val)
MYH7 NM_000257.2 c.2713T>C p.(Cys905Arg)
MYH7 NM_000257.2 c.2863G>A p.(Asp955Asn)
MYH7 NM_000257.2 c.415G>T p.(Val139Leu)
MYH7 NM_000257.2 c.495G>A p.(Met165Ile)
MYH7 NM_000257.2 c.547G>A p.(Gly183Arg)
MYH7 NM_000257.2 c.5754C>G p.(Asn1918Lys)
MYH7 NM_000257.2 c.5773C>G p.(Arg1925Gly)
MYH7 NM_000257.2 c.689T>C p.(Phe230Ser)
MYH7 NM_000257.2 c.715_717delGAC p.(Asp239del)
MYH7 NM_000257.2 c.732+1G>A p.(?)
MYH7 NM_000257.2 c.798T>A p.(Tyr266*)
MYH7 NM_000257.2 c.847T>G p.(Tyr283Asp)
MYH7 NM_000257.2 c.902T>A p.(Leu301Gln)
PLN NM_002667.3 c.25C>T p.(Arg9Cys)
PLN NM_002667.3 c.40_42delAGA p.(Arg14del)
PRDM16 NM_022114.3 c.2848C>T p.(Arg950*)
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PRDM16 NM_022114.3 c.56delA p.(Asn19fs)
RBM20 NM_001134363.1 c.1900C>T p.(Arg634Trp)
RYR2 NM_001035.2 c.169-198_273+823del p.(?)
SCN5A NM_198056.2 c.4299+1delG p.(?)
TAZ NM_000116.3 c.646G>A p.(Gly216Arg)
TNNT2 NM_001001430.1 c.629_631delAGA p.(Lys210del)
TPM1 NM_000366.5 c.250G>A p.(Asp84Asn)
TTN NM_001267550.1 c.104421_104425del5 p.(Arg34807fs)
TTN NM_001267550.1 c.4459G>T p.(Glu1487*)
TTN NM_001267550.1 c.4583G>A p.(Trp1528*)
TTN NM_001267550.1 c.48313-1G>A p.(?)
TTN NM_001267550.1 c.49917delC p.(Ser16640fs)
TTN NM_001267550.1 c.53656_53663del8 p.(Pro17886*)
TTN NM_001267550.1 c.68484delG p.(Lys22828fs)
TTN NM_001267550.1 c.74666dupA p.(Tyr24889*)
TTN NM_001267550.1 c.77254_77255delAA p.(Lys25752fs)
TTN NM_001267550.1 c.7967delG p.(Gly2656fs)
TTN NM_001267550.1 c.80514delA p.(Val26839fs)
TTN NM_001267550.1 c.82309_82312dupGGTA p.(Asn27438fs)
TTN NM_001267550.1 c.89165delC p.(Pro29722fs)
TTN NM_001267550.1 c.92683C>T p.(Arg30895*)
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Abstract
Hypertrabeculation is fairly common in healthy study populations. Genetic testing 
plays an important role distinguishing genetic from non-genetic noncompaction 
cardiomyopathy patients. A retrospective studyof 62 noncompaction cardiomyopathy 
patients, of whom 53% had a (likely) pathogenic variant ((L)PV) showed that correlation 
between different CMR diagnostic criteria varied from moderate to very strong. 
In multivariate regression analysis independent positive predictors for having a (L)
PV were familial cardiomyopathy, trabecular mass, and meeting Petersen criteria in 
≥2 long axis views, while left bundle branch block and hypertension were negative 
predictors. These predictors may help guiding referral for genetic diagnostics, cascade 
screening. 
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Introduction
Noncompaction is characterized by excessive trabeculations of the left ventricle 
(LV) (165), and includes patients with a genetic cardiomyopathy (CMP) and 
patients with secondary, pathologic remodeling of the LV. In addition, physiologic 
hypertrabeculation occurs in people without CMP (175). In the patients with 
genetic NCCM identification of a (likely) pathogenic variant ((L)PV) allows to 
perform genetic cascade family screening, identify accurately relatives with the 
genetic risk for having a CMP. In this way, early (subclinical) detection may help 
to reduce morbidity and mortality of cardiomyopathies. In the non-genetic NCCM 
patients (without a (L)PV or a family history) a low risk for relatives is expected . 
For the diagnosis of noncompaction many different, partially overlapping, 
echocardiographic and cardiac magnetic resonance (CMR) imaging criteria have 
been proposed (21, 139, 176-179). On echocardiography the Jenni criteria (end-
systolic short axis noncompacted (NC)/compacted (C) ratio >2) and on CMR the 
Petersen criteria (end-diastolic long-axis diastolic NC/C ratio >2.3) are used most 
frequently in clinic practice (20). Population surveys suggested that up to 40% of 
thepopulation may  have signs of hypertrabeculation meeting diagnostic criteria 
for NCCM. Since there is a wide range of noncompaction in  patients with (genetic) 
NCCMis may be complicated to distinguish NCCM from hypertrabeculation in 
healthy people. In this perspective, recognizing cases with a high risk of having 
a genetic cardiomyopathy, before doing a genetic test may help to identify the 
patients and their families who would benefit most from referral for  genetic 
counseling and DNA testing.   
In NCCM like in hypertrophic CMP, younger age at presentation and family history 
of CMP, are associated with having  a (L)PV (180, 181). In hypertrophic CMP also 
morphological characteristics (i.e. maximum wall thickness of the LV and reverse 
curve morphology of the septum) may help distinguish genetic from sporadic 
disease (182). For NCCM it has not been established if cardiac morphology of 
NCCM is related to genetic cause. The aim of the current study was to assess the 
association between clinical and morphological characteristics, and find which 
of the different proposed diagnostic CMR criteria allows distinguishing NCCM 
patients with high risk of having a mutation. 
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Methods
Study population
This retrospective study consisted of 62 adult NCCM patients diagnosed by 
echocardiography using Jenni criteria (21), who also had CMR and were referred 
to the clinical genetics department in the Erasmus Medical Center between 2006 
and 2017. Due to the retrospective study design the Medical Research Involving 
Human Subjects Act did not apply for this study. Clinical data were retrieved from 
the medical records of the patient, including age, gender, body surface area (BSA), 
ECG and echocardiography. The date of CMR was defined as baseline. Familial 
CMP was defined as having at least one first-degree relative with a non-ischemic 
CMP. Information on the occurrence of adverse cardiac events at follow-up was 
collected from the medical records. Heart failure that required hospitalization 
was defined as hospitalization for new-onset or worsening signs of chronic heart 
failure.. Ventricular arrhythmias included sustained ventricular tachycardia, 
ventricular fibrillation, or appropriate ICD shock.
DNA variant classification
Ascertainment of family history, genetic counseling, and DNA testing were 
performed at the clinical genetics department . DNA was isolated from peripheral 
blood with informed consent of the patients. DNA next generation panels for 
testing CMP genes were gradually introduced starting with 8 genes in 2006 to 
52 CMP genes in 2017. Of the 46 index patients, 35 (76%) has been tested with 
next generation sequencing panel of ≥42 cardiomyopathy genes. In 3 (10%) of 
the patients without a (L)PV less than 42 cardiomyopathy genes were tested. 
Assessment of the pathogenic effect of genetic variants was performed with the 
use of Alamut Interactive Biosoftware (Rouen, France). The classification system 
of variants was adapted from the proposed sequence variation classification of the 
American College of Medical Genetics (55).Variants classified as likely pathogenic 
(class IV) or pathogenic (class V) were included in this study.
CMR protocol
CMR imaging was performed on clinical 1.5T (n=46) and 3T (n=16) MRI systems 
(Signa Excite, n=27; Discovery MR750, n=16; Discovery MR450, n=12; Signa HDxt, 
n=6; Signa Genesis, n=1, all GE Healthcare, Milwaukee, WI, USA). Functional 
imaging was performed using a segmented, balanced steady-state free precession 
cine imaging with breath holding. Cine images were performed with slice thickness 
8mm and interslice gap of 2mm. Late gadolinium enhancement (LGE) images were 
acquired 10–15 min after the administration of 0.1-0.2mmol/kg of gadolinium-
based contrast agent using an inversion-recovery gradient-echo pulse sequence 
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with continued adjustment of inversion time to null normal myocardium. Cine and 
LGE images were acquired in standard long-axis views and short axis orientations 
covering the entire LV. 
CMR analysis
All CMR images were evaluated blinded to the results of DNA testing. On the 
cine short-axis stack endo- and epicardial contours were manually traced in 
end-diastole and end-systole according to Society for Cardiovascular Magnetic 
Resonance guidelines on CMR image post-processing (183), including papillary 
muscles and excluding trabeculations, to determine LV end-diastolic volume, end-
systolic volume, ejection fraction (EF) and mass. Volumes and mass were corrected 
for BSA calculated using the formula of Haycock (184). Maximum thickness of the 
septal and inferolateral wall in the end-diastole were measured. 
For global longitudinal strain (GLS) measurements two-dimensional feature 
tracking CMR analyses were performed. GLS was assessed by manually drawing 
endocardial borders, without inclusion of papillary muscles and trabeculations, 
in both end-diastolic and end-systolic phases at the long axis 2, 3 and 4 chamber 
(CH) views. Subsequently, endocardial borders were automatically tracked during 
the entire cardiac cycle. Visual assessment of the endocardial feature tracking was 
performed, in case of inaccurate tracking the endocardial contours were adjusted. 
Counterclockwise rotation was assigned a positive value and clockwise rotation 
a negative value. Absolute twist was the sum of the basal and apical rotation, 
neglecting the clockwise or counterclockwise direction (185). 
The following diagnostic CMR criteria described in the literature as markers for 
NCCM were measured and summarized in figure 1: 1. Petersen criteria in long-
axis (139), 2. Petersen criteria in short-axis (139), 3. Stacey criteria in short-axis (176), 
4. Jacquier criteria using LV mass (177), 5. Captur criteria using fractal dimension 
(FD) (178) and 6. Choi criteria (179).
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Petersen criteria in long-axis NC/C ratio assessed by evaluating long-axis 2, 3, 
and 4CH cine images for a distinct 2-layered appearance of a NC endocardial 
layer versus a C endocardial layer during end-diastole. The maximal 
NC layer and the according C wall thickness were measured in the same 
segment. The LV true apex and papillary muscles were excluded from the 
measurements. A NC/C ratio of >2.3 in any segment during end-diastole 
was the diagnostic requirement for the Petersen long-axis criteria (139). 
Petersen criteria and Stacey criteria in short-axis The LV was divided according 
to the 17 segments model of the LV by the American Heart association using 
Figure 1: CMR imaging criteria in noncompaction cardiomyopathy .
Petersen criteria in long-axis NC/C ratio assessed by evaluating long-axis 2, 3, and 4CH cine images 
for a distinct 2-layered appearance of a NC endocardial layer versus a C endocardial layer during 
end-diastole. The maximal NC layer and the according C wall thickness were measured in the same 
segment. The LV true apex and papillary muscles were excluded from the measurements. A NC/C 
ratio of >2.3 in any segment during end-diastole was the diagnostic requirement for the Petersen 
long-axis criteria (139).
1 2
64 5
3
CMR criteria Measurement Cut off forpositive criteria
1. Petersen long axis (4) Ratio of NC/C layer measured during end-diastole in all
3 long-axis views (2, 3 and 4 chamber)
Ratio >2.3 in any
long-axis view
2. Petersen short axis (4) Ratio of NC/C layer measured during end-diastole in short axis Ratio >2.3 in any segment
3. Stacey (5) Ratio of NC/C layer measured during end-systole in short axis Ratio ≥2.0 in any segment
4. Jacquier (6) [LV mass with trabeculations - LV mass without trabeculations]/ [LV mass
without trabeculations] x 100 measured in end-diastole
>20%
5. Captur (7) Fractal dimension measured in short axis slices of the apical third of the left
ventricle
>1.30 in any slice
6. Choi (8)
Ratio of the thickness of apical trabeculation to that of C myocardium in the
apical lateral segments (apex/C ratio) measured during end-diastole in all 3
long-axis views
Ratio >3.15 in any
long-axis view
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short-axis stack cine images (186). In 16 segments the maximum NC and the 
according C layer was measured. Segment 17 (the apex) and the papillary 
muscles were excluded from the measurements. The diagnostic criteria used 
for short-axis end-diastole were a NC/C ratio of >2.3 in end-diastole for Petersen 
criteria (139) and a NC/C ratio of ≥2.0 in end-systole for Stacey criteria (176). 
Jacquier criteria using LV mass After measuring LV end-diastolic mass 
(including papillary muscles), a second measurement was performed where 
we adjusted the endocardial tracings to include also the trabeculations. 
The percentage of trabeculation was derived by the following equation: 
[LV mass with trabeculations - LV mass without trabeculations]/[LV mass 
without trabeculations] x100. A percentage of >20% end-diastolic LV 
trabeculated mass of total LV mass was diagnostic for the Jacquier criteria 
(177). Also the higher cut-off of >35% proposed by Choi et al. was used (179). 
Captur criteria using fractal dimension We recorded maximal FD for the apical third 
of the LV excluding the most apical short-axis slice because of partial voluming. A 
maximum FD of ≥1.30 for the apical third was considered diagnostic for the Captur 
criteria (178). Eleven patients were not eligible for analysis because automated 
contour detection and FD assessment failed. This was mainly due to low contrast 
between blood and myocardium/trabeculations (1.5T 8 (17%) and 3.0T 3 (19%)). 
Choi criteria We measured the ratios of the thickness of apical trabeculation to that 
of C myocardium in the apical lateral segments (apex/C ratio) in all 3 long axis views. 
A ratio of >3.15 was diagnostic for the Choi criteria (179). We also scored the presence 
of an apical type NCCM, which was defined by Choi et al. as involving >3 segments 
meeting a NC/C ratio in diastole of >2.3 in the apical level (segment 13 through 17) (179). 
Number of criteria To evaluate how many diagnostic criteria were fulfilled per 
patient we included the sum of fulfilled criteria. We included: 1. the Petersen long 
axis, 2. Petersen short axis, 3. Stacey short axis, 4. Jacquier with the cut-off by Choi 
et al. and 5. Choi criteria. Choi’s cut-off (>35% trabeculae) for the Jacquier criteria 
was used, because this cut-off has higher sensitivity (179). The Captur criteria 
were not included because the FD could not be measured in all patients. Also this 
criterion was not significant in the univariate regression analysis. 
For CMR imaging analysis post processing ReportCARD 4.0 (GE Healthcare, 
Milwaukee, WI, USA) and Medis software were used (QMass software version 8.1 
and Qstrain software version 2.0, Medis, Leiden, The Netherlands). To calculate 
the FD we used software that was made available by Captur et al. (187) on OsiriX 
lite (version 8.5, Pixmeo SARL, Geneva, Swiss). 
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Volunteers
Because normal values of GLS, absolute twist, and FD are not yet well established 
and may vary depending on the software, these parameters were measured in 
18 adult healthy volunteers (age 32 ± 7 years, 33% male). These volunteers were 
previously described by van der Zwaan et al. and were scanned on Signa Excite 
1.5T scanner (188). In 1 volunteer the FD could not be correctly assessed. The GLS 
was -24 ± 3%, absolute twist 12.7 ± 7.0°, and maximum FD of the apical third was 1.30 
± 0.08. Using the cut off ≥1.30, 8 (47%) fulfilled the criteria of Captur.
Statistical analysis
Statistical analysis was performed with SPSS statistical software, version 25.0 
(SPSS Inc., Chicago, IL). Continuous variables were compared by Mann-Whitney 
U test because small samples are often not normally distributed. Categorical 
data were compared with Pearson Chi-Squared or with Fishers exact test when 
appropriate. Odds ratios (OR) with 95% confidence interval (CI) for having a (L)
PV were calculated using binary logistic regression. To identify independent 
predictors of a positive genetic test, variables were tested in a multivariate logistic 
regression analysis using forward stepwise selection. Variables were entered if 
the p-value was less than 0.10 and removed if the p-value was more than 0.10. We 
used receiver operating characteristics (ROC) curves to determine the area under 
the curve (AUC) of the different diagnostic criteria and the multivariate logistic 
regression model.
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Results
Table 1: Baseline characteristics of NCCM patients.
Total
(n=62)
(L)PV 
(n=33)
No (L)PV
(n=29)
p-value
Male
Caucasian
Body surface area, m2
Age at CMR, years
Familial cardiomyopathy
Diagnosed by family screening
Diabetes Mellitus
Hypertension
Coronary artery disease
Left bundle branch block
35 (56%)
54 (87%)
2.0 (0.3)
39 (16)
35 (56%)
17 (27%)
2 (3%)
9 (15%)
1 (2%)
10 (16%)
18 (55%)
31 (94%)
1.9 (0.3)
38 (15)
23 (70%)
11 (33%)
1 (3%)
2 (6%)
0 (0%)
2 (6%)
17 (59%)
23 (79%)
2.0 (0.3)
40 (16)
12 (41%)
6 (21%)
1 (3%)
7 (24%)
1 (3%)
8 (28%)
0.75
0.13
0.52
0.71
0.03
0.27
0.93
0.02
0.47
0.04
CMR parameters
LV EDV index, ml/m²
Dilated LV*
LV ESV index, ml/m²
LV EF, %
LV EF <40%
LV mass index, gr/m2
Global longitudinal strain, % 
LV absolute twist (deg)
Maximal septal wall thickness, mm
Septal hypertrophy (≥13mm)
Maximal inferolateral wall thickness, mm
Presence of LGE†
117 (32)
43 (69%)
70 (30)
42 (11)
19 (31%)
54 (14)
-18.0 (4.4)
10.5 (5.9)
6.7 (1.7)
0 (0)
6.1 (1.5)
12 (23%)
123 (34)
26 (79%)
75 (33)
41 (12)
11 (33%)
53 (12)
-17.3 (4.4)
10.1 (6.0)
6.4 (1.6)
0 (0)
5.8 (1.4)
7 (26%)
111 (29)
17 (59%)
63 (25)
44 (9)
8 (28%)
55 (16)
-18.9 (4.4)
11.1 (5.7)
7.1 (1.7)
0 (0)
6.5 (1.6)
5 (20%)
0.25
0.09
0.10
0.32
0.78
0.71
0.09
0.42
0.11
0.19
0.79
Data is presented as number (percentage) or mean (standard deviation).
CMR: cardiac magnetic resonance imaging, EDV: end-diastolic volume, EF: ejection fraction, ESV: 
end-systolic volume index, LGE: late gadolinium enhancement, LV: left ventricular.
* LV EDVindex for males >105 ml/m², females >96 ml/m²
† LGE was performed in 27 patients with a (L)PV and 25 without a (L)PV patients.
Baseline characteristics 
The study population consisted of 62 patients from 45 families and was categorized 
into two groups: 33 patients with a (L)PV and 29 without a (L)PV (table 1). Of the 
33 patients with a (L)PV 14 (42%) had a (L)PV in MYH7 (figure 2). Two (3%) patients 
had two (L)PVs (online table 1). In 22 (49%) of the families a (L)PV was identified. 
Seventeen (27%) patients were relatives and 11 of them had a (L)PV. Familial CMP 
was documented in 35 (56%) patients, which was more common in patients with 
a (L)PV (n=23, 70%), than in the patients without a (L)PV (n=12, 41%; p=0.03). 
Hypertension was more common in patients without a (L)PV (with a (L)PV n=2 (6%), 
without a (L)PV n=7 (24%); p=0.02). The LV was dilated in 43 (69%) patients and in 
19 (31%) LV-EF was <40%. There were no differences in LV-EF, GLS, LV mass, LV 
wall thickness and LV absolute twist between the patients with and without a (L)
PV. During a median follow-up of 4 years (interquartile range 1 - 7 years) 19 (31%) of 
the patients had a major adverse cardiac event consisting of heart failure requiring 
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hospitalization, transient ischemic attack, stroke, ventricular arrhythmia, heart 
transplant or cardiac death. There were no differences in outcome between the 
two groups (online table 2).
Diagnostic criteria on CMR
An overview of the diagnostic CMR criteria and the corresponding parameters 
are shown in table 2. Only one patient did not meet any of the NCCM criteria 
on CMR. All but one (2%) patient fulfilled the diagnostic criteria proposed by 
Petersen in long axis and criteria by Jacquier. In contrast, the Stacey’s short axis 
criteria were fulfilled in less than half of the cases. Figure 3 shows the distribution 
of the noncompacted segments meeting diagnostic criteria in the American 
Heart association 17 segment model in short axis view in diastole (Petersen) and 
systole (Stacey). The apical and mid-lateral segments were the dominant locations 
for meeting Petersen and/or Stacey criteria. More segments fulfilled the short 
axis Petersen than the Stacey criteria (meeting Petersen criteria 23% (232/992 
segments); meeting Stacey criteria 8% (80/992 segments); p<0.01). In online table 3 
the correlation of all CMR criteria are shown. Correlation between criteria varied 
from moderate (47%) to very strong (97%). Of the criteria, Petersen long-axis with 
Figure 2: Genetics of 62 NCCM patients.
In 53% patient of the study population a (L)PV was identified, with highest prevalence of MYH7 (L)
PVs. Other sarcomere genes: 2 MYBPC3, 2 TPM1; Non sarcomere genes: 1 LMNA, 2 PLN, 1 DSP, 1 MIB1, 
1 PRDM16, 1 RYR2; Complex 1 TTN and MIB1, 1 ACTN2 and SCN5A.
MYH7
23%
TTN
10%
Other 
sarcomere
6%
Non sarcomere
11%Complex
3%
No (L)PV
47%
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Table 2: Diagnostic CMR imaging criteria in NCCM patients.
Total
(n=62)
(L)PV 
(n=33)
No (L)PV
(n=29)
p-value
Petersen long axis end-diastole
Meeting criteria (ratio >2.3)
  Maximum NC/C ratio
  Number of long axis views with ratio >2.3
   0 or 1
   2 or 3
  Maximum NC, mm
  Maximum C, mm
61 (98%)
3.6 (0.9)
19 (31%)
43 (35%)
14.2 (4.1)
4.1 (0.9)
33 (100%)
3.8 (1.0)
5 (15%)
28 (85%)
15.2 (4.2)
4.1 (1.0)
28 (97%)
3.3 (0.8)
14 (48%)
15 (52%)
13.0 (3.8)
4.0 (0.8)
0.47
0.02
0.01
0.04
0.93
Petersen short axis end-diastole
Meeting criteria (ratio >2.3 in ≥1 segment)
  Maximum NC/C ratio
  Mean number of segments meeting criteria
  Maximum NC, mm
  Maximum C, mm
52 (84%)
3.9 (1.5)
3.7 (2.3)
17.0 (4.4)
7.5 (1.9)
29 (88%)
4.2 (1.6)
3.9 (2.4)
17.5 (4.7)
7.4 (2.1)
23 (79%)
3.6 (1.4)
3.3 (2.2)
16.5 (4.0)
7.5 (1.7)
0.36
0.07
0.41
0.51
0.48
Stacey short axis end-systole
Meeting criteria (ratio ≥2.0 in ≥1 segment)
  Maximum NC/C ratio
  Mean number of segments meeting criteria
  Maximum NC, mm
  Maximum C, mm
30 (48%)
2.2 (0.8)
1.3 (1.9)
14.2 (3.6)
10.8 (2.5)
17 (52%)
2.3 (0.8)
1.6 (2.1)
14.7 (3.8)
10.4 (2.9)
13 (45%)
2.1 (0.7)
0.9 (1.5)
13.7 (3.3)
11.1 (1.9)
0.60
0.28
0.31
0.50
0.06
Jacquier
Meeting criteria (>20%)
  Meeting criteria with Choi cut off (>35%)
  Trabecular mass, (±SD)
61 (98%)
39 (63%)
39 (9)
33 (100%)
24 (73%)
42 (10)
28 (97%)
15 (52%)
36 (7)
0.47
0.09
<0.01
Captur*
Maximum fractal dimension apical third ≥1.30
  Maximum fractal dimension apical third
48 (94%)
1.43 (0.09)
26 (93%)
1.43 (0.09)
22 (96%)
1.43 (0.09)
0.67
0.91
Choi criteria
Meeting criteria (ratio >3.15)
  Choi ratio
  Apical type
35 (57%)
3.4 (1.9)
22 (36%)
21 (66%)
3.8 (1.6)
14 (42%)
14 (48%)
3.0 (2.2)
8 (28%)
0.22
0.15
0.22
Number of fulfilled criteria†
Average number of criteria (0-5)
≥4 criteria
3.5 (1.1)
31 (50%)
3.8 (1.1)
21 (64%)
3.2 (1.1)
10 (34%)
0.06
0.02
Data is presented as number (percentage) or mean (standard deviation). C: compacted, NC: 
noncompacted, * In 11 patients Cardiac Magnetic Resonance (CMR) imaging was not eligible for 
analysis 
† Sum of meeting the following 5 criteria: Petersen long axis, Petersen short axis, Stacy short axis, 
Jacquier with Choi’s cut-of, and Choi criteria.
Jacquier had the highest agreement (97%), while Stacey with Jacquier had the 
lowest (47%). 
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Figure 3a: Segments meeting Petersen (diastole) short axis criteria.
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Patients with a mutation n=33 Patients without a mutation n=29
Figure 3b: Segments meeting Stacey (systole) short axis criteria.
Greener shades indicate low frequency of LV segment meeting diagnostic criteria to red shades 
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(L)PV status and CMR criteria
On average the NCCM patients in this cohort met 3.5 of 5 CMR diagnostic criteria 
(table 2). Patients with a (L)PV had more extensive trabeculations; a higher 
maximum NC/C ratio measured in any long axis (p=0.02), more often fulfilling 
Petersen criteria in ≥2 long axis views per patient (p=0.01), and higher percentage 
of trabecular mass (p<0.01). Patients with a (L)PV were more often meeting at least 
4 CMR diagnostic criteria than patients without a (L)PV (with a (L)PV 64%, without 
a (L)PV 34%; p=0.02). In figure 4, ROC analysis illustrate the association between 
different diagnostic CMR parameters and NCCM with a (L)PV. 
In multivariate binary logistic regression analysis including both CMR and non-
CMR parameters, independent positive predictors for having a (L)PV were familial 
CMP (OR: 10.1, 95%CI: 1.9-54.5), percentage increase in trabecular mass (OR: 1.2, 
95%CI: 1.0-1.3) and meeting Petersen criteria in ≥2 long axis views (OR: 7.9, 95%CI: 
1.5-42.5), while left bundle branch block (OR: 0.03, 95%CI: 0.0-0.8) and hypertension 
(OR: 0.03, 95%CI: 0.0-0.4) were negative predictors (table 3). The ROC-curve of this 
multivariate model had an AUC of 0.89 (95%CI 0.82-0.97) (central illustration). In 
patients with familial disease without a (L)PV, a genetic cause can be expected. 
Excluding these patients from the group without a (L)PV led to similar results, 
except for hypertension, which was not a significant predictor anymore (Online 
table 4).
Figure 4: ROC curve analysis of association for different diagnostic CMR criteria with 
finding a (L)PV.
Only trabecular mass was a good predictor using diagnostic criteria for finding a (L)PV with an area 
under the curve of 0.70 (95% CI 0.57-0.83). C: compacted, CI: confidence interval, NC: noncompacted, 
ROC: Receiver-operator characteristic.
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Different (L)PVs
The results of the different diagnostic criteria were similar for patients with single 
(L)PVs , MYH7 n=14, TTN n=6, other sarcomere n=4 (2 MYBPC3 and 2 TPM1), non-
sarcomere n=7 (1 LMNA, 2 PLN, 1 DSP, 1 MIB1, 1 PRDM16 and RYR2) and complex 
genotypes n=2 (patients with two (L)PVs: 1 TTN and MIB1; 1 ACTN2 and SCN5A) 
(Online table 5). Around two third of the patients with a MYH7, TTN or a non-
sarcomere (L)PV fulfilled more than 4 diagnostic criteria, compared to 34% of the 
patients without a (L)PV. Patients with a complex genotype fulfilled almost all the 
different diagnostic criteria. The patient category with other sarcomere (L)PVs (2 
MYBPC3, 2 TPM1) fulfilled the least diagnostic criteria on CMR.
Central illustration: Receiver-operator characteristic (ROC) curve analysis in noncompaction 
cardiomyopathy for prediction of finding a mutation.
Noncompaction cardiomyopathy (NCCM) was genetic in half of the study population. Genetics may 
play an important role distinguishing patients from people with physiologic hypertrabeculations. 
In multivariate regression analysis independent positive predictors for a positive genetic test were 
familial cardiomyopathy, trabecular mass, and meeting Petersen criteria in ≥2 long axis views, 
while left bundle branch block and hypertension were negative predictors. The ROC-curve of this 
multivariate model had an area under the curve of 0.89 and provided a good model for finding a 
(likely) pathogenic variant in NCCM.
AUC: area under the curve, CI: confidence interval.
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1,00,80,60,40,20,0
Se
ns
iti
vi
ty
1,0
0,8
0,6
0,4
0,2
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Multvariate regression model         0.89 (0.82-0.97)         <0.01  
Trabecular mass    0.70 (0.57-0.83)           0.01
≥2 long axis views with (Petersen) ratio >2.3           0.67 (0.53-0.80)           0.03
No left bundle branch block  0.61 (0.47-0.75)           0.15
No hypertension   0.59 (0.45-0.73)           0.22
Familial cardiomyopathy    0.64 (0.52-0.78)           0.06
        AUC (95% CI)         p-value
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Table 3: Univariate and multivariate binary logistic regression for the prediction of a positive 
genetic test in NCCM patients.
Variable Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Male
Age at CMR , years
Familial cardiomyopathy
Hypertension
Left bundle branch block
LV end-diastolic volume index, ml/m2
LV ejection fraction, %
Reduced LV ejection fraction (<50%)
Global longitudinal strain, %
LV absolute twist, deg
0.85 (0.31-2.32)
0.99 (0.96-1.02)
3.26 (1.14-9.29)
0.20 (0.04-1.07)
0.17 (0.03-0.88)
1.01 (1.00-1.03)
0.96 (0.92-1.02)
2.13 (0.61-7.46)
0.91 (0.80-1.03)
0.97 (0.89-1.06)
0.75
0.62
0.03
0.06
0.03
0.15
0.18
0.24
0.15
0.49
10.08 (1.87-54.53)
0.03 (0.00-0.44)
0.03 (0.00-0.75)
0.01
0.01
0.03
CMR imaging criteria
Petersen long axis end-diastole NA
  Maximum NC/C ratio
  ≥2 long axis views with ratio >2.3
1.79 (0.98-3.28)
5.23 (1.58-17.32)
0.06
0.01 7.85 (1.45-42.46) 0.02
Petersen short axis end-diastole 1.89 (0.48-7.51) 0.37
  Maximum NC/C ratio 1.33 (0.93-1.90) 0.11
Stacey short axis end-systole 1.31 (0.48-3.56) 0.60
  Maximum NC/C ratio 1.44 (0.72-2.91) 0.31
Jacquier end-diastolic (Choi >35%) 2.49 (0.87-7.16) 0.09
  Trabecular mass, % 1.10 (1.03-1.18) 0.01 1.16 (1.04-1.30) 0.01
Captur fractal dimension 0.59 (0.05-6.96) 0.68
  Maximum fractal dimension apical third 0.53 (0.00-303.11) 0.84
Choi criteria 2.05 (0.73-5.73) 0.17
  NC/C ratio 1.25 (0.95-1.65) 0.11
Number of fulfilled criteria*
Number of criteria
≥4 criteria
1.59 (0.98-2.58)
3.33 (1.17-9.44)
0.06
0.02
C: compacted, CI: confidence interval, LV: left ventricle, CMR: cardiac magnetic resonance imaging, 
NC: noncompacted, OR: odds ratio
* Sum of meeting the following 5 criteria: Petersen long axis, Petersen short axis, Stacy short axis, 
Jacquier with Choi’s cut-of, Choi criteria.
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Discussion
This study included cardiomyopathy patients fulfilling the echocardiographic 
Jenni criteria for NCCM to investigate the association between clinical and 
CMR characteristics and if CMR features allowed to distinguish which patients 
had  high risk of having a  mutation. Approximately half of the patients had a 
(L)PV. In patients with and without a (L)PV the correlation between the different 
CMR criteria ranged from moderate to very strong. We presented a model with 
the combination of clinical as well as CMR parameters that could predict finding 
a mutation with an AUC of 0.89. Patients with a (L)PV had more often familial 
cardiomyopathy and more extensive trabeculations. However, the common used 
cut offs used for the CMR criteria were not associated with finding a (L)PV. Patients 
with hypertension or left bundle branch block were less likely to have a (L)PV. We 
also showed that important factors for cardiomyopathy like LV systolic dysfunction 
and LV dilatation did not predict finding a (L)PV. 
Genetic NCCM patients
Identification of the causative (L)PV is of importance. Firstly, it facilitates cascade 
family screening. This allows identifying accurately relatives at risk of having a 
cardiomyopathy and also helps to reassure relatives, who do not have the familial 
(L)PV. Secondly, it may help to distinguish patients with a genetic CMP from the 
frequently observed healthy cases with physiologic hypertrabeculation (16, 17). 
Thirdly, it was shown that the prognosis of patients with a (L)PV, can be predicted 
by the LV systolic function in contrast to cases without a (L)PV (180). In conclusion, 
identification of patients who are most likely to have a genetic defect may help in 
the clinic to know which patient will benefit most from referral for  genetic testing 
and may save costs and clinical resources.
Secondary causes for hypertrabeculation
The genetic yield in index patients in this study (49%) was higher than in previous 
studies (32 to 38%) (8, 155). An explanation may be that in this cohort of selected 
patients of a tertiary referral center, a high prevalence of LV systolic dysfunction 
was noted. In the literature having a reduced LV-EF is associated with finding 
a (L)PV in NCCM (147, 185). Another explanation in this cohort may be that no 
significant difference in age at presentation was observed between patients with or 
without a (L)PV. Previous studies showed that patients without a (L)PV are older 
(8, 189). When no (L)PV is identified, noncompaction may be attributed to non-
genetic, secondary causes for hypertrabeculation or still unknown genetic (L)PVs. 
In this study left bundle branch block and hypertension were negatively associated 
with having a (L)PV. Other studies also found a higher prevalence of hypertension 
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in patients without a (L)PV (8, 9). These characteristics may influence loading 
conditions leading to cardiac remodeling into the noncompaction phenotype. 
Previous studies showed that pregnancy, athletes and race might be secondary 
causes for noncompaction (26, 40, 61, 152). In this study no athletes or pregnant 
women were included. We did not found race to be a predictor of having a (L)PV 
however the majority in our population was Caucasian and the sample size was 
small. Our results need to be validated in larger cohorts and possibly other factors 
like age or secondary causes may play a role in distinguishing genetic patients.
Diagnostic criteria
In NCCM gold standard for the diagnostic criteria are still missing. In this study 
different diagnostic criteria were fulfilled in patients meeting Jenni criteria on 
echocardiography with the lowest yield of Stacey short axis criteria of 48% and 
highest yield of the Petersen long axis-criteria were fulfilled in 98%. However, in 
large population studies 15% up to 40% of the people fulfilled the Petersen long 
axis criteria for noncompaction on CMR (16, 17). Despite this low specificity of 
some of the criteria, poor agreement between criteria was noted in this study. For 
a more accurate diagnosis the criteria may need to change from imaging criteria 
solely to a diagnostic model in which imaging criteria are combined with clinical 
characteristics, genetics, and functional features. Identifying the causative (L)PV 
in individuals with hypertrabeculation may help to confirm a diagnosis of NCCM, 
since people without a cardiomyopathy are expected not to carry a (L)PV. Following 
this analogy identification of characteristics of patients who are most likely to 
have a (L)PV may also help in the clinic, to distinguish patients from physiologic 
trabeculations. A composed diagnostic tool including the morphological and 
functional criteria may help to more accurately distinguish cases with physiologic 
hypertrabeculation from (asymptomatic) patients with a genetic CMP requiring 
lifelong follow-up.
Study limitations
This study may have some limitations. Firstly, the group of patients without a (L)
PV included patients with familial CMP. In these familial patients novel genetic 
causes are expected, which may have led to misclassification of these patients. 
However, additional analysis showed that excluding patients with familial CMP in 
the group with no (L)PV gave similar results. Secondly, a selection bias could have 
been introduced since the study only included patients presenting in a tertiary 
referral center and only patients with a CMR and genetic testing were included. 
Other limitations may be due to the retrospective design of the study. Over time 
different MRI scanners were used, and newer scanners have better image quality, 
Chapter 4
146
making it easier to distinguish trabeculae from other structures or blood. This 
was also an important reason why fractal analysis could not be performed in all 
patients. Furthermore, not all participating NCCM index cases had extensive 
next-generation DNA sequencing cardio-panel testing, which may have led to 
underreporting of genetic causes.
Conclusion
NCCM patients with a (L)PV can be distinguished from patients without a (L)
PV using clinical and morphologic features. Important predictors of having a 
(L)PV were familial CMP, no left bundle branch block, no hypertension, higher 
trabecular mass and meeting Petersen criteria in ≥2 long axis views. These 
predictors may help guiding genetic diagnostics, cascade screening and clinical 
treatment strategies. 
Perspectives
Competency in medical knowledge
Genetics in NCCM may help assessing prognosis, guide family screening and 
predict risks for relatives. This study shows NCCM patients with a (likely) 
pathogenic variant can be distinguished by having familial cardiomyopathy, no 
left bundle branch block, no hypertension, higher trabecular mass and meeting 
Petersen criteria in ≥2 long axis views.
Translational Outlook
Frequently patients can be diagnosed with noncompaction according to diagnostic 
criteria on CMR. This makes it difficult to distinguish patients with a genetic 
cardiomyopathy from patients with physiologic hypertrabeculation. Predictors 
for finding a (likely) pathogenic variant can help the clinician to decide  to refer 
patients for genetic testing. 
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Abstract
Background: A genetic cause can be identified in 30% of noncompaction 
cardiomyopathy patients (NCCM) with clinical features ranging from asymptomatic 
cardiomyopathy to heart failure with major adverse cardiac events (MACE). 
Methods and Results: To investigate genotype-phenotype correlations, the genotypes 
and clinical features of genetic NCCM patients were collected from the literature. We 
compared age at diagnosis, cardiac features and risk for MACE according to mode of 
inheritance and molecular effects for defects in the most common sarcomere genes 
and NCCM subtypes. Geno- and phenotypes of 561 NCCM patients from 172 studies 
showed increased risk in children for congenital heart defects (p<0.001) and MACE 
(p<0.001). In adult NCCM patients the main causes were single missense mutations 
in sarcomere genes. Children had more frequently an X-linked or mitochondrial 
inherited defect (p=0.001) or chromosomal anomaly’s (p<0.001). MYH7 was involved 
in 48% of the sarcomere gene mutations. MYH7 and ACTC1 mutations had lower risk 
for MACE than MYBPC3 and TTN (p=0.001). The NCCM/DCM cardiac phenotype 
was the most frequent subtype (56%; p=0.022) and was associated with an increased 
risk for MACE and high risk for left ventricular (LV) systolic dysfunction (<0.001). 
In multivariate binary logistic regression analysis MYBPC3, TTN, arrhythmia -, 
non-sarcomere non arrhythmia cardiomyopathy – and x-linked genes were genetic 
predictors for MACE. 
Conclusions: Sarcomere gene mutations were the most common cause in adult 
patients with lower risk of MACE. Children had multi-systemic disorders with severe 
outcome, suggesting that the diagnostic and clinical approaches should be adjusted 
to age at presentation. The observed genotype-phenotype correlations endorsed that 
DNA diagnostics for NCCM is important for clinical management and counselling of 
patients. 
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Introduction
Noncompaction cardiomyopathy (NCCM) is a rare cardiomyopathy characterised 
by excessive trabeculation of the left ventricle (21), and is also known as left 
ventricular hypertrabeculation/ noncompaction (LVHT/LVNC). Diagnostic 
criteria are based on cardiac imaging with echocardiography or cardiac magnetic 
resonance imaging (CMR) requiring at least a twofold increase of ratio of 
endocardial hypertrabeculation (21, 25, 190). Genetics plays an important role 
in NCCM in at least half the case; 30% of the index patients have a mutation or 
chromosome defect. In addition, unknown genetic causes are expected in in 20% 
of the index patients with familial disease, who do not have a mutation (8). In 
cardiomyopathy patients, who do not have familial disease or a mutation, the cause 
of NCCM may involve unknown low penetrance genetic causes and/or cardiac 
stress induced mechanism (11, 175). In addition physiologic hypertrabeculation 
occurs in people without a cardiomyopathy.
The most prevalent genetic causes for NCCM are defects in the same sarcomere 
genes that are frequent causes for hypertrophic cardiomyopathy (HCM) and dilated 
cardiomyopathy (DCM); MYH7, MYBPC3 and TTN (8, 191), and are autosomal 
dominantly inherited with reduced penetrance. Less frequent are cases of NCCM 
inherited as X-linked or mitochondrial traits, or chromosome defects, which are, 
usually associated with complex congenital malformations in children (6, 192, 193).
Establishing genotype-phenotype correlations is important for genetic 
counselling and clinical management of NCCM. Previous studies suggested that 
the genetic defect, left ventricular systolic function and age at diagnosis were 
important predictors of cardiac features and risk for major adverse cardiac (8, 194). 
Since NCCM is a relatively rare, genetically heterogonous cardiomyopathy, large 
studies are needed to establish a correlation between genetic defects and clinical 
outcome. By performing a systematic review of the NCCM literature for reports of 
NCCM patients with documented genotype and phenotypes, we could combine 
and analyse the results of smaller studies to determine the genetic spectrum of 
NCCM and establish if genetic causes could help predict high risk profiles for 
major adverse cardiac events in NCCM. 
Methods
Data Availability
The data of this study is extracted from publications, which were available online. 
The authors declare that all supporting data are available within the article and its 
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online supplementary files. Since data was obtained from publications, no consent 
from an institutional review committee was required. 
Data collection 
The collection of data included publications from 1999 to march 2018. We selected 
English publications. Inclusion criteria were that the complete results of DNA-
testing or cytogenetic analysis and the cardiologic data of each individual patient 
were available. Only NCCM patients fulfilling the current diagnostic criteria 
were included in the study. Patients presumed to be reported more than once by 
different studies (based on mutation specifics: same amino acid change and base 
change in the same gene; sex; age, also with respect to date of publication; and 
corresponding authors) were included once. A detailed description of the search 
terms used for this study, the collection of studies and inclusion of patient data is 
presented in online methods and online figure 1. 
Specifics of the genetic defects of each patient and information on family histories 
of cardiomyopathies (NCCM, HCM or DCM) or sudden death below age of 50 
years in relatives were collected. The included cardiologic data consisted of ECG, 
the applied diagnostic criteria used to diagnose NCCM, the modality of diagnosis 
(echocardiography, cardiac magnetic resonance imaging (CMR), computed 
tomography (CT), and the cardiac symptoms. Information on the occurrence of 
congenital heart disease (CHD) and neuromuscular disease in NCCM patients was 
recorded. Patients were classified as having left ventricular dilatation when this was 
reported. In case this information was missing the occurrence of left ventricular 
(LV) dilatation was determined from presented LV measurements; patients were 
classified with LV dilation when left ventricular end diastolic diameter (LVEDD) 
was ≥60mm in males or ≥54mm in females, or left ventricular end diastolic 
diameter index (LVEDDi) was ≥31mm in males or ≥32mm in females (195). For 
children, dimensions of the left ventricle of <2 SDs from the reference range were 
classified as dilated (145). Patients were classified as having left ventricular systolic 
dysfunction if reported, or if fractional shortening (FS) was <25% in males or <27% 
in females, or if LV ejection fraction was <55% in males and females. We recorded 
the occurrence and the age of a patient suffering sudden cardiac death (SCD), 
heart transplantation, having a left ventricular assist device, stroke, or heart failure 
requiring hospital admission.
NCCM subtypes
NCCM patients were classified into the four NCCM subtypes (when LV diameters 
were known): Isolated NCCM, NCCM/HCM, NCCM/DCM and NCCM/HCM/
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DCM. Patients were classified as isolated NCCM if when they had normal LV 
dimensions without LV hypertrophy. NCCM patients were categorized into 
NCCM/HCM if they also had LV wall hypertrophy of ≥13mm or the diagnosis 
HCM was reported. A NCCM patient was classified as NCCM/DCM if the patient 
had LV dilatation. The NCCM patient was classified as NCCM/HCM/DCM if the 
patient had LV dilation and LV wall hypertrophy.
Genetic causes
In total 80 genes were reported as the genetic causes for NCCM, of which 14 were 
excluded from this review, because there was not sufficient evidence to support 
that these genes could be the cause of a cardiomyopathy. The genetic defects 
were grouped according to the molecular function of the gene, into sarcomere- 
or arrhythmia cardiomyopathy genes, non-sarcomere and non-arrhythmia 
cardiomyopathy genes. Genes involved in cardiac development, mitochondrial 
genes, X-linked inherited disorders and chromosome defects were also analysed 
separately. Figure 1 presents an overview of the genetic causes: the sarcomere genes 
were ACTC1, ACTN2, DES, LDB3, MYBPC3, MYH7, MYL2, NEBL, OBSCN, TNNC1, 
TNNI3, TNNT2, TPM1 and TTN. The arrhythmia genes were 10 genes associated 
with ion channels and transport: ABCC9, ANK2, CACNA2D1, CASQ2, HCN4, KCNE3, 
KCNH2, KCNQ1, RYR2 and SCN5A. The group of cardiomyopathy genes, which 
were not sarcomere or arrhythmia genes: DMPK, DSP, DTNA, FKTN, HFE, JUP, 
LMNA, PKP2, PLEC, PLN, PRDM16, RBM20 and SGCD. Eight genes were previously 
associated with developmental defect of the heart: MIB1, MIB2, NKX2.5, NOTCH1, 
NSD1, PTPN11, TBX20 and TBX5. X –linked inherited NCCM included the DMD, 
FHL1, GLA, LAMP2, RPS6KA3 and TAZ genes. Mitochondrial dysfunction as the 
cause of NCCM was considered when a mutations occurred in a gene affecting 
mitochondrial functioning, including the nuclear genes with a mitochondrial 
function or the mitochondrial DNA genes: HADHB, HMGCL, MIPEP, MLYCD, 
MT-ATP6, MT-CO1, MT-CO3, MTFMT, MT-ND1, MT-ND2, SDHA, SDHD, TMEM70 
and VARS2. Some additional genes were only reported in patients with complex 
genotypes, including: BB2, BMPR1A, CSRP3, EMD, ITGA7, MT-TL1, MYH6, MYH7B, 
MYLK2, MYPN, PLEKHM2, RANGRF, and SH3PXD2B. The current analysis did 
not include single cases of genetic causes for which there was little evidence 
for involvement in cardiomyopathy (ARFGEF2, CYP2C9*2, GARS, LMX1B, MBL2, 
MMACHC, MSH6, NONO, PKD1, PKD2, PMP22, POMT2, SMC1A and YWHAE). 
We compared the clinical features in patients according to the genetic causes, 
i.e. in patients with sarcomere gene mutations, in patients with mutations in 
cardiomyopathy genes (i.e. sarcomere, arrhythmia, and other cardiomyopathy 
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genes). In patients with non- autosomal dominant inherited NCCM, the phenotypes 
of patients were compared according to the characteristics of the genetic cause 
(complex genotypes, X-linked, mitochondrial defects, and chromosome defects).
Statistical analysis
Categorical data were analysed with Pearson’s chi-squared test or Fisher exact test. 
For comparison of medians the independent samples Kruskal-Wallis test was used. 
Odds ratios (OR) with 95% confidence interval (CI) for MACE were calculated using 
binary logistic regression. To identify independent predictors for MACE, variables 
were tested in a multivariate logistic regression analysis using the enter method. 
Age, sex and other parameters with a p-value <0.05 were stepwise entered in to 
the multivariate model. Multiple imputation for the entered predictors was used 
to handle missing data in the multivariate regression models. Statistical analysis 
was performed with SPSS statistical software, version 21.0 (SPSS Inc., Chicago, IL). 
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Results
Table 1: Cardiac features of 541 genetic NCCM patients*.
Children (<18 yrs) 
n=244
Adults n=297 Total n=541 p-value
NCCM index patients
Male (%)
Median age at diagnosis in years (IQR)
195/244 (80%)
122/238 (51%)
0 (0-10)
201/297 (68%)
154/297 (52%)
41 (30-53)
396/541 (73%)
276/535 (52%)
23 (1-43)
0.001
ns
NA
Congenital heart disease
Ebstein anomaly
Atrial septal defect
Ventricular septal defect
Patent ductus arteriosus
Patent foramen ovale
Hypoplastic left heart
Aortic coarctation
45/244 (18%)
11/45 (24%)
17/45 (38%)
20/45 (44%)
11/45 (24%)
4/45 (9%)
2/45 (4%)
2/45 (4%)
13/297 (4%)
10/13 (77%)
7/13 (54%)
2/13 (15%)
1/13 (8%)
1/13 (8%)
0/13 (0%)
0/13 (0%)
58/541 (11%)
21/58 (36%)
24/58 (41%)
22/58 (38%)
12/58 (21%)
5/58 (9%)
2/58 (3%)
2/58 (3%)
<0.001
<0.001
ns
ns
ns
ns
ns
ns
Heart failure
Left ventricular dilatation
Left ventricular systolic dysfunction
115/244 (47%)
101/150 (67%)
123/179 (69%)
153/297 (52%)
105/170 (62%)
131/233 (56%)
268/541 (50%)
206/326 (64%)
254/412 (62%)
ns
ns
0.010
Pacemaker
ICD
12/244 (5%)
19/244 (8%)
14/297 (5%)
63/297 (21%)
26/541 (5%)
82/541 (15%)
ns
<0.001
Major adverse cardiac events
Stroke
Heart failure requiring hospital admission
Left ventricular assist device
Heart transplantation
Sustained VT/VF or appropriate shock
Cardiac death
94/244 (39%)
2/244 (1%)
34/244 (14%)
6/244 (3%)
25/244 (10%)
30/244 (12%)
35/244 (14%)
55/297 (18%)
6/297 (2%)
6/297 (2%)
2/297 (1%)
5/297 (2%)
23/297 (8%)
10/297 (3%)
149/541 (28%)
8/541 (1%)
40/541 (8%)
8/541 (1%)
30/541 (5%)
53/541 (10%)
45/541 (9%)
<0.001
ns
<0.001
ns
<0.001
ns
<0.001
Neuromuscular symptoms 35/60 (58%) 15/83 (18%) 50/143 (35%) <0.001
ICD implantable cardiac device; IQR interquartile range; LV left ventricular; ns not significant; NA 
Not applicable; NCCM noncompaction cardiomyopathy 
* age at diagnosis was missing for 20 cases.
Study population
The literature searches yielded 1978 publications reporting NCCM patients. After 
removing duplicates from the different searches 990 papers remained of which 
172 fulfilled the inclusion criteria. In total 561 patients were included in this review 
(online figure 1). Age at presentation was reported in 541/561, and sex was reported 
in 554 cases. Among the NCCM patients 415 (72%) were index cases (the first patient 
diagnosed with NCCM in a family) and 159 (28%) were affected family members 
(table 1). The study population consisted of 244 children, diagnosed before the 
age of 18 years and 297 adults. The diagnosis was based on echocardiography in 
402 NCCM patients, cardiac magnetic resonance imaging (CMR) in 66, 104 had an 
echocardiography and CMR and 2 patients were diagnosed at autopsy. 
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Genetics of  NCCM
In total 369 unique genetic defects in 66 genes were included. The majority of ge-
netic causes were single mutations (85%) of which autosomal dominantly inheri-
ted missense mutation were the most frequent (55%; table 2). In 7% of the patients 
an X-linked inherited genetic defect was reported, mostly in TAZ (n=31, 6%). In 
32 (6%) of the patients a chromosome defect was reported, of whom 28 (88%) 
were diagnosed in childhood (table 2, 3). Detailed descriptions of the reported 
mutations are presented in the online supplement table 1. More than 50 percent 
(292/651) of the genetic defects were reported in sarcomere genes, most prevalent-
ly in MYH7 (n=142, 25%; figure 1, table 4, 5). Mutations in arrhythmia genes were 
observed in 11% of the patients, in particular in HCN4 (n=22, 4%)(table 4). Details 
of the complex genotypes are presented in the online supplement table 2. The 
complete list of reported chromosome defects is presented in the online sup-
plement table 3, showing the 1p36 locus was the most frequently reported, in 13 
patients, and 22q11 defects in three patients. 
Table 2: Genetics of 396 NCCM index patients.
Children* Adults n=297 Total n=541 p-value
Type of mutation
Missense mutation
Other mutations†
Complex genotype**
Chromosome defect
98 (50%)
56 (29%)
14 (7%)
27 (14%)
119 (59%)
63 (31%)
15 (7%)
4 (2%)
217 (55%)
119 (30%)
29 (7%)
31 (8%)
<0.001
Mode of inheritance***
Autosomal dominant
X-Linked
Mitochondrial
105 (75%)
26 (19%)
9 (6%)
162 (89%)
10 (5%)
10 (5%)
267 (83%)
36 (11%)
19 (6%)
0.001
Familial cardiomyopathy
NCCM in family
HCM / DCM in family
SCD before age 50 yrs in family
60 (31%)
38 (20%)
28 (14%)
34 (17%)
109 (54%)
68 (34%)
49 (24%)
44 (22%)
169 (43%)
106 (27%)
77 (19%)
78 (20%)
<0.001
0.001
0.012
ns
DCM dilated cardiomyopathy; HCM hypertrophic cardiomyopathy; SCD sudden cardiac death 
* presentation before age 18 years, ** at least two mutations, † nonsense- or frameshift mutations, 
small deletions or insertions *** Chromosome defects and complex genotypes excluded.
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Figure 1: Genetic noncompaction cardiomyopathy.
Other sarcomere genes: ACTN2, DES, LDB3, MYL2, NEBL, OBSCN, TNNC1 and TNNI3. 
Other arrhythmia genes: ABCC9, ANK2, CACNA2D1, CASQ2, KCNE3, KCNH2 and KCNQ1
Non-sarcomere, non-arrhythmia-cardiomyopathy genes: DMPK, DSP, DTNA, FKTN, HFE, JUP, 
LMNA, PKP2, PLEC, PLN, PRDM16, RBM20 and SGCD
Other X-linked genes: DMD, FHL1, GLA, LAMP2 and RPS6KA3 
Other genes associated with CHD: MIB2, NKX2.5, NOTCH1, NSD1, PTPN11, TBX20 and TBX5. 
Mitochondrial-functioning: HADHB, HMGCL, MIPEP, MLYCD, MT-ATP6, MT-CO1, MT-CO3, 
MTFMT, MT-ND1, MT-ND2, SDHA, SDHD, TMEM70 and VARS2.
Chromosome defect: see online table 3
Complex genotypes: see online table 2.
Chapter 5
160
Children and adult NCCM patients 
Overall genetic NCCM in children was associated with more severe features, CHD 
(p<0.001), LV systolic dysfunction (p=0.010), MACE (p<0.001), and neuromuscular 
signs (p<0.001; table 1). The NCCM index cases diagnosed in childhood were more 
likely to have a chromosomal anomaly (p<0.001), an X-linked inherited disorder 
(p=0.001; table 2) or mitochondrial defect. In 52% of the patients diagnosed 
before the age of 10 years there was an autosomal dominant inheritance, 37% had 
a sarcomere gene defects, 8% had an arrhythmia gene, 5% non-sarcomere non-
arrhythmia cardiomyopathy genes and 3% a gene associated with CHD. In contrast, 
84% of the patients above 20 years had an autosomal dominant inheritance of 
which 64% in a sarcomere gene (p<0.001; figure 2). Familial cardiomyopathy was 
reported more frequently in families of adult - than paediatric index patients 
(adults 54% vs children 31%, p<0.001; table 2). In 93 (57%) families all affected 
relatives were reported to have NCCM. Sudden cardiac death (SCD <50y) in 
relatives was reported in 78 (20%) of the families (table 2). 
Table 3: Genotype- phenotype correlations in 561 genetic NCCM patients.
Cardiomyopat-
hy genes*
Complex
Genotype**
X-linked Mitochondrial Chromosome 
defects 
n=416 (74%) n=33 (6%) n=41 (7%) n=39 (7%) n=32 (6%)
Male
Median age at diagnosis in years (IQR)
Congenital heart disease
Neuromuscular symptoms
LV dilatation
LV systolic dysfunction 
Major adverse cardiac events†
Stroke
Heart failure requiring hospital admission
Left ventricular assist device
Heart transplantation
Sustained VT/VF or appropriate shock
Cardiac death
203/411 (49%)
29 (10-45)
38/416 (9%)
12/90 (13%)
142/245 (58%)
177/307 (43%)
97/416(23%)
6/416 (1%)
18/416 (4%)
6/4316 (1%)
21/416 (5%)
38/416 (10%)
23/416 (6%)
18/32 (44%)
23 (0-45)
2/33 (1%)
4/9 (44%)
14/16 (88%)
19/28 (68%)
10/33 (30%)
2/33 (6%)
2/33 (6%)
0/33 (0%)
2/33 (6%)
5/33 (15%)
1/33 (3%)
35/41 (83%)
0 (0-29)
0/41 (0%)
14/16 (88%)
24/27 (89%)
27/36 (75%)
21/41 (51%)
0/41 (0%)
9/41 (22%)
1/41 (2%)
4/41 (10%)
5/41 (12%)
9/41 (22%)
22/38 (58%)
0 (0-27)
6/39 (15%)
9/16 (56%)
17/18 (94%)
21/29 (72%)
10/39 (26%)
0/39 (0%)
3/39 (8%)
1/39 (3%)
2/39 (5%)
2/39 (5%)
7/39 (18%)
7/32 (22%)
0 (0-9)
13/32 (41%)
11/12 (92%)
10/15 (67%)
11/21 (52%)
11/32 (34%)
0/32 (0%)
8/32 (25%)
0/32 (0%)
1/32 (3%)
3/32 (9%)
5/32 (16%)
 IQR interquartile range; LV left ventricular; NCCM noncompaction cardiomyopathy
*cardiomyopathy genes: sarcomere-, arrhythmia-, non-sarcomere non-arrhythmia cardiomyopathy 
genes or a NCCM gene associated with congenital heart disease
** Patients with multiple mutations
† Major adverse cardiac events was composed of stroke, heart failure requiring hospital admission, 
left ventricular assist device, heart transplantation, sustained VT/VF or appropriate shock and 
cardiac death.
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Figure 2: Genetic causes by age at diagnosis in 541 NCCM patients.
Genotype-phenotype correlations across the 5 groups of  genetic causes
Comparing the occurrence of cardiac features, risk for MACE, concomitant 
CHD and neuromuscular signs in the five groups of genetic causes depicted in 
table 3 showed that LV dilatation was most prominent in (94%) patients with a 
mitochondrial defect, and risk for MACE was highest in patients with X-linked 
inherited NCCM. Patients (23%) with a mutation in a cardiomyopathy gene 
had lowest risk for MACE (p<0.001). CHD occurred in 41% of the cases with a 
chromosome defect and in 9% of the patients with a mutation in a cardiomyopathy 
gene (p<0.001). No CHD were reported in patients with X-linked NCCM. 
Neuromuscular disease was more frequent in patients with X-linked NCCM and 
patients with a chromosome defect and was rarely reported in patients with a 
cardiomyopathy gene mutation (p<0.001). 
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Genotype-phenotype correlation: cardiomyopathy genes
Altogether 74% of the patients had a mutation in a cardiomyopathy gene, i.e. in 
a sarcomere -, arrhythmia -, non-sarcomere non-arrhythmia cardiomyopathy -, 
or a CHD gene (table 4). LV systolic dysfunction was more frequent in patients 
with a mutation in a sarcomere gene, or in a non-sarcomere, non-arrhythmia 
cardiomyopathy gene mutation than in those with a mutation in an arrhythmia 
gene or a gene associated with CHD (p<0.001). In this group of patients defects in 
non-sarcomere, non-arrhythmia cardiomyopathy genes were associated with an 
increased risk for MACE (p=0.009). 
Table 4: Genotype- phenotype correlations in 416 NCCM patients with a mutation in a single 
cardiomyopathy gene.
Sarcomere 
gene
Arrhythmia 
genes
Non-sarcomere 
non-arrhythmia 
cardiomyopathy 
genes
Genes 
associated 
with CHD
n =292 (70%) n =52 (12%) n=44 (11%) n=28 (7%) p-value 
Male
Median age at diagnosis in years (IQR)
Congenital heart disease
Neuromuscular symptoms 
LV dilatation 
LV systolic dysfunction 
Major adverse cardiac events†
Stroke
Heart failure requiring hospital admission
Left ventricular assist device
Heart transplantation
Sustained VT/VF or appropriate shock
Cardiac death
147/290 (51%)
30 (13-44)
27/292 (9%)
6/72 (8%)
112/199 (56%)
136/211 (65%)
57/292 (20%)
6/292 (2%)
15/292 (5%)
6/292 (2%)
13/292 (5%)
15/292 (5%)
16/292 (6%)
21/52 (40%)
15 (4-43)
1/65 (2%)
0/4 (0%)
3/6 (50%)
9/35 (26%)
16/52 (31%)
0/52 (0%)
0/52 (0%)
0/52 (0%)
0/52 (0%)
12/52 (23%)
2/52 (4%)
19/41 (46%)
28 (13-46)
4/44 (9%)
6/12 (50%)
18/22 (82%)
23/35 (66%)
18/44 (41%)
0/44 (0%)
3/44 (7%)
0/44 (0%)
6/44 (14%)
9/44 (21%)
5/44 (11%)
16/28 (57%)
23 (13-47)
6/28 (21%)
0/2 (0%)
8/18 (44%)
9/26 (35%)
6/28 (21%)
0/28 (0%)
0/28 (0%)
0/28 (0%)
2/28 (7%)
2/28 (7%)
0/28 (0%)
ns
ns
-
-
-
<0.001
0.009
-
-
-
-
-
-
IQR interquartile range; LV left ventricular; MACE major adverse cardiac event; NCCM 
noncompaction cardiomyopathy; ns not significant
† Major adverse cardiac events was composed of stroke, heart failure requiring hospital admission, 
left ventricular assist device, heart transplantation, sustained VT/VF or appropriate shock and 
cardiac death.
Systematic review of  genotype- phenotype correlations in noncompaction cardiomyopathy
Ch
ap
te
r 
5
163
Table 5: Genotype- phenotype correlations in 292 NCCM patients with a mutation in a 
sarcomere gene.
MYH7 ACTC1 MYBPC3 TTN Other 
sarcomere 
genes*
Total number of patients with a mutati-
on in a sarcomere gene
n=142 (48%) n=38 (13%) n=39 (13%) n=22 (8%)  n=51 (17%) p-value 
Male
Median age at diagnosis in years (IQR)
Congenital heart disease
Neuromuscular disease
LV dilatation
LV systolic dysfunction
Major adverse cardiac events
Stroke
Heart failure requiring hospital admission
Left ventricular assist device
Heart transplantation
Sustained VT/VF or appropriate shock
Cardiac death
71/141 (50%)
30 (10-42)
16/142 (11%)
4/32 (13%)
49/80 (61%)
68/106 (64%)
19/142 (13%)
4/142 (3%)
6/142 (4%)
0/142 (0%)
4/142 (3%)
4/142 (3%)
3/142 (2%)
20/38 (53%)
26 (13-48)
6/38 (16%)
0/1 (0%)
7/36 (19%)
8/14 (57%)
4/38 (10%)
0/38 (0%)
1/38 (3%)
0/38 (0%)
1/38 (3%)
2/38 (5%)
0/38 (0%)
17/39 (44%)
28 (11-46)
3/39 (8%)
1/13 (8%)
17/24 (71%)
18/27 (67%)
16/39 (41%)
1/39 (3%)
3/39 (8%)
4/39 (10%)
2/39 (5%)
6/39 (15%)
9/39 (23%)
15/21 (68%)
43 (29-54)
1/22 (5%)
1/19 (5%)
15/21 (71%)
16/21 (76%)
7/22 (32%)
1/22 (4%)
1/22 (5%)
1/22 (5%)
2/22 (9%)
1/22 (5%)
2/22 (9%)
24/50 (48%)
30 (8-44)
1/51 (2%)
0/7 (0%)
24/38 (63%)
26/43 (61%)
11/51 (22%)
0/51 (0%)
4/51 (8%)
1/51 (2%)
4/51 (8%)
2/51 (4%)
2/51 (4%)
ns
0.043
-
-
<0.001
ns
0.001
-
-
-
-
-
-
IQR interquartile range; LV left ventricular; MACE major adverse cardiac event; NCCM 
noncompaction cardiomyopathy; ns not significant
* ACTN2, DES, LDB3, MYH7B, MYL2, NEBL, OBSCN, TNNC1, TNNC1, TNNI3, TNNT2 and TPM1.
Genotype-phenotype correlations: sarcomere genes
In 52% (n=292) NCCM was caused by a sarcomere gene mutation, in particular 
in MYH7, MYBPC3, ACTC1, and TTN, representing about 43% of the published 
genetic causes (figure 1). Other sarcomere mutations were reported in the 11 genes: 
ACTN2, DES, LDB3, MYL2, NEBL, OBSCN, TNNC1, TNNI3, TNNT2 and TPM1. The 
TTN mutations were reported in adult patients. Mutation in ACTC1 had less LV 
dilatation (p<0.001; table 5). Among the patients with a sarcomere gene defect, the 
MYBPC3 mutations were associated with increased risk for MACE. Patients with 
a mutation in MYH7 or ACTC1 had the lowest risk of MACE of all patients with a 
sarcomere gene defect (p=0.001).
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Noncompaction cardiomyopathy subtypes
The NCCM subtypes were isolated NCCM (n=95), NCCM with HCM (n=47), 
NCCM with DCM (n=195) and NCCM with HCM and DCM (n=12) (table 6). In 225 
patients there were insufficient data to classify the patients to the NCCM subtypes, 
and these patients were excluded from this analysis. The NCCM/HCM and 
NCCM/DCM cardiac phenotypes were mostly reported in patients with defects in 
sarcomere genes (p=0.006). Patients with mutations in the tail of MYH7 (starting 
at c.2524) were more likely to have the NCCM/DCM subtype (83%), than patients 
with MYH7 mutations in the head of the gene (42%). The NCCM/DCM had more 
often LV systolic dysfunction (p<0.001). The patients with NCCM/HCM had the 
least often LV systolic dysfunction and had the lowest risk for MACE (p<0.001). 
The NCCM/HCM/DCM phenotype occurred mostly in children (p=0.014) with 
mutations in other than cardiomyopathy genes and was associated with severe 
outcome (p<0.001).
Table 6: NCCM subtypes in 349 patients*.
Isolated 
NCCM
n=95 (27%)
NCCM/HCM 
n=47 (13%)
NCCM/DCM 
n=195 (56%)
p-value** NCCM/HCM/
DCM n=12 (3%)
Adult 54/95 (57%) 25/45 (58%) 104/194 (54%) 0.798 1/12 (8%)
Cardiomyopathy gene
• Sarcomere
• Arrhythmia
• Non-sarcomere-, non-arrhythmia- cardiac
• Genes associated with CHD
X-Linked
Mitochondrial
Chromosomal
Complex genotype
84/95 (88%)
72/95 (76%)
3/95 (3%)
4/95 (4%)
5/95 (5%)
3/95 (3%)
1/95 (1%)
5/95 (5%)
2/95 (2%)
37/47 (80%)
30/47 (81%)
3/47 (8%)
0/47 (0%)
  4/47 (11%)
3/47 (7%)
3/47 (7%)
3/47 (7%)
1/47 (2%)
139/195 (76%)
110/195 (79%)
3/195 (2%)
17/195 (12%)
9/195 (6%)
19/195 (10%)
15/195 (8%)
10/195 (5%)
12/195 (6%)
<0.001
0.006
-
-
-
-
-
-
-
3/12 (30%)
2/12 (67%)
0/12 (0%)
1/12 (33%)
0/12 (0%)
5/12 (50%)
2/12 (20%)
0/12 (0%)
2/12 (17%)
Left ventricular systolic dysfunction 42/86 (49%) 4/18 (22%) 148/185 (80%) <0.001 11/12 (92%)
Major adverse cardiac events
Stroke
Heart failure requiring hospital admission
Left ventricular assist device
Heart transplantation
Sustained VT/VF or appropriate shock
Cardiac death
21/95 (22%)
1/95 (1%)
6/95 (6%)
0/95 (0%)
4/95 (4%)
3/95 (3%)
5/95 (5%)
7/47 (15%)
1/47 (2%)
3/47 (6%)
0/47 (0%)
0/47 (0%)
4/47 (9%)
2/47 (4%)
66/195 (34%)
3/195 (2%)
16/195 (8%)
3/195 (2%)
15/195 (8%)
23/195 (12%)
28/195 (14%)
<0.001
-
-
-
-
-
-
9/12 (75%)
1/12 (8%)
5/12 (42%)
1/12 (8%)
4/12 (33%)
2/12 (17%)
3/12 (25%)
*225 patients could not be classified because of missing data
** Comparing isolated NCCN, NCCM/HCM and NCCM/DCM.
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Patient characteristics, genetics and outcome
Univariate binary logistic regression analysis including both phenotype and 
genetic parameters predictors for MACE are presented in table 7. Sex was missing 
in 1%, age at diagnosis in 4%, LV systolic function in 38%, NCCM subtype in 
38% and LV dilatation in 43%. In online table 4 we show stepwise multivariate 
regression. In the final model age (OR 0.99, 95%CI 0.97-1.00) LV systolic function 
(OR 2.71, 95%CI 1.19-6.15) and a number of genes were associated with MACE. 
These genes include MYBPC3 (OR 4.73, 95%CI 1.98-11.26), TTN (OR 3.45 95%CI 1.17-
10.22), arrhythmia genes (OR 3.94 95%CI 1.71-9.08), non-sarcomere non-arrhythmia 
cardiomyopathy genes (OR 4.56, 95%CI 2.00-10.42) and X-linked genes (OR 5.65, 
95%CI 2.32-13.81) (table 7). Complex genotypes and chromosome defects did not 
remain as significant predictors for MACE after correction. 
Table 7: Univariate and multivariate binary logistic regression for the prediction of major 
adverse cardiac events in genetic NCCM patients.
Variable univariate multivariate
Model 5*
OR (95% CI) p-value OR (95% CI) p-value
Male
Age at diagnosis in years
Congenital heart disease
Neuromuscular symptoms
LV dilatation
LV systolic dysfunction 
0.87 (0.60-1.28) 
0.98 (0.97-0.99)
1.24 (0.69-2.24)
1.92 (0.92-3.99)
2.52 (1.45-4.37)
3.65 (2.24-5.94)
0.486
<0.001
0.469
0.082
0.001
<0.001
0.69 (0.41-1.15)
0.99 (0.97-1.00)
1.39 (0.19-10.23)
2.71 (1.19-6.15)
0.154
0.010
0.716
0.021
Isolated NCCM
NCCM/HCM
NCCM/DCM
NCCM/HCM/DCM
1
0.62 (0.24-1.58)
1.80 (1.02-3.18)
10.57 (2.62-42.60)
-
0.312
0.042
0.001
1
0.56 (0.07-4.65)
0.87 (0.10-7.36)
1.66 (0.04-62.08)
-
0.560
0.883
0.742
MYH7
ACTC1
MYBPC3
TTN
Other sarcomere genes
Arrhythmia genes
Non-sarcomere-, non-arrhythmia- cardiomyopathy
Genes associated with CHD
X-linked
Mitochondrial
Chromosome defect
Complex genotype
1
0.76 (0.24-2.39)
4.50 (2.02-10.03)
3.02 (1.09-8.37)
1.78 (0.78-4.06)
2.88 (1.34-6.16)
4.48 (2.07-9.69)
1.77 (0.63-4.92)
6.80 (3.12-14.83)
2.23 (0.94-5.31)
3.39 (1.41-8.13)
2.81 (1.16 -6.83)
-
0.641
0.000
0.033
0.170
0.007
0.000
0.277
0.000
0.069
0.006
0.022
1
1.05 (0.29-3.82)
4.73 (1.98-11.26)
3.45 (1.17-10.22)
1.76 (0.75-4.15)
3.94 (1.71-9.08)
4.56 (2.00-10.42)
2.52 (0.83-7.63)
5.65 (2.32-13.81)
1.67 (0.66-4.24)
2.41 (0.89-6.54)
2.58 (1.00-6.68)
-
0.936
0.000
0.025
0.195
0.001
0.000
0.101
0.000
0.284
0.083
0.051
*Model 5 included:  sex, age, LV dilatation, LV systolic function and NCCM subtype.
CHD congenital heart disease; DCM dilated cardiomyopathy, HCM hypertrophic cardiomyopathy; 
LV left ventricular; NCCM noncompaction cardiomyopathy.
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Discussion
A large number of reported NCCM cases were reviewed to investigate if genetic 
cause could predict the clinical risk profile for age at diagnosis, NCCM subtype, 
clinical features, risk for MACE, and LV systolic dysfunction. The collected data 
concerned only reported genetic NCCM patients (i.e. excluded about one third 
of the mutation carriers, who are expected to be non-penetrant carriers (without 
cardiomyopathy) who were not reported) (194, 196). Of the reported patients, children 
were more likely to have syndromic forms of NCCM with complex genotypes, 
X-linked inherited conditions, mitochondrial and chromosomal defects. These 
forms of NCCM had high risk for severe outcome, with congenital heart defects 
and neuromuscular symptoms. In contrast, patients diagnosed in adulthood had 
significant less severe outcome associated with autosomal dominantly inherited 
mutations in predominantly sarcomere genes. The correlation between genetic 
causes, outcome and age at diagnose suggests that different diagnostic approaches 
and clinical care may be needed for children, for instance including neurological 
examinations. Although the application of large panels of cardiomyopathy genes, 
allowed identification of mutations in 80 genes, in case regular NGS DNA testing 
is inconclusive a genetic cause cannot be excluded and additional mitochondrial 
gene - and chromosome analysis are important subsequent diagnostics steps, in 
particular when the NCCM is diagnosed in a child. 
Genotype-phenotype correlations
Mutations in genes affecting sarcomere function represented more than half of 
the genetic causes of genetic NCCM, in particular in adults. Mutations in MYH7 
were most prevalent, followed by mutations in ACTC1, MYBPC3 and TTN as 
described previously (8, 155). Patients with a mutation in the sarcomere genes 
had lowest risk for MACE compared to patients with other genetic causes for 
NCCM. Comparing the clinical features of patients with different sarcomere gene 
mutation showed major differences for risk of MACE; patients with a mutation 
in MYBPC3 and TTN had a much higher risk for MACE than the patients with a 
MYH7 mutation. This endorses the importance of DNA testing in NCCM, because 
the DNA diagnosis may help to predict outcome. Secondly these results show that 
further large studies of NCCM patients with mutations are needed to confirm 
and refine the identified genotype-phenotype correlations for improved patient 
tailored clinical management. Extensive phenotyping of NCCM may be the next 
step for finding more precise genotype-phenotype correlations. Recently, NCCM 
has been classified into subtypes based on concurrent occurrence of dilated and/or 
hypertrophic LV (165). This subdivision improves prediction of genetic defect and 
helps to predict LV systolic dysfunction and risk for MACE (194, 196). This review 
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shows that isolated NCCM was associated with defects in cardiomyopathy genes. 
Family history
In genetic diseases a high prevalence of familial disease is expected. In this review 
familial cardiomyopathy was observed in 43% of genetic NCCM. The explanation 
for this low rate of familial cardiomyopathy may be that patients without familial 
disease had a de novo mutation or large chromosome defects. Another explanation 
might be that family histories were differentially ascertained across studies, or that 
patients may not have been aware that relatives had a cardiomyopathy or relatives 
were diagnosed after the completion of the study. In addition the underreporting 
of familial disease may be explained because relatives may be asymptomatic 
carriers of a cardiomyopathy mutation. Previously we observed that 48% of 
affected relatives who were diagnosed by family screening were asymptomatic 
(194). In NCCM 37% of relatives who are carriers of a mutation in a cardiomyopathy 
gene are asymptomatic and approximately 30% of the carriers have no signs of a 
cardiomyopathy (non-penetrance), which is similar to the rate of asymptomatic 
or unaffected carriers in families with HCM (194, 197). Familial cardiomyopathy 
was reported more frequent in adult index patients, although it is usually easier 
to attain genetic and/or cardiologic testing of the parents of young cases than of 
patients diagnosed in adulthood. An explanation for the discrepancy of familial 
disease could be that X-linked NCCM and chromosomal abnormalities were 
more frequent in children, and detection of patients in families with X-linked 
inheritance depends on the number of male relatives of the mother of the patient, 
and therefore it may be more difficult to detect affected relatives than in families 
with autosomal dominant inherited forms. 
Noncompaction phenotype
NCCM is associated with a large number mutations in a large number of genes, 
leading to different defective molecular functions in cardiomyocytes. This raises 
the question if these defects have a common final effect on the myocardium or that 
different pathogenic mechanisms are involved. For now the observed differences 
in clinical features, NCCM phenotype and risk profiles suggest the latter. Future 
expansion of genetic testing with whole genome sequencing may identify 
regulatory influences on gene expression explaining the phenotype. In particular 
because many genetic defects occur also in HCM and DCM. It is expected that also 
the newly developed models using induced pluripotent stem cells differentiated 
into cardiomyocytes can be used to investigate genetic and epigenetic modifiers 
explaining cardiomyopathy phenotypes.
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Limitations
The majority of the included studies were case-reports or small case-series. 
Therefore the included patients were expected to have been subject to referral, 
selection and publication bias. We cannot exclude overrepresentation in reporting 
of rare genetic causes like for instance mutations in TAZ gene in children. This 
review focussed only on the genetically confirmed NCCM patients, which are 
approximately one third of all NCCM (8). The design of this study precludes 
identifying differences in prognosis between known genetic and other causes for 
NCCM.
Conclusions 
The most frequent causes of genetic NCCM are mutations in sarcomere genes, 
with a relatively low risk of adverse events, occurring mostly in adults. In general, 
age at diagnosis and cardiac outcome were related to specific genetic causes. Rare 
X-linked and chromosome defects were more frequent among children with severe 
outcome. These observations endorsed to adjust molecular diagnostics and clinical 
approaches to age at presentation. The observed genotype-phenotype correlations 
show that DNA diagnostics for NCCM is important. Identifying the genetic cause 
for NCCM allows risk stratification and may help clinical management and 
counselling of patients and their relatives.
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Missense FLNC Mutations associated with familial noncompaction 
Cardiomyopathy and Congenital Heart Defects, Cardiogenetics, 9(1).
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Abstract
The majority of familial noncompaction cardiomyopathy (NCCM) is explained by 
pathogenic variants in the same sarcomeric genes that associated with hypertrophic 
(HCM) and dilated (DCM) cardiomyopathy. Pathogenic variants in the filamin C gene 
(FLNC) have been linked to HCM and DCM. We expand the spectrum of FLNC related 
cardiomyopathies by presenting two families with likely pathogenic FLNC variants 
showing familial segregation of NCCM and concurrent coarctation of the aorta and/or 
mitral valve abnormalities. 
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Introduction
Noncompaction cardiomyopathy (NCCM) is characterized by excessive 
trabeculation of the left ventricle (LV) with a noncompacted to compacted ratio of 
more than 2 according to current echocardiographic criteria, or 2.3 on CMR(3, 25). 
Approximately 10% of patients diagnosed with NCCM have concurrent congenital 
heart defects (CHD)(22, 165).
In 30-40% of cases diagnosed with NCCM a pathogenic variant can be identified. 
Around 80% of these pathogenic variants involve the same sarcomere genes, 
that are the major causes for hypertrophic cardiomyopathy (HCM) and dilated 
cardiomyopathy (DCM), in particular MYH7, MYBPC3 and TTN (54, 147). Filamin 
C (FLNC) plays a central role in muscle functioning by maintaining the structural 
integrity of the muscle fibers. Pathogenic variants in FLNC were found to be 
associated with a wide spectrum of myopathies ranging from cardiomyopathies to 
distal skeletal myopathies. Truncating FLNC variants were previously associated 
with dilated cardiomyopathy (198-200) and missense variants were identified 
in familial HCM and restrictive cardiomyopathy (15, 20). FLNC has not been 
associated with NCCM or CHD before.
We present two Dutch families where familial NCCM with CHD were linked to 
rare FLNC missense variants. These observations suggest that the spectrum of 
clinical manifestations of FLNC variants include familial NCCM with CHD.
Figure 1: Pedigrees of families A and B.
Pedigrees of NCCM families with missense FLNC variants. Black filled symbols are affected 
family members. Gray filled symbols are family members with hypertrabeculation not meeting 
NCCM criteria. The + sign indicates family members carrying a FLNC likely pathogenic variant 
(p.(Arg2133Cys) in family A and p.(Pro2393Ser) in family B. CM, cardiomyopathy; CoA, coarctation 
of the aorta; MVP, mitral valve prolapse; NCCM, non-compaction cardiomyopathy; VSD, ventricular 
septal defect.
I:1 I:2 I:1 I:2
II:1 II:2II:1 II:2 II:3 II:4 II:5+ +++
III:1 III:2+ III:3 + III:2
CM, VSD, CoA, MVP
NCCM, VSD, MVPNCCM, CoA
NCCM NCCM
NCCM
+ III:3 _III:1 +
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Case reports
Family A 
In this family (figure 1A), a 52-year-old woman (II:3) was first diagnosed with NCCM 
when she underwent cardiologic examination for a suspected perimyocarditis. 
Echocardiography showed pericardial effusion and normal LV dimensions without 
LV dysfunction. The LV walls showed hypertrabeculation with end-systolic non-
compacted/compacted (NC/C) ratio >2. Electrocardiographically, inferolateral 
repolarization abnormalities were observed. Cardiac magnetic resonance imaging 
(CMR) confirmed the diagnosis of NCCM with diastolic NC/C ratio >2.3 in the LV 
inferoseptal wall. She had elevated CK levels of 1234 U/L [ref <200U/l]. No signs 
for neuromuscular disease were detected at neurologic examination. After seven 
years of follow-up, she remained cardiologically asymptomatic (NYHA class I).
Family screening revealed NCCM in two relatives. A niece (III:3), was diagnosed 
with NCCM at age 21 and had surgery at age seven for coarctation of the aorta (CoA). 
She fulfilled both the echocardiography- and CMR diagnostic criteria for NCCM 
and had excessive long chordae of the anterior mitral valve leaflet (figure 2A and 
2B). The noncompaction had not been recognized in the past on echocardiography. 
Cardiologic screening of an asymptomatic brother (II:4) at age 54 years showed 
that he also had NCCM; with a NC/C ratio of 2.3 on echocardiography and a ratio 
of 2.9 on CMR. No previous cardiac imaging had been performed. He had elevated 
CK-levels of 265 U/L without neuromuscular signs. Ten years after the diagnosis 
NCCM he had an episode of atrial fibrillation that required electric cardioversion. 
CMR from the brother (II:1) and the son (III:1) of the proband were performed at 
age 57 and 15 years, respectively, showing borderline NC/C ratios of respectively 
2.1 and 2.2 on MRI, i.e. just below the diagnostic criteria. Proband III-2 did not 
participate in the family screening.
Figure 2: Imaging of two NCCM patients.
Family A. patient III.3 2A: Short axis of the left ventricle 
on cardiac magnetic resonance (CMR) showing the 
prominent trabeculae and intertrabecular recesses in 
NCCM. 2B. Echocardiogram of the LV of patient (III.3) 
with NCCM and excessive long chordae of the anterior 
mitral valve leaflet (arrow). Family B. patient III.1 2C: 
Two-chamber long-axis of the left ventricle on CMR. 2D. 
Short axis view of the left ventricle on CMR showing the 
prominent trabeculae and intertrabecular recesses in 
NCCM.
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Family B
In family B (figure 1B) the diagnosis NCCM in a 17-year-old boy (III:1) was made 
by echocardiography. He was referred because of multiple unexplained episodes 
of syncope. He also had a ventricular septal defect (VSD) and a mild mitral valve 
prolapse (MVP). CMR revealed partial LV noncompaction from the apex to 
midventricular region with an NC/C ratio of 3.0 (figure 2C and 2D). An implantable 
cardioverter-defibrillator (ICD) was implanted. After 9 years of follow-up, the LV 
function remained normal without ICD shocks. CK-levels were elevated (419-1188 
U/l) in the absence of neuromuscular signs
His mother (II:2) was under cardiologic surveillance because she had a VSD, 
MVP, CoA and a bicuspid aortic valve. The CMR showed that she complied for 
the diagnostic criteria for NCCM with a NC/C ratio of 2.4. She had diastolic LV 
dysfunction, with preserved LV systolic function and underwent multiple cardiac 
ablations for atrial fibrillation. At age 44 years she experienced severe bradycardia, 
which necessitated cardiac resuscitation, resulting from combined flecainide and 
metoprolol treatment. A pacemaker was implanted. Her highest CK-level was 1174 
U/l. The proband’s brother (III:2) also suffered multiple episodes of syncope and 
was diagnosed with NCCM at age 19, with a NC/C ratio of 3.1 on CMR. His highest 
CK-level was 294U/l. Proband III-3 was screened cardiologically and had no signs 
of NCCM on echocardiography. No DNA analysis was performed. 
Genetic testing
Diagnostic DNA NGS targeted testing of a panel of 54 cardiomyopathy genes, that 
did not include FLNC, as presented in online supplement 1, did not reveal a genetic 
causes for NCCM in the two index cases. Also single-nucleotide polymorphism-
array DNA testing showed no structural DNA changes. Subsequently, whole exome 
sequencing was performed in the NCCM patients II:1, III:1 and III:3 from family A 
and III:1, III:2, and II:2 from family B. Patients II-2 from family B was included 
because we suspected that a causative mutation may underlie a spectrum of cardiac 
phenotypes. Written informed consent was obtained from all participating family 
members. The investigation conforms to the principles outlined in the Declaration 
of Helsinki. Variants were annotated using ANNOVAR(201) and filtered using an in-
house developed pipeline. Only variants segregating within each family, affecting 
exons or splice sites, with a population frequency below 0.01 in ExAC, NFE, GoNL 
were kept. For in silico prediction of the effect of nonsynonymous variants we used 
align GVGD (202), SIFT (203) and Polyphen (204) and ensemble scores LR and 
Radial SVM (205). We selected variants who were predicted to be damaging by 3 of 
5 prediction programs. Segregating synonymous variants and variants predicted to 
be tolerated were excluded. 
Chapter 6
178
In Family A, two candidate genes remained after filtering, MYH4 and FLNC, of 
which only the last was previously associated with cardiomyopathy. A variant in 
FLNC (c.6397C>T, p.(Arg2133Cys), NM_001458.4, confirmed by sanger sequencing) 
segregated with the cardiac phenotype of NCCM in the three NCCM patients and 
in the two relatives with borderline NCCM features. A variant in the same location 
(p.(Arg2133His)) was previously reported in a family with HCM and classified 
as probably pathogenic (206). In family B, a novel FLNC variant (c.7177C>T, 
p.(Pro2393Ser)) was identified. The two FLNC variants were absent in the Genome 
Aggregation Database (http://gnomad.broadinstitute.org), affect highly conserved 
amino acids, and were predicted to be deleterious by multiple in silico prediction 
programs. No FLNC variants were found in thirteen unrelated NCCM patients 
without a CHD and without a pathogenic variant in 48 cardiomyopathy genes.
Histology 
Right ventricular endomyocardial biopsy (RVEMB) samples from the proband 
of family B (III:1) were stained with hematoxylin and eosin as well as Masson’s 
trichrome. To visualize protein aggregation and autophagic activity in 
cardiomyocytes, immunohistochemistry for microtubule-associated protein 
1A/1B-light chain 3 (LC3) was performed, as described previously (207). Light 
microscopic analysis showed nonspecific cardiomyopathic changes of myocyte 
hypertrophy and increased interstitial fibrosis (Online Figure 3.A). The RV did 
not show an excessively thickened endocardial layer or hypertrabeculation, or 
intracellular aggregates or autophagic activity (Online Figure 3.B).
Figure 3: Myocardial tissue staining of FLNC likely pathogenic variant carrier (Family B. III:1).
Myocardial Tissue Analysis of RVEMB samples from FLNC likely pathogenic variant carrier 
(Family B. III:1). 3A. Masson’s trichrome staining, original magnification x20, shows mild fibrosis. 
3B. Immunohistochemical staining (LC3), original magnification x200, does not show protein 
aggregates with autophagic activity in cardiomyocytes. Faint LC3 background cytoplasmic staining 
can be observed.
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Discussion
This is the first report linking FLNC to NCCM in two families with rare FLNC 
variants. In these two families the cardiac phenotype included NCCM, NCCM 
with concurrent CoA, NCCM with concurrent VSD and MPV and also a NCCM 
patient with a complex CHD consisting of VSD, MVP, CoA and bicuspid aortic 
valve, and myocardial dysfunction. These observations suggest that missense 
FLNC variants may cause familial NCCM with or without one or more structural 
heart defects. Missense FLNC variants in the N and C terminal domains of FLNC 
have been associated with hypertrophic- and restrictive cardiomyopathy, causing 
sarcomeric aggregates containing FLNC leading to sarcomere dysfunction (206). 
Other FLNC domains were associated with myofibrillar myopathy, showing 
similar intracellular aggregates in skeletal muscles (208, 209). A large study of 
inherited cardiovascular disease patients showed that truncating FLNC variants 
were associated predominantly with an overlapping phenotype of severe dilated- 
and arrhythmogenic cardiomyopathies (199). The cardiomyopathy phenotypes 
associated with FLNC variants have not included NCCM so far, however signs of LV 
hypertrabeculation not fulfilling NCCM diagnosis in some carriers of a truncating 
FLNC variants have been reported (199). FLNC has not been linked to CHD, sofar, 
to the best of our knowledge.
Aortic coarctation in NCCM patients seems rare with an estimated prevalence 
of less than 1% (22). We report two families with familial NCCM and a likely 
pathogenic FLNC variant in which CoA occurred; in one family one patient had 
NCCM with concomitant CoA. In the other family a NCCM patient with the 
familial FLNC variant had complex congenital cardiac defects including a CoA. It 
remains to be elucidated how FLNC and other genes can cause a cardiomyopathy 
with or without a CHD, and skeletal myopathy in other patients. It may be that 
FLNC resembles MYH7 in that aspect. Because among all the known genes 
associated with cardiomyopathies as well as skeletal myopathies, MYH7 variants 
occurs the most frequent in NCCM, and is also linked to Ebstein anomaly with 
and without NCCM, HCM, DCM, or Laing distal myopathy (23, 210). Suggesting 
that variants affecting distinct domains of sarcomeric proteins may define the 
spectrum of cardiac and skeletal muscle phenotypes. 
Pathogenic FLNC variants are expected to disrupt the structure of the sarcomeric 
protein, leading to the formation of protein aggregates resulting in an impairment 
of the sarcomere function (206, 211). One of the identified variants in this study, FLNC 
p.(Arg2133Cys), may have a similar effect as the reported FLNC variant p.(Arg2133His) 
at the same location with another amino-acid substitution, that was shown to have 
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disrupting actin aggregates in cardiac tissue (206). We found elevated CK levels in 
two of the three NCCM patients in both affected families. Elevated CK levels were 
also noted in a previous study regarding FLNC variants with myopathy but also in 
patients with only a cardiac phenotype of HCM (206). For the novel FLNC variant 
p.(Pro2393Ser), we observed fibrosis in the RV myocardium samples, indicating a 
damaging effect of the variant on the cardiac muscle. Fibrosis was also observed in 
previous reports with FLNC mutations (199, 206). The cardiac fibrosis observed in 
the patients with the FLNC variant suggests that similar pro-fibrotic mechanisms 
may be involved as observed in MYBPC3 cardiomyopathy (212). Similarly, to the 
original report no signs of intracellular aggregates or autophagic activity in the 
RV of the patient or were noted in patients with a FLNC related cardiomyopathy 
(199, 206). The RV of this patient did not show evidence for hypertrabeculation 
morphologically or on imaging. However this does not exclude an effect of the 
FLNC variant on the left ventricle, since RV hypertrabeculation in NCCM is rarely 
reported, and the NCCM presents predominantly with a LV phenotype. 
As previous studies showed, genetics plays an important role in approximately half 
of the NCCM cases (8). The genetics of NCCM are complex and affect mostly genes 
associated with myopathies including sarcomere or mitochondrial dysfunctioning. 
In this perspective FLNC fits into the genetically heterogeneous background of 
NCCM. Further studies are needed to assess the exact role and mechanisms of 
FLNC in NCCM, aortic coarctation and mitral valve abnormalities.
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Discussion
Genetics of  NCCM
Our goal was to find out what proportion of NCCM may have a genetic cause. 
We identified a (likely) pathogenic variant ((L)PV) in 32% of the patients (8). With 
a higher prevalence in children (45%) than in adult patients (30%). In 16% of the 
patients familial disease was present, without an identified genetic cause. These 
findings suggest that approximately half of the cases can be considered genetic. 
The prevalence of pathogenic variants found in our studies is supported by other 
NCCM cohorts studies in which 35% to 38% of NCCM patients had a pathogenic 
variant (9, 10). One study showed a somewhat lower (23%) prevalence of genetic 
causes in children (<21 years) (213). This could be explained by the fact that a smaller 
number of genes were tested and also by differences in patient ascertainment. The 
conclusion is that for now overall approximately one third of NCCM patients have 
a pathogenic variant. 
Cases with a mutation as well as familial cases, even if still a mutation has to be 
identified, can be classified as genetic. Our study, with data on systematic screening 
of first-degree relatives, as recommended in the Netherlands, suggest that 37% 
of NCCM cases is familial. Of the familial cases 44% (16% of the total NCCM 
population) had familial disease without a mutation. It needs to be explained that 
the healthcare system in the Netherlands allows performing extensive cardiologic 
family screening, also in families without a mutation (15). In other countries, 
other regulations for screening relatives might apply and this may explain that 
few studies addressed the issue of frequency of familial NCCM. Also, in Erasmus 
Medical Center, a tertiary referral center for cardiomyopathies, screening of 
relatives is offered in a special designed multidisciplinary out-patient clinic, and 
the results of cardiologic exams of the family members are available together 
with the results of DNA testing. In situations when cardiologic family screening 
is not available for all at risk relatives, familial NCCM may go unnoticed leading 
to underreporting of familial disease. This may explain why the prevalence of 
familial disease in previous studies were lower than in our study (37%) ranging 
from 13% to 26% (9, 10, 147, 213). The information that a high percentage of familial 
cases did not have a mutation in a known cardiomyopathy gene (44%), as observed 
in our study could not be extracted from other studies. 
There are several explanations for not finding the genetic cause in families with 
familial cardiomyopathy. For instance, there may be a yet unknown genetic 
cause, that may be identified in the near future when whole exome or genome 
sequencing are used for diagnostic purposes. With future broad application of 
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whole genome sequencing, we will not only look for exonic genetic defects, but 
also for defects in intronic DNA regions regulating the expression of known and 
unknown cardiomyopathy genes. Mutations in intronic regions may cause, just 
like truncating exonic mutations, haplo-insufficiency. Secondly, to date only 
monogenetic causes for NCCM are identified. With the increasing insight into the 
effects of DNA variants in the future with the wider use of novel DNA sequencing 
techniques, modifying genes and even complex genetic burdens associated with 
NCCM may be identified. These novel genetic analyses may help to identify 
complex genetic causes, consisting of multiple – in themselves- non penetrant 
variants that together may act as modifiers or as a susceptibility with additive 
pathogenic effects. We should also consider that familial occurrence of secondary 
causes may occur in NCCM in multiple relatives. For instance, hereditary 
hypertension in multiple relatives may provoke remodeling of the left ventricle 
into the NCCM phenotype with or without additional genetic susceptibility or 
genetic modifiers. In conclusion, if we assume that a genetic cause can be found 
in all familial patients. The proportion of genetic patients is between one third 
and half of the NCCM patients. In the other half hypertrabeculation may be 
provoked by environmental factors, an underlying cause leading to altered loading 
conditions or an interaction between environmental factors or other causes and 
genetic susceptibility for noncompaction. 
Since NCCM is clearly heterogonous, we wanted to know if the clinical feature 
and outcome could be linked to the underlying causes. Genetic NCCM involves 
more than 66 genes and other genetic causes (24). Most of the identified genetic 
defects cause isolated sarcomeric damage, some defect also cause congenital heart 
disease and have other multi systemic manifestations (24). In patients with isolated 
NCCM MYH7, TTN and MYBPC3 are the most prevalently affected genes (9, 10, 
15, 147). Patients with congenital heart disease may have different genetic causes. 
For instance NCCM patients with Ebstein anomaly often have a mutation in the 
MYH7 gene or -as we showed- NCCM patients with an aortic coarctation may have 
a defect in the FLNC gene (23, 214). Patients with neuromuscular manifestations 
are more likely to have defects in X-linked TAZ-gene, defects in mitochondrial 
genes or genes predisposing to skeletal myopathies (215). The age at presentation 
may play an important role in predicting the genetic cause. Patients presenting at 
younger age have more often extra cardiac manifestation, associated with complex 
defects in sarcomere genes, or have other rare genetic causes that are seldom 
observed in adult patients (24). The severity of the disease may be linked to specific 
genetic causes, like in other cardiomyopathies. For instance, adult HCM patients 
with truncating MYBPC3 mutations were found to have a more severe disease than 
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patients with missense mutations (216, 217). In time, it is expected that by sharing 
information on specific variants and clinical features between cardiogenetic 
centers all over the world, more insights in genotype-phenotype associations 
emerge, explaining the specific features of the spectrum of cardiomyopathies. 
The overlap of major genetic cause indicates that the NCCM, HCM and DCM 
phenotypes represent a cardiomyopathy spectrum. Sarcomere gene mutations 
are the main causes of NCCM as well as of other cardiomyopathies (i.e. HCM or 
DCM) (218, 219). Different cardiac phenotypes could to some degree be explained 
by the location of the mutation, and the function of the affected domain. These 
observations do not explain how the exact same genetic defect (i.e. (L)PV)) can lead 
to different cardiomyopathy phenotypes even within families. Deep phenotyping 
of NCCM (i.e. ascertainment of concomitant signs of HCM or DCM in NCCM 
patients) did show overlapping characteristics of other cardiomyopathies in NCCM 
patients and their relatives (15). Our study showed that the location of the mutations 
in MYH7 could predict cardiac phenotype in NCCM (15). Patient with mutations 
in the tail were more likely to have NCCM with a dilated ventricle, the main 
characteristic of DCM. An explanation may be that mutations in the tail domain 
may interfere with the binding site for TTN, and thus may have a similar effect as 
TTN mutations, which are important causes of DCM (220). Also, NCCM patients 
with TTN mutations, had a higher prevalence of left ventricular dilatation and had 
more relatives with DCM with and without NCCM. A molecular study strengthens 
the observation that mutations in the head and tail domain may lead to different 
phenotypes by showing differences in interaction with actin (221). NCCM patients 
with a pathogenic variant in MYBPC3, the most frequent cause of HCM- but less 
frequent in NCCM-, were more likely to have signs of left ventricular hypertrophy 
and have relatives with HCM without NCCM (15). Analyses of the contractile 
function showed that type of mutation (missense vs. truncating mutations) in same 
gene could lead to marked differences in contractility of heart tissue (222). Other 
explanations for the difference in phenotypes may include individual differences 
in genetic modifiers, epi-genetic factors and/or different pathway activation.
Consequences of  identifying a disease causing mutation 
Since a large part of NCCM is caused by genetic defects, genetic testing plays 
an important role in NCCM. Finding the causative gene in genetic diseases has 
multiple advantages. Most importantly, identifying the genetic cause may facilitate 
family screening. Patients have been shown to benefit from early diagnosis and 
this has been proven to be cost effective in HCM (223, 224). A molecular diagnosis 
helps to identify accurately which relatives are at risk and/or also reassures family 
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members in whom the genetic defect can be excluded. DNA testing may also help 
to distinguish genetic from sporadic patients, with low risk for relatives. This of 
course has major implications for family screening strategies. Eventually, leading 
for low risk families, to adjust follow up frequencies of adult relatives with normal 
cardiologic exams, once there is sufficient evidence. We are now, at the beginning 
of finding genotype-phenotype correlations in patients with a mutation, and larger 
studies are needed to validate and expand these novel identified correlations. Still 
an important aspect of genetic testing are possible socio-economic consequences 
of being a mutation carrier. We also have to remain aware of and offer help with 
the psychological impact of a positive test result and the burden of needing lifelong 
cardiologic follow-up, for a patients who may or may not ever exhibit symptoms 
(126). 
Also in this perspective, prediction of prognosis for relatives who were identified 
by family screening to be carriers of a mutation is of great importance, and this 
had not been extensively studied yet. We found that relatives with a mutation and 
the noncompaction phenotype had lower risk for cardiac symptoms and cardiac 
events compared to index cases (15). Probably because relatives were diagnosed by 
screening, in an earlier disease stage with less symptoms. More than one third of 
the relatives with a positive genetic test had a normal cardiac function and cardiac 
phenotype, indication a high percentage of non-penetrance. However, these 
patients cannot be excluded from cardiac follow-up since age related penetrance 
is a well-known feature in genetic cardiomyopathies, and they still may develop a 
cardiomyopathy later in life (133, 225). In HCM cohort studies 6-14% of relatives with 
a mutation without cardiomyopathy at initial screening developed HCM later on 
(133, 197, 226). For NCCM, it has not yet been established if relatives who do not have 
cardiac phenotype at initial screening, may develop a cardiomyopathy later on. 
Information on the risk of having a cardiomyopathy and the risk for severe cardiac 
complications is needed to counsel and design follow-up schedules for relatives at 
risk of familial NCCM with and without a mutation. This also applies to relatives 
of apparently sporadic cases (without a family history and mutation), because we 
cannot rule out that these patients carry a genetic risk for cardiomyopathy. Since 
these patients may have a mutation in an unknown cardiomyopathy gene, or that 
they have a more complex genetic etiology, carrying smaller but still elevated risk 
for cardiomyopathy for relatives. We observed that asymptomatic relatives with a 
phenotype had a low risk for cardiac events. And this may hold also for relatives 
without a cardiomyopathy phenotype (15). However, longer follow-up studies are 
needed to assess accurately the risks for relatives carrying a mutation with and 
without a cardiomyopathy phenotype. 
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Etiology
Noncompaction cardiomyopathy (NCCM) refers to an imaging-based description 
of the trabecular morphology of the left ventricular wall. The myocardial phenotype 
results from an incompletely understood pathophysiological mechanisms. A 
discussion about the etiology of the phenotype has been going on for a number 
of years (11-14). The theories are mainly based on circumstantial evidence on 
possible underlying mechanisms involved in the formation of noncompaction or 
hypertrabeculation. The most heard view is that NCCM should be considered a 
congenital heart defect (227). 
The highly trabeculated left ventricle of NCCM patients resembles the heart of 
all vertebrate animals, including humans, during early embryogenesis (227). 
In the early embryo the heart is a loose interwoven mesh of muscle fibers. This 
mesh, looking like a trabecular network –or sponge-, provides the heart muscle 
with oxygen and nutrients from luminal blood. In week 4-6 of gestation the heart 
starts to form coronary arteries, the noncompaction is no longer needed and the 
myocardium solidifies. The compaction of the heart begins at the base of the heart 
to the apex and from epicard to endocard (227). According to the congenital heart 
defect theory the compaction process fails to complete in a NCCM patient and 
NCCM would thus be regarded as an embryological deformation. This would 
explain why NCCM patients predominantly have hypertrabeculation at the apex 
of the heart. It is hypothesized that this unfinished myocardium could lead to 
heart failure and arrhythmias. More unfinished myocardium would lead to worse 
outcome and also explains prenatally diagnosed NCCM and early presentation 
in childhood (124). In NCCM, patients diagnosed in childhood often have a worse 
prognosis than adults (24). 
However, there are also arguments against this theory, based on opposite 
observations. To begin with, it is not sure whether the hypertrabeculation in 
noncompaction cardiomyopathy has an embryological origin. In a histology study 
only a miniscule subset of the postnatal trabeculations expressed ANF/NPPA (228). 
The absence of ANF/NPPA, the hallmark of embryonic cardiac trabeculations 
before the compaction stage, makes it unlikely that trabeculation observed in 
adults, are remnants of an arrest in embryologic development (228). Also age-related 
penetrance of NCCM is observed, like in other cardiomyopathies, for instance 
dilated cardiomyopathy (DCM) or hypertrophic cardiomyopathy (HCM). In fact, 
the majority of patients is diagnosed in adulthood, not in childhood (217). Another 
argument against the hypothesis of a prenatal arrest in cardiac development was 
presented by a study showing transient increased trabeculations in women during 
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pregnancy, in as much as 25% of pregnancies, which resolved post-partum in the 
majority of the women (152). It is unlikely that a congenital heart defect appears 
and resolves in adulthood. Moreover as the disrupted embryogenesis hypothesis 
would be true one would expect that disturbance of developmental genes play an 
important role in the pathogenesis. Most frequently defects in sarcomere genes were 
identified, defects in developmental genes are only scarcely reported, especially in 
adult patients (24). When defects in developmental genes were identified, patients 
had a higher incidence of congenital heart disease (24). We believe that defects 
in these genes cause congenital heart defects and secondary to the heart defect 
loading conditions of the LV may alter, leading to hypertrabeculation. This would 
also explain the high incidence of congenital heart disease in NCCM (22).
Another question is whether hypertrabeculation leads to cardiomyopathy. Cold-
blooded animals, unlike humans, have highly trabeculated hearts. The degree of 
trabeculation was not related to the cardiac performance of animal species (229). 
Some large cold-blooded animals, showing characteristic hypertrabeculated 
ventricles, have blood pressures in range of the human blood pressure and same 
stroke work per gram ventricular heart tissue (230, 231). In humans, higher incidence 
hypertrabeculation is observed in healthy cohorts, especially in individuals of 
Hispanic or African origin (17, 29, 31, 40). Loading conditions (volume/pressure 
load) play an important role in remodeling of the left ventricular myocardium. 
Transient increased loading conditions may explain the appearance of 
trabeculations in athletes and in women during pregnancy (26, 61, 152). Which also 
makes a congenital arrest in heart development less likely. Increased incidences 
of hypertrabeculation in other conditions with increased loading conditions of 
the heart are also known, including hematologic diseases, chronic renal failure 
and hypertension (8, 9, 40, 232-234). In this scenario, NCCM may be caused by 
different mechanisms that activate the same remodeling pathway leading to the 
noncompaction phenotype. 
A common pathway leading to noncompaction may also be an explanation for the 
many different genes associated with NCCM. This relatively rare cardiomyopathy, 
has a large spectrum of genetic causes, like HCM or DCM (218, 219). To date genetic 
defects in as much as 66 different genes, involving different cellular functions, 
explain approximately one third of the NCCM, approximately half the familial 
cases (8, 24). The majority of genetic variants associated with NCCM in humans 
occurs in genes encoding for the sarcomeric protein, but also genetic defects 
encoding for mitochondrial genes, affecting cellular energy management or in 
genes involved in calcium handling regulating the sarcomere contraction force, 
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have were related to NCCM. These genetic defects have a damaging effect on the 
cardiomyocyte functioning. How these damaged cardiomyocytes may respond 
to loading conditions and how this may lead to common remodeling pathway 
activation has still to be unraveled (figure 1).
Figure 1: Spectrum of cases with the myocardial phenotype noncompaction.
The myocardial phenotype noncompaction can have different causes, which activate common 
pathway(s) leading to the same noncompacted phenotype. (LBBB: left bundle branch block, LV: left 
ventricular).
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Our data indicates that NCCM may have different etiologies leading to the same 
myocardial phenotype. As demonstrated in figure 1 three main group can be 
distinguished. Two of the three groups involve cardiomyopathy patients which 
require medical follow-up and one group includes healthy cases. In the genetic 
group of patients heredity plays an important role. As our study showed in around 
one third of the patients a genetic defect can be identified (8). In 37% of the patients 
family members with a cardiomyopathy can be observed (8). Since the genetic 
defects identified in NCCM patients overlap with other cardiomyopathies also 
patients with other genetic cardiomyopathies can be observed within families, 
making NCCM a part of the spectrum of genetic cardiomyopathies (15). It is likely 
that genetic modifiers and epigenetics determine the myocardial phenotype in 
these patients. 
In the group of patients with pathologic remodeling NCCM is associated with 
other medical traits, which influence loading conditions and cardiac remodeling, 
activating similar genetic modifiers leading to same pathway activation requiring 
the formation of the hypertrabeculation phenotype. In these patients the 
hypertrabeculation may be a sign of myocardial distress. In the sporadic cases 
found in our study a higher incidence of hypertension was observed (8). This 
would indicate that hypertension is a secondary cause for NCCM, which is may 
also be a cause for left ventricular hypertrophy (235). This may also indicate that 
different genetic modifiers in patients lead to different myocardial phenotypes. In 
our sporadic patients also a higher incidence of left bundle branch blocks was 
observed (8). Left bundle branch blocks may lead to increased leading loading 
conditions of the left ventricle, which may lead to left ventricular remodeling (153). 
In these way congenital heart defects, which are frequently identified, may also 
lead to the NCCM phenotype (22). 
The last group, the group of people with physiologic remodeling, are the healthy 
cases in which benign factors may lead to a phenocopy of the hypertrabeculated 
left ventricle. These cases include cases from Hispanic and African descend, but 
also athletes and women who are pregnant (26, 40, 61, 152). These cases are probably 
not at risk for cardiac events. In the clinic it may be important to distinguish 
the different groups. In the hereditary group family screening is important for 
early identification of patients at risk for serious cardiac events. The group with 
pathologic remodeling may also needs medical surveillance, while the last group 
do not need follow-up and can be discharged from medical follow-up. Concluding 
that still genetic modifiers leading to NCCM need to be identified, to confirm this 
theory. 
Discussion
E
pi
lo
gu
e
195
Mouse models for NCCM
In the past decade different mice models have been developed to study NCCM. These 
mouse models have shown that some genes were related to a NCCM phenotype 
in mice hearts. A good example is a mice model for the TAZ-gene, associated with 
Barth syndrome, (236). TAZ-gene knock down mice showed hypertrabeculation at 
early gestation (237). Other genetic defects leading to NCCM in humans and in 
mice includes gene mutations in MIB1, YWHAE, NKX 2-5 and PTPN11 (81, 238-242). 
These genes are very rare identified causes in NCCM patient cohorts, regulating a 
variety of cellular mechanisms like cell differentiation. None of these genes were 
primarily associated with sarcomere or cardiomyocyte dysfunction. Of the current 
mouse models with the more common identified causes for NCCM, i.e. defects 
in MYH7 and MYBPC3, none showed noncompaction. A mice model of a TNNT2 
mutation was established using the same mutation as in a family with NCCM 
(243). TNNT2 encodes for the protein cardiac troponin T which is located in the 
thin filament of the sarcomere and is a rare sarcomeric cause for NCCM. The mice 
with the TNNT2 defect showed reduction of left ventricular systolic function, 
but no marked hypertrabeculation. Concluding that some mice models exhibit 
NCCM, including a model of the TAZ-gene, but an animal model for NCCM with 
a sarcomere gene mutation is still missing. 
Some of the mice studies were searching for common pathways for the 
noncompaction phenotype. The Notch pathway, was found to be involved 
in the process leading to noncompaction (81, 244-247). The Notch pathway is 
highly conserved among species and has a key role in cellular proliferation and 
differentiation. Defects in the MIB1 gene are a good example how disturbed Notch 
signaling can cause NCCM. Ubiquitination of JAG1 by MIB1 in the myocardium 
allows Notch1 activation in the endocardium. NOTCH1-dependent chamber 
maturation leads to compacted ventricular myocardium in the adult mouse. In 
mice with a MIB1 loss of function allele, NOTCH1 activity is impaired and compact 
myocardium remains abnormally proliferative. This disruption in compaction 
results in the NCCM phenotype. The involvement of NOTCH1 in NCCM seems 
to be more complicated. Some reports showed a down-regulation of the Notch 
pathway (81, 244, 246), while others found that up-regulation of this pathway lead to 
hypertrabeculation (245, 247). A possibility might be that other pathways are more 
important for the hypertrabeculation phenotype. Other pathways not directly 
linked to the Notch pathway are proposed, like the non-canonical Wnt pathway 
(191, 248, 249). This pathway is among others involved in cellular polarization. 
The knock-down mice-models had normal cardiomyocyte proliferation, however 
cardiomyocyte myofibrillogenesis and cardiomyocyte polarization were altered. 
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Also, in Fkbp1a-deficient mice, which up-regulated the Notch pathway, have shown 
defects in cardiomyocyte myofibrillogenesis and polarity (247). This raises the 
possibility of a common pathogenic pathway for hypertrabeculation (250).
The data collected in our studies and the presented mouse models show that 
NCCM is a very heterogeneous syndrome. The idea of a common pathway does 
also apply to other heterogeneous cardiomyopathies, like HCM. The hallmarks 
of HCM; hypertrophy, fibrosis, and myofilament disarray were linked to hyper-
contractility of the cardiomyocyte (251). Different mechanisms may underlie this 
pathogenic common hypercontractility including: changes in actin-activated 
ATPase (252, 253), an increase in the number of functionally accessible heads in the 
sarcomere for interaction with actin (254) or increased myofilament Ca2+ sensitivity 
(255). Interestingly, defects in MYBPC3 are directly linked to the above described 
mechanisms, which is the most common cause for HCM. In NCCM these 
associations of a common pathway, with the more common causes in patients 
cohorts have not been identified. The hallmark of HCM, interstitial fibrosis, occurs 
also frequently in NCCM and may be related to a chronic pressure overload (48). 
In this perspective the myocardial reaction on increased loading conditions may 
explain a proportion of NCCM. This may also partly explain the identified overlap 
in cardiac phenotype and genotype of HCM and NCCM patients. How pathways 
are activated by damaged sarcomeres or loading conditions, how these pathways 
work and lead to the noncompaction phenotype is still unknown and remains to 
be elucidated.
Future perspectives
After more than two decades we are still at the beginning of defining and 
understanding NCCM. The morphological expression of hypertrabeculation of 
the left ventricle is associated with defects in (mainly) the sarcomere genes. The 
application of whole exome or genome sequencing of NCCM patients in the near 
future will reveal novel genetic causes and genetic interactions with modifiers, 
some of which may explain remodeling into different cardiomyopathy phenotypes 
within families. This will also lead to a surplus of variants of unknown clinical 
significance (VUS). A better understanding of these variants is needed. Therefor 
a functional model needs to be constructed for testing the pathogenicity of these 
variants. This may be facilitated by worldwide sharing of data or by functional 
analysis of the variants using clustered regularly interspaced short palindromic 
repeats (CRISPR) gene editing in cell or animal studies. Functional evidence for 
pathogenicity of a variant will improve classification of variants. This will make 
the variants of unknown significance a group for additional testing, rather than a 
big question mark.
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Risk stratification models
It is important to develop risk stratification models for risk prediction of 
susceptibility for heart failure or life-threatening arrhythmias in NCCM. Large 
international, multicenter prospective registries are crucial to clarify genotype-
phenotype correlations in NCCM. Mutation associated risks will help in making 
clinical decisions, like if an ICD needs to be implanted. 
Not only estimating risk for patients, but also for their relatives is imperative. For 
now, the risk for relatives of having inherited a familial genetic defect is mostly 
50%, since the most common genetic causes are inherited as autosomal dominant 
traits (rare X-linked and mitochondrial causes are mostly encountered in severely 
affected children). However, for families of patients, non-penetrance in a relatively 
large part of relatives, results in a much lower actual risk for cardiac symptoms and 
events. Risk prediction for relatives with the morphological phenotype without 
symptoms or even for the relatives carrying the genotype without a phenotypical 
expression seems low. The risk for relatives of non-familial index patient in which 
no mutation is identified is low, but remains elevated, since genetic susceptibilities 
cannot be excluded. Improved risk classification for this group may lead to 
improved guidelines for family screening. In the distant future with a more 
complete picture of disease-causing genetic defects and mechanisms for NCCM, 
genetic predisposition may be estimated in all NCCM patients. This will allow 
to make a distinction between high and low genetic risks for NCCM and provide 
accurate risk prediction for relatives of the patients. 
The specificity of the current diagnostic criteria is not satisfactory. The 
extension of normal trabeculation has to be established and this will help 
to improve specificity of the diagnostic criteria. Also, distinguishing people 
with physiologic excessive trabeculation, from patients with NCCM, who 
are at risk for cardiac events, would be an important step in risk stratification 
of the hypertrabeculation spectrum. For this reason, we believe that novel 
diagnostic criteria for NCCM leading to improved accuracy of the NCCM 
diagnosis, should include; 1) imaging criteria to identify trabeculation; 2) 
cardiac functioning parameters like left ventricular function (including left 
ventricular volumes, ejection fraction and strain analysis) could help in 
separating the benign trabeculation from cardiomyopathy; 3) genetic status 
to incorporate patients, who are at risk to develop cardiac dysfunction in the 
future and for risk assessment of their relatives; 4) histological criteria are 
needed, to confirm the diagnosis and to support these diagnostic criteria 
in NCCM patients. To achieve this, we have to aim at performing large 
Epilogue
198
population studies and create international registries. On the basis of such 
registries international committees may reach a consensus on improved 
diagnostic criteria. 
In conclusion, genetic causes currently explain a large proportion of NCCM. 
Improved diagnostic criteria, incorporating genetics, cardiac function and histology, 
may help to distinguish NCCM patients from the benign cases. The majority of 
genetic causes involve cardiomyocyte sarcomere functioning, but also genetic 
defects involving mitochondrial function, affecting cellular energy management 
or in genes involved in calcium handling regulating the sarcomere contraction 
force, have been identified. These genetic defects may have a damaging effect on 
the cardiomyocyte functioning in common. How these damaged cardiomyocytes 
may lead to hypertrabeculation is yet unclear. Likewise, it is not known why left 
ventricular remodeling occurs in the cases, who do not have a genetic cause, which 
is approximately half of the NCCM population. The role of the sarcomere, of 
loading conditions and mitochondrial functioning in activating similar remodeling 
pathways in these different groups of patients remains challenging.
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Summary 
Noncompaction cardiomyopathy (NCCM) is a rare disease. NCCM is characterized 
by hypertrabeculation of myocardium the left ventricle. Recent improvements 
in cardiac imaging techniques led to an increasing in detection and showed 
that NCCM occurs less frequently than hypertrophic (HCM) and dilated 
cardiomyopathy (DCM). The noncompaction phenotype is hypothesized to be 
a morphologic expression of different pathophysiologic mechanisms in patients 
with a cardiomyopathy. Interestingly signs of hypertrabeculation may be observed 
in healthy population without signs of cardiomyopathy, for instance in athletes or 
in women during pregnancy. In these cases cardiac overload might be related to 
localized hypertrabeculation of the left ventricle. 
In patients diagnosed with NCCM the clinical symptoms range from mild to severe 
outcomes. Heritability plays an important role in NCCM. In around one third of 
NCCM patients a genetic defect can be identified. In an additional 15% there is 
familial disease without a known genetic cause. In around 50% of the NCCM 
patients there is no evidence for a genetic disease; no mutation in a cardiomyopathy 
gene or familial disease. These cases may have yet unknown (complex) genetic 
cause(s) carrying small risk for relatives. Alternatively, NCCM may be attributed to 
non-genetic, secondary causes for hypertrabeculation.
Finding a genetic cause for NCCM is of importance for patients and their families, 
enabling to predict genetic risk and perform family cascade screening. This allows 
accurate identification of relatives which have an increased risk of developing a 
cardiomyopathy and it also offers the possibility to reassure relatives who do not 
carry the genetic risk variant. It is important to know if specific causes are related 
to outcome. In this thesis we investigated if the genotype is of additional value for 
clinical management. More precisely whether specific genetic defects could predict 
the clinical features and the outcome (i.e. the risk of severe cardiac complications) 
in NCCM. 
Chapter 1. This thesis starts with a chapter that was published in a monography 
on NCCM. It presents practical guidelines for the genetic diagnosis of NCCM for 
clinical geneticists and cardiologists with an overview of the genetic causes for 
NCCM, a description of the routine of genetic diagnostics, genetic counseling, 
DNA testing and the current view on family screening for NCCM. The chapter 
illustrates the importance of integrating genetic diagnostics to clinical management 
of NCCM patients by conveying appropriate information to patients and their 
families, in order to make early diagnosis and timely treatment accessible for the 
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families of all NCCM patients
Chapter 2. This chapter presents the largest genetic NCCM study performed 
worldwide to date. The retrospective multicenter study was performed in 
collaboration with the four major cardiogenetic centers in the Netherlands (EMC, 
UMCG, UMCU and AMC) to establish 1) spectrum of genetic causes for NCCM 
and 2) correlations between genetics, clinical features, and outcomes, in 327 
unrelated children and adults with NCCM. In this study we identified differences 
in genetic causes between children and adults. Children had more often a genetic 
cause, had more complex genetic causes with multi-systemic features and severe 
outcome. In contrast NCCM in adults was mostly linked to missense mutations in 
sarcomere genes. In about half the cases, mostly diagnosed in adulthood, there 
was no evidence for a genetic cause. These cases did not have familial disease and 
DNA testing did not result in the identification of a disease causing variant. The 
main findings of this study were that NCCM is a heterogeneous condition and 
genetic stratification has an important role in clinical care. NCCM was due to an 
inherited cause in half of the cases; in 32% a mutation could be identified and in 
15% there was familial cardiomyopathy without a known mutation. Mutations in 
MYH7, MYBPC3 and TTN were the most common (71%). Adults were more likely to 
have sporadic NCCM (no disease causing variants nor affected family members). 
The risk of having a reduced left ventricular systolic dysfunction was higher for 
genetic patients, with highest risk for patients with multiple mutations and TTN 
mutations. In children, high risk for major cardiac events was related to having 
a mutation. In adults risk for major cardiac events was related to left ventricular 
systolic dysfunction in mutation carriers. This was not observed in sporadic cases. 
Patients with MYH7 mutations had low risk for major adverse cardiovascular 
events (MACE). Our results showed that DNA diagnostics and family history 
carry information that may help to distinguish genetic from non-genetic NCCM. 
Moreover, it complement cardiologic management and, prediction of outcome 
and subsequently guide management of patients with follow-up tailored to genetic 
status and associated risk. Hence, it showed the importance of genetic testing in 
NCCM.
Chapter 3. The third chapter of the thesis focused on family screening in NCCM. In 
this chapter we looked for a way of predicting the severity and cardiac morphology 
in relatives of NCCM patients. In this chapter we investigated the results of family 
screening for NCCM in the families that are followed at the cardiogenetic clinic 
at the Erasmus Medical Center. We focused on familial NCCM and present the 
outcome of – cardiac examinations and (when appropriate) genetic family testing 
Epilogue
220
of the families of 114 NCCM index patients. We were particularly interested if the 
specific NCCM phenotypes, NCCM with DCM, NCCM with HCM, and isolated 
NCCM (without HCM or DCM) segregated within families, and if these specific 
NCCM phenotypes were linked to distinct genetic defects and were related 
to outcome. Cardiac family screening revealed that 109 (23%) of 472-screened 
relatives from 58 (51%) families had a cardiomyopathy; 81 relatives from 39 families 
(of 54 index patients) with a mutation and 28 relatives from 19 families (of 60 index 
patients) without a mutation. A third of the relatives with an inherited mutation 
did not have a cardiomyopathy (non-penetrance), which is important information 
for the counseling of relatives. The relatives who were diagnosed with NCCM were 
less likely to have left ventricular systolic dysfunction or major adverse cardiac 
events than the index cases. NCCM with DCM occurred in 56% of all NCCM 
patients and was associated LV systolic dysfunction, mutations in the tail of MYH7 
and 38% was asymptomatic. Isolated NCCM (43%) was associated with milder 
course, mutations in the head of MYH7, and 42% were asymptomatic. NCCM with 
HCM was associated with MYBPC3 mutations. Familial segregation of distinct 
NCCM phenotypes was observed in 47% of the affected relatives; 55% isolated 
NCCM, 34% NCCM with DCM and 33% NCCM and HCM. Thirty-six relatives 
from 24 families had HCM or DCM without hypertrabeculation. The conclusion 
was that the distinct NCCM phenotype and related risk for relatives might be 
predicted by the phenotype and genotype of the index cases. These insights can 
be applied to personalize clinical management and family screening of NCCM. 
Chapter 4. In this chapter we investigated if cardiac magnetic resonance imaging 
(CMR) could help to distinguish which NCCM patients have a mutation. As the 
previous studies have indicated, it is important to distinguish genetic NCCM with 
high risk for relatives, from patients with sporadic NCCM and low risk for relatives. 
Since NCCM is frequently diagnosed on CMR, we were interested if CMR could 
help to identify which patients were most likely to have a genetic defect. For this 
purpose we evaluated 62 NCCM patients referred for CMR who had genetic testing 
at the Erasmus Medical Center between 2005 and 2017. Thirty-three (53%) patients 
had a mutation. In all patients previously proposed CMR diagnostic modalities 
were ascertained (i.e. criteria according to Petersen (short- and long-axis), Stacey, 
Jacquier, Captur and Choi). Correlation between different CMR criteria varied 
from moderate to very strong. On average the NCCM patients met four of the 
different diagnostic modalities. Genetic patients met more diagnostic modalities 
than patients without a mutation. In multivariate binary logistic regression 
analysis with CMR and non-CMR parameters, independent positive predictors 
for a genetic defect were familial cardiomyopathy, trabecular mass, and meeting 
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Petersen criteria in ≥2 out of 3 long axis views, while left bundle branch block and 
hypertension were negative predictors. The ROC-curve of this multivariate model 
had a good area under the curve of 0.89. Concluding that CMR criteria and patient 
characteristics may help to predict if a patient has a genetic defect. In this way 
CMR interpretations may contribute in guiding cardiologists to refer patients for 
genetic testing. 
Chapter 5. Since NCCM is a relatively rare, genetically heterogeneous 
cardiomyopathy, there are few studies that are large enough to have sufficient 
statistical power to establish a correlation between the genetic defects and the 
clinical features. By performing a systematic review of the NCCM literature for 
reports of NCCM patients with documented genotype and phenotypes, we could 
combine and analyze the results of smaller studies to determine the genetic 
spectrum of NCCM and establish if genetic causes could help predict high-risk 
profiles for major adverse cardiac events (MACE) in NCCM. For this purpose we 
have conducted a systematic search of the literature regarding genetics and clinical 
features of NCCM. The literature search for patients diagnosed with noncompaction 
cardiomyopathy yielded 1978 papers. After removing duplicates from the different 
searches 990 reports remained of which 172 fulfilled our inclusion criteria. In this 
way, clinical and genetic data of 561 patients were included. In total 244 (43%) 
children were included showing a high prevalence of congenital heart disease and 
increased risk for MACE compared to adults. Children had more frequently an 
X-linked or mitochondrial inherited defect or chromosomal anomalies. In adult 
NCCM patients the main causes were single missense mutations in sarcomere 
genes. Overall, MYH7 was involved in 48% of the sarcomere gene mutations. MYH7 
and ACTC1 mutations had lower risk for MACE, than MYBPC3 and TTN. In this 
analysis, the combination of NCCM and DCM was the most frequent observed 
among the different NCCM phenotypes – as described in the previous chapter, 
with more than half of the cases showing these overlapping cardiac features. The 
NCCM-DCM phenotype was associated with an increased risk for MACE and 
high risk for left ventricular systolic dysfunction. The literature review showed 
that genetic defects were related to age at presentation, concomitant congenital 
heart defects and cardiac outcome. These observations endorsed the conclusions 
from our study presented in Chapter 2 of this thesis, that DNA diagnostics for 
NCCM are important for clinical management and counseling.
Chapter 6. In nearly half of the families with familial NCCM sequencing of 
cardiomyopathy gene panels consisting of approximately 50 genes cannot identify 
a mutation. In the last chapter we present a novel NCCM gene in two families. 
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To identify the genetic cause for familial NCCM whole exome sequencing was 
performed in two families, one from the University Medical Center Groningen 
and one from our center and. In these two families a variant in the filamin C gene 
(FLNC) segregated with the NCCM phenotype. Also in both families there was 
a patient with coarctation of the aorta and mitral valve abnormalities. Based on 
these results we present FLNC as a novel NCCM gene. Pathogenic variants in FLNC 
have been linked previously to HCM and DCM. We expand the spectrum of FLNC 
related cardiomyopathies with familial segregation of NCCM and concurrent 
coarctation of the aorta, mitral valve abnormalities.
Conclusions
Distinguishing which NCCM patients and their relatives have a high genetic 
risk, has important implications for both the patients and their relatives 
in health management and cardiac surveillance. Genetic patients can be 
distinguished by using DNA testing, family history and clinical markers. 
We showed that for prediction of adverse events in patients, information 
on genotype and phenotyping the left ventricle is important. The distinct 
cardiac phenotypes: isolated NCCM, NCCM with DCM and NCCM with 
HCM were related to genotypes, outcome and segregated within families. 
These studies contributed to our understanding of the etiology of NCCM 
and in the relation between the cause of the disease and the clinical features. 
We hope that patients and their families may benefit from these insights 
and that our study results may contribute to the development of new and 
improved diagnostic criteria, and guidelines for NCCM.
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Nederlandse samenvatting 
Noncompactie cardiomyopathie (NCCM), ook wel LVNC (linkerventrikel 
non-compactie cardiomyopathie) genoemd, is een ziekte van de hartspier. De 
diagnose NCCM is gebaseerd op het belangrijkste kenmerk van de ziekte, de 
hypertrabecularisatie van de linkerhartkamer (ventrikel). Hypertrabecularisatie 
zijn bijzonder grove spiervezelbundels, waartussen zich holtes vormen, die 
bij NCCM patiënten meer herkenbaar zijn (figuur 1). Verbeteringen van de 
beeldvormingstechnieken van het hart hebben ertoe geleid dat NCCM steeds 
vaker herkend wordt. Ook is het duidelijk geworden dat deze cardiomyopathie 
minder vaak voorkomt dan andere cardiomyopathieën zoals hypertrofische (HCM) 
en dilaterende cardiomyopathie (DCM). Opvallend is dat hypertrabecularisatie 
van de linkerventrikel ook kan optreden bij personen die geen cardiomyopathie 
hebben, bijvoorbeeld bij sporters of bij vrouwen tijdens de zwangerschap. De 
veronderstelling is dat in deze gevallen een cardiale overbelasting de oorzaak zou 
zijn. 
Figure 1: Schematische weergaven van NCCM.
Een schematische weergave van het normale hart (links) en een hart met noncompaction 
cardiomyopathie (rechts). Het hart met noncompaction cardiomyopathie heeft hypertrabecularisatie 
van het hartspierweefsel van de linkerventrikel. De afbeelding is overgenomen van: 
https://www.cincinnatichildrens.org/service/c/cardiomyopathy/types/left-ventricular-non-
compaction-cardiomyopathy.
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De klinische symptomen (het fenotype) bij cardiomyopathie patiënten met NCCM 
kunnen van persoon tot person sterk verschillen, variërend van mild tot ernstig 
hartfalen (5). Erfelijkheid speelt een belangrijke rol; ongeveer één derde van de 
NCCM patiënten heeft een (waarschijnlijk) ziekte veroorzakende gen variant (10). 
Een deel van deze varianten, voornamelijk die in sarcomeer genen, komen ook vaak 
voor bij patiënten met HCM of DCM. In NCCM komen daarnaast ook zeldzamere 
genetische defecten voor die leiden tot syndromale beelden, waarbij meerdere 
orgaansystemen zijn aangedaan (54). In ongeveer een derde van de patiënten komt 
NCCM bij meerdere mensen in de familie voor (familiaire NCCM). Bij ongeveer de 
helft van de familiare patiënten kan een oorzakelijk gendefect worden aangetoond. 
In de andere helft van de patiënten, kan ondanks het familiair voorkomen van de 
ziekte, de genetische oorzaak niet worden aangetoond. 
Het vinden van de genetische oorzaak is belangrijk voor NCCM patiënten en hun 
familieleden. Als een genetische oorzaak is gevonden kan met DNA-onderzoek op 
betrouwbare wijze worden vastgesteld welke familieleden een verhoogd risico op 
een cardiomyopathie hebben. Indien het genetische defect wordt geïdentificeerd 
in familieleden kunnen ze poliklinisch door de cardioloog worden gecontroleerd, 
om in een vroeg stadium symptomen van de ziekte te kunnen behandelen en 
eventuele ernstige complicaties te voorkomen. Indien bij een familielid van 
een patiënt met genetisch defect met DNA-onderzoek de erfelijke aanleg wordt 
uitgesloten, kan het betreffende familielid worden gerustgesteld met het feit dat er 
geen verhoogde kans is voor het ontwikkelen van een cardiomyopathie. Tevens is 
er dan geen verhoogd risico voor zijn of haar nageslacht. Echter bij ongeveer twee 
derde van de NCCM patiënten kan geen ziekte veroorzakende genetisch defect 
worden aangetoond en kan bij familieleden de ziekte niet worden aangetoond of 
worden uitgesloten met een DNA-onderzoek. 
Ook is het voor de behandelaars en de patiënten en hun familie van belang om 
de kans op ernstige symptomen te weten. Om die reden was de correlatie tussen 
de genetische oorzaak (het genotype) en de ernst van de ziekte (het risico op 
levensbedreigende cardiale ritmestoornissen en hartfalen), het fenotype, de 
focus van dit promotieonderzoek. Inzichten in het verband tussen genotype en 
fenotype kunnen belangrijk zijn voor het bepalen van risico’s van symptomen en 
complicaties. Op die manier zou een gepersonaliseerde behandeling mogelijk zijn 
en de counseling van de patiënt en zijn of haar familieleden aangepast kunnen 
worden aan het genotype.  
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Hoofdstuk 1. Dit proefschrift begint met een overzicht over de genetische 
achtergrond van NCCM, en hoe genetische onderzoek en familieonderzoek van 
NCCM verloopt. Dit hoofdstuk kan worden beschouwd als een leidraad voor 
klinisch genetici en cardiologen. In ten minste de helft van de patiënten met 
NCCM speelt erfelijkheid een belangrijke rol speelt. Bij erfelijke NCCM is net als 
bij andere erfelijke cardiomyopathieën tijdige herkenning en behandeling van 
risicogroepen belangrijk. De genetische oorzaken voor NCCM worden besproken, 
zoals de cardiomyopathie-genen, andere – meer zeldzame- genetische oorzaken, 
en structurele chromosoom defecten, evenals de nieuwe DNA-analyse technieken 
en de interpretatie van de resultaten van DNA-diagnostiek. Ook is er aandacht voor 
de overervingspatronen en het informeren van familieleden. Dit hoofdstuk geeft 
het belang van het genetisch counselen van NCCM-patiënten en hun familieleden 
weer.
Hoofdstuk 2. Dit hoofdstuk beschrijft de grootste NCCM studie wereldwijd 
tot op heden. Dit onderzoek had ten doel te onderzoeken wat de relatie is tussen 
de genetische achtergrond van NCCM en de ernst van de symptomen in de 
NCCM patiënten. Hiermee wilden we bekijken of genetische achtergrond 
kon worden gebruikt voor het bepalen van de prognose van verschillende 
patiënten. Een retrospectief multi-centeronderzoek werd uitgevoerd in 
samenwerking met de vier belangrijkste cardiogenetica centra in Nederland 
(Erasmus Medisch Centrum, Universitair Medisch Centrum Groningen, 
Universitair Medisch Centrum Utrecht en Amsterdam universitair 
Medische Centra, locatie AMC) om correlaties tussen erfelijke oorzaken, 
klinische kenmerken en complicaties vast te kunnen stellen. Deze studie 
populatie bestond uit 327 kinderen en volwassenen met NCCM, die geen 
familie van elkaar waren. We observeerden dat er verschillen in genetische 
oorzaken waren tussen kinderen en volwassenen. Kinderen hadden vaker 
complexe genetische oorzaken met aangeboren hartafwijkingen, terwijl 
volwassenen NCCM patiënten vooral aminozuur veranderingen (missense-
mutaties) in sarcomeer genen hadden. NCCM was erfelijk in de helft van 
de gevallen; bij 32% werd een mutatie gevonden en bij 16% was er sprake 
was van meerder patiënten in de familie (familiare cardiomyopathie). 
In de laatste groep konden we ondanks het feit dat meerdere mensen 
NCCM hadden geen mutatie identificeren. Het meest voorkomend waren 
mutaties in MYH7, MYBPC3 en TTN (71%). Mutaties kwamen vaker voor 
bij kinderen en werden geassocieerd met ernstige cardiale complicaties. 
Volwassen patiënten hadden vaker sporadische NCCM, dat wil zeggen dat 
zij geen mutatie hadden of familiaire cardiomyopathie. Bij sporadische 
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NCCM kwam vaker hypertensie (hoge bloeddruk) en linker bundeltakblok 
(ritmestoornis) voor. In patiënten met een erfelijke vorm van NCCM was 
er een verhoogd risico op een verminderde hartfunctie door een linker 
ventriculaire systolische dysfunctie (minder bloed wordt weg gepompt door 
de linkerhartkamer), met het hoogste risico voor patiënten met meerdere 
mutaties of TTN-mutaties. Kinderen waarbij een genetische oorzaak werd 
gevonden hadden een hoger risico op ernstige cardiale complicaties. Bij 
volwassenen was het risico op ernstige cardiale complicaties gerelateerd 
aan linkerventrikel systolische dysfunctie bij mutatiedragers, maar niet 
bij sporadische patiënten. Patiënten met MYH7-mutaties hadden een 
laag risico op complicaties. Deze resultaten benadrukken dat voor het 
voorspellen van het risico op complicaties het nuttig is een onderscheid 
te kunnen maken tussen erfelijke en niet-erfelijke NCCM, en dat zo een 
genetische stratificatie een belangrijke rol kan gaan spelen in de klinische 
zorg van de patiënt. Deze verschillen tussen sporadische en genetische 
patiënten lieten ook zien dat het NCCM-fenotype waarschijnlijk het 
verschil in symptomen (de morfologische expressie) is van verschillende 
factoren (pathofysiologische mechanismen). Deze studie benadrukte het 
klinische belang van genetische onderzoek bij NCCM patiënten. 
Hoofdstuk 3. Het derde hoofdstuk van dit proefschrift richtte zich op het 
bepalen van het risico voor de familieleden van NCCM patiënten. Het doel 
was om te kijken of de prognose en ernst van cardiomyopathie bij familieleden 
van NCCM-patiënten kon worden voorspeld. Ook waren we geïnteresseerd of 
specifieke NCCM-fenotypes: NCCM met DCM, NCCM met HCM en geïsoleerde 
NCCM (zonder HCM of DCM, zie figuur 1), altijd samengaat in families. Ook 
bekeken we of deze specifieke NCCM-fenotypes gekoppeld waren aan bepaalde 
genetische defecten en cardiologische complicaties voorspelde. Dit deden we 
met behulp van de gegevens van cardiale- en genetische- familiescreening van 
114 NCCM-indexpatiënten uit het Erasmus Medisch Centrum. Uit cardiologische 
familiescreening bleek dat 23% van de 472 gescreende familieleden een 
cardiomyopathie hadden. In ongeveer de helft van de families waren er aangedane 
familieleden (familieleden met een cardiomyopathie). De aangedane familieleden 
werden voornamelijk geïdentificeerd in families waarin de erfelijke oorzaak 
bekend was. Opvallend was dat een derde van de familieleden, die drager waren 
van de familiaire mutatie, (nog) geen cardiomyopathie (non-penetrantie) had. Dit 
is belangrijke informatie voor het counselen van familieleden. De familieleden 
bij wie de diagnose NCCM werd gesteld, hadden minder kans op ventriculaire 
systolische dysfunctie of ernstige cardiale complicaties dan de index-patiënten. Van 
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alle NCCM-patiënten had 56% NCCM met DCM. Dit fenotype was geassocieerd 
met linkerventrikel systolische dysfunctie, mutaties in de staart van MYH7 en 
slechts 38% was asymptomatisch. Geïsoleerde NCCM (43%) werd geassocieerd 
met een milder beloop van de ziekte, met mutaties in de kop van MYH7 en 42% 
was asymptomatisch. NCCM met HCM was geassocieerd met MYBPC3-mutaties. 
Familiare segregatie van verschillende NCCM-fenotypes werd waargenomen bij 
47% van de aangedane familieleden; 55% had geïsoleerde NCCM, 34% NCCM met 
DCM en 33% NCCM en HCM. Zesendertig familieleden uit 24 families hadden 
HCM of DCM zonder hypertrabecularisatie. De conclusie was dat het NCCM-
fenotype en het daar bijhorende risico voor familieleden kon worden voorspeld 
door het fenotype en het genotype van de index-patiënt. Deze inzichten kunnen 
belangrijk zijn voor het inschatten van risico’s voor patiënten en familieleden.
Hoofdstuk 4. In dit hoofdstuk hebben we onderzocht of cardiale magnetic 
resonance imaging (CMR) kan helpen bij het voorspellen of een NCCM-patiënt 
een mutatie heeft, d.w.z. dat er bij DNA-onderzoek een (waarschijnlijk) pathogene 
variant wordt ontdekt, zoals bij ongeveer een derde van de NCCM-patiënten. 
Aangezien NCCM vaak wordt gediagnosticeerd via CMR, waren we geïnteresseerd 
of aan de hand van de CMR-beelden kon worden voorspeld of een NCCM patiënt 
een genetisch defect had. Hiervoor hebben we 62 NCCM-patiënten onderzocht die 
tussen 2005 en 2017 werden verwezen voor CMR en ook een genetisch onderzoek 
hebben gehad in het Erasmus Medisch Centrum. Van deze NCCM patiënten had 
53% een mutatie. Alle patiënten werden beoordeeld volgens een aantal bekende 
diagnostische CMR-criteria beoordeeld; de Petersen (korte en lange as), Stacey, 
Jacquier, Captur en Choi criteria. De correlatie tussen verschillende diagnostische 
CMR-criteria varieerde van matig tot zeer sterk. Gemiddeld voldeden de NCCM-
patiënten aan vier van de verschillende diagnostische criteria. Genetische 
patiënten voldeden gemiddeld aan meer diagnostische criteria dan patiënten 
zonder een mutatie. Positieve voorspellers voor een genetisch defect waren: 
familiare cardiomyopathie, trabekel massa en het voldoen aan Petersen-criteria 
in ≥2 van de 3 lange-as beelden. Een linker bundeltakblok en hypertensie waren 
negatieve voorspellers. De conclusie was dat CMR-criteria samen met andere 
cardiale kenmerk kunnen helpen met het voorspellen of een patiënt een genetisch 
defect heeft. Op deze manier kunnen cardiologen op grond van de CMR-resultaten 
een indruk krijgen welke patiënten en familieleden met voorrang geïnformeerd 
moeten worden over de erfelijkheid en voor welke patiënten genetische diagnostiek 
van NCCM het belangrijkste is. 
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Hoofdstuk 5. Aangezien NCCM een relatief zeldzame genetisch cardiomyopathie 
is, zijn er weinig onderzoeken groot genoeg om met voldoende statistische power 
een verband tussen genetische defecten en de klinische kenmerken vast te kunnen 
stellen. Door het uitvoeren van een systematische review van de literatuur, waarbij 
NCCM-patiënten met zowel genotype als fenotypes werden geselecteerd, konden 
we de resultaten van kleinere studies combineren en analyseren. Met deze data 
konden we het genetische spectrum van NCCM bepalen. Ook bekeken we of 
de genetische oorzaak bijdraagt aan de risico voorspelling op ernstige cardiale 
complicaties in NCCM. Het literatuuronderzoek naar patiënten met de diagnose 
NCCM leverde 1978 wetenschappelijke publicaties op. Na het verwijderen van 
duplicaten uit de verschillende zoekopdrachten bleven 990 artikelen over, waarvan 
172 voldeden aan onze inclusiecriteria. De klinische en genetische gegevens van 
561 patiënten konden op deze manier worden geïncludeerd. In totaal waren er 
244 (43%) kinderen, die vaak een aangeboren hartaandoeningen hadden en ook 
een verhoogd risico op cardiale complicaties bleken te hebben in vergelijking met 
volwassen patiënten. Kinderen hadden vaker een mutatie in van een gen dat op 
het X-chromosoom ligt, een mitochondrieel defect of een chromosoomafwijking. 
Bij volwassen NCCM-patiënten waren de belangrijkste oorzaken aminozuur 
veranderingen (missense-mutaties) in sarcomeer genen, waarvan bij 48% het 
MYH7gen betrokken was. Patiënten met MYH7- en ACTC1-mutaties hadden een 
lager risico op ernstige cardiale complicaties dan die met MYBPC3- en TTN-
mutaties. In deze studie kwam het NCCM/DCM-fenotype het meest voor en dit 
fenotype werd geassocieerd met een verhoogd risico op cardiale complicaties en 
een hoog risico op systolische disfunctie van de linkerventrikel. De literatuurstudie 
bevestigde derhalve dat genetische oorzaken gerelateerd waren aan leeftijd bij 
presentatie, prevalentie van aangeboren hartafwijkingen en cardiale complicaties 
zoals wij hebben beschreven in hoofdstuk 2. Deze observaties benadrukte dan ook 
de conclusies uit hoofdstuk 2, dat DNA-diagnostiek voor NCCM patiënten van 
belang is voor risico predictie en counseling.
Hoofdstuk 6. In hoofdstuk zes presenteren we een nieuw NCCM-gen in twee 
families. In bijna de helft van de families met familiare NCCM wordt geen 
oorzaak gevonden bij reguliere DNA-diagnostiek. In twee van dit soort families 
werd ‘whole exome sequencing’ verricht om alsnog de oorzaak te vinden. Eén van 
deze families was bekend in het Erasmus Medisch Centrum en de ander in het 
Universitair Medisch Centrum Groningen. In deze twee families segregeerden 
varianten in het filamine C-gen (FLNC) met het NCCM-fenotype. In beide families 
kwamen patiënten voor met coarctatio van de aorta (aangeboren vernauwing in de 
aorta) of een afwijking aan de mitralisklep (de hartklep tussen linkerboezem en 
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linkerkamer). Ziekteverwekkende varianten in FLNC werden eerder ontdekt bij 
patiënten met HCM of DCM en ook in patiënten met skeletspierziekte. Op basis 
van deze resultaten presenteren we FLNC als een nieuw NCCM-gen. Hiermee 
werd het spectrum van mogelijke genetische oorzaken voor NCCM nog verder 
uitgebreid, waardoor mogelijk in de toekomst in meer patiënten de genetische 
oorzaak kan worden geïdentificeerd. 
Conclusie
Het is van belang voor patiënten met NCCM en hun familieleden om een 
onderscheid te kunnen maken tussen patiënten met een hoog genetisch 
risico op NCCM en die met een laag genetisch risico. Het genetische risico 
kan worden ingeschat met behulp van DNA-onderzoek, familiegeschiedenis 
en klinische kenmerken en cardiale magnetic resonance imaging. De 
uitslag van het DNA-onderzoek kan ook gebruikt worden om NCCM-
fenotypes te voorspellen binnen families en geeft een beeld van de kans op 
ernstige complicaties. We hopen dat vooral de patiënten en de families van 
de patiënten van de resultaten van dit onderzoek profijt zullen hebben. We 
hopen dat deze informatie toegepast zal worden in de dagelijkse praktijk en 
mede aanleiding zijn tot en bijdragen aan het tot stand komen van nieuwe 
diagnostische criteria en leidraden voor diagnostiek en behandeling.
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